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Abstract
This work contains two modelling projects, studying the neuroendocrine systems
of the hypothalamus, with a view to deriving general principles of neural function.
Growth hormone (GH) is released from the pituitary in a pulsatile pattern under
the control of two hypothalamic peptides, growth hormone releasing hormone
(GHRH) and somatostatin. Pulses of GHRH trigger pulses of GH but the overall
pattern of GH release appears to be controlled in a permissive manner by
somatostatin, which inhibits pituitary GH release. The hypothalamic sites of release
for GHRH and somatostatin have been identified but we have been unable to observe
the endogenous patterns of peptide release or electrical activity in these neurons.
To understand the hypothalamic network which controls GHRH and somatostatin
we need to use less direct lines of approach. There is a lot of behavioural level
evidence about how GH release is affected by removing these hormones or applying
them artificially. At the electrophysiological level we have some knowledge about
how the GHRH neurons respond to artificial stimuli and we have anatomical and
histological evidence about what substances and connections affect the behaviour of
the GHRH and somatostatin neurons. The goal of this project was to gather this
evidence, to try and build a model of the hypothalamic network which controls these
hormones and use it to derive further clues about how this system might work.
A model has successfully been built, which is able to reproduce the patterns of GH
release observed in male and female rats. The model has been used to investigate the
system's behaviour and also compared with behavioural experiments in the real
system, suggesting new lines of experimental investigation.
In previous work a model of oxytocin cell firing was developed based on the
classic leaky integrate and fire model with the addition of a hyperpolarising
afterpotential (HAP). The model was successfully used to explain the unusual linear
increase in firing activity in response to increased input stimulation, demonstrating
the apparently counter intuitive idea that this could be achieved by giving an equal
amount of excitatory and inhibitory input pulses. It was also successfully fitted to
real data by comparing firing rates and the inter-spike interval (ISI) histograms
generated with the model and from experimental recordings. However, recent novel
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analysis work has demonstrated a correlation between spike intervals such that a
longer inter-spike interval is more likely to be proceeded by a shorter interval and
vice-versa indicating that there is some other behavioural component which is
capable of remembering previous activity. One candidate for this is the after-
hyperpolarisation (AHP) which is much smaller in magnitude than the HAP but lasts
much longer, beyond the range of a single spike. The model data generated with just
the HAP showed no such correlation but adding the AHP to the model successfully
reproduced the spike interval correlation.
Fitting on the basis of ISI histograms takes no account of behavioural properties
which are observed over a longer time course and so a new parameter fitting
mechanism has been developed which takes account of the relation between
successive spike intervals. This is able to retrieve parameters values for the AHP's
magnitude and time course as well as the level of afferent input activity, from a cell
recording. If the system can be tuned to produce sufficiently accurate values then it
will provide a powerful tool for tool for measuring otherwise inaccessible properties
of neurons and their firing patterns.
In future work, it should be possible to use this model to study recordings from






Much of the information communicated between cells and systems in the brain,
and the body, is represented not by amplitude, but by the pattern of activity. This has
always been the more obviously useful and robust alternative, but it also requires that
we attribute memory to very low-level components of the brain, in order to produce
and interpret these patterns.
One part of the brain that exhibits very definite temporally patterned activity is the
neuroendocrine system. This system forms the brain's interface to much of the
body's internal systems and its function is essential to many fundamental processes,
particularly development and reproduction. It also has the advantage of producing an
easily accessible and relatively simple output, in the form of hormone release into the
bloodstream. We know that for several hormones, including growth hormone (GH), a
pulsatile pattern of release is optimal for their actions within the body. In male rats,
as in humans and many other animals, GH is released in large pulses every three
hours. A pattern of large pulses rather than continuous release allows a maximal
response to the hormone without desensitising the target receptors, and the pattern of
mixed high and low activity may also be used to instruct different systems, with
some responding to high and some low activity. These patterns are triggered by
neurons, but they operate on a timescale of hours, far longer than the milliseconds
over which action potentials fire. We need to understand how processes which
operate at very different speeds can integrate with each other and what the dynamics
of such interactions might be.
In order to understand such systems, an important approach is to gather the
experimental evidence and attempt to model the system. This provides a structure in
which to formalise existing knowledge and test theories on how the system functions
as a whole. This thesis attempts to model the GH release system, with the objective
of reproducing the behaviour of the real system, and predicting and aiding the




The goal of this project is to try and further understand the mechanisms controlling
GH release by using the knowledge derived from experiments to build a
mathematical model of the system. By implementing this set of static mathematical
equations on a computer we can give life to the artificial system and observe its
behaviour. If we have based it on what lower level mechanistic knowledge we have
of the real system and can show that it is able to accurately reproduce higher level,
such as the endogenous release profiles, then it may be able to predict properties of
the real system which we have not been able to observe and be able to simulate
experiments, as well as providing a possible solution to how the parts of the system
function as a whole.
The project follows on from previous PhD work of Elinor Stephens who
constructed a model of GH release at the pituitary. By constructing a model of the
hypothalamic systems and then adding it on to the pituitary model we will be able to
construct a model of the whole growth hormone release system.
1.2.1 Objectives
The primary objective of the project was to produce a model of the hypothalamic
network controlling GH release. The first part of this, which formed the research
review presented below, involved an investigation of evidence in the literature that
might be used to build the model. The second stage was to re-implement the pituitary
model, (chapter 2). It was also used for new experiments, testing plausible patterns of
GHRH and somatostatin release in preparation for developing the hypothalamic
components. This produced a specification for the model in terms of what was
available to build it from and what its output had it to be, and formed the basis for the
design stage (chapter 3) where a basic model of the complete system was developed.
The final part of the model's development (the first part of chapter 4) was
experimentation, testing new components, based on less definite experimental
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evidence, in the attempt to more closely reproduce the real system and suggest
further real experiments.
The second objective was to be able to accurately reproduce real experiments by
fitting the model to real data. To do this the values used in the model had to be scaled
to fit real units, particularly blood GH concentration. The parameters used in the
equations were refined so that the model could reproduce real GH output as
accurately as possible. If we had been unable to reproduce data by scaling and
refinement then this would have suggested that there was something wrong with the
model and its design would have needed to be changed. However, it was successful,
and for the final part of the work with the GH system, the second part of chapter 4,
the model was used to recreate and extend in-vivo experiments, particularly those
which test the system by adding exogenous substances. This was an important further
test of the model, but it also allowed further interpretation of the original
experimental results.
1.2.2 The Research Review
The research evidence divides into three levels of examination; behavioural,
electrophysiological, and neuroanatomical. Behavioural results describe the system
being examined as a whole, measuring the pattern of GH release during normal
function, and in response to administration and blocking of the main substances
which appear to control GH; GHRH, somatostatin, and GH itself. These give
important clues about how GH is controlled, and establish the output and behaviour
which the model must reproduce. GH release is triggered by pulses of GHRH, under
the control of somatostatin, which blocks this action. The long period of low GH
release, observed particularly in male rats, appears to be controlled by a prolonged
release of somatostatin, which is somehow triggered or charged by the GH pulse




The second level is the electrophysiological results. Normal GHRH neuronal
activity is blocked by the anaesthetic required to record from these cells, but we do
have recordings from the GHRH neurons indicating inhibition of their remaining low
level activity in response to stimulation at the periventricular somatostatin neurons.
The somatostatin neurons are spread in a thin layer near the third ventricle, making
the more accurate electrode placement required for recording too difficult. GH
release in response to electrical GHRH stimulation is also measured, indicating a
highly non-linear relation where release is dependent on the number of stimulation
pulses.
The lowest level, the neuroanatomical, examines the histological and chemical
evidence, looking at the connections that might exist in the system, based on
anatomical tracing and correlating substances which are released by and effect the
involved cells. There is a lot of circumstantial evidence for many substances which
effect GH release, the interpretation of which is complicated by the interaction
between GHRH and somatostatin, which appear to have reciprocal connections
within the hypothalamus. The two better defined substances are galanin, which
appears to mediate an inhibitory GHRH-somatostatin connection, and NPY which
may mediate GH feedback on GHRH and somatostatin. However, there is also
evidence for direct GH-somatostatin feedback.
Together the results provide enough to put together an idea of how the system
functions as a whole (presented in chapter 3) and to give a functional description of
the system's components.
1.3 GH Release System Research
Growth hormone (GH) is released in a pulsatile pattern (Tannenbaum and Martin
1976) by the somatotroph cells of the anterior pituitary. In the male rat, as in humans,
GH release is highly pulsatile. In female rat it is less so, but the pulsatile pattern of
release is always an important feature, and one of the main goals of GH research is to
precisely define and understand the generation of this pattern.
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Many factors influence GH release, but the two most important substances are
growth hormone releasing hormone (GHRH) (Guillemin et al 1982) and
somatostatin, which are released from the hypothalamus and act directly at the
pituitary. At the simplest level, GHRH excites GH release and somatostatin inhibits
release, but the two also interact in the hypothalamus, and may be modulated by GH
itself, complicating their apparent effects. GHRH also acts at the pituitary to increase
GH content in the somatotrophs (Barinaga et al 1983) by triggering GH synthesis.
Building a model requires an understanding of the system at a functional level, and
so the research review concentrates on higher level, behavioural, experiments which
examine the system's response to modulation of the substances which directly
control GH release. Lower level experimental evidence, such as electrophysiology
and anatomy, is examined in order to understand how these substances themselves
are controlled.
1.3.1 Profiling GH Release and the Controlling Factors
ln-vivo behavioural experiments test the complete system. The results provide
detailed evidence on the endogenous pattern of GH release and how this is controlled
by GHRH and somatostatin. This information will suggest how the model should
work and also provide functional criteria to test the model against.
Pulsatile GH Release
In 1985 Clark et al administered varied patterns of GH to hypophysectomized rats
and observed their growth response (Clark et al 1985). The optimum pattern of GH
to promote growth is 3-hourly pulses, similar to endogenous GH release observed in
male rats. Administering the same total dose in less frequent pulses produced a much
smaller growth response. Continuous infusion of GH initially produces a similar or
5
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even slightly greater response than the 3-h pulses, but after 5 or 6 days the response
to continuous infusion declined, whereas pulsatile administration continued to be
effective. This suggested that the peripheral GH receptors become desensitised when
continuously exposed to GH. The 3-h pulses of GH provide the frequent exposure
required for a good growth response while avoiding long term desensitisation.
GH Release in Response to GHRH
In 1982 Wehrenberg et al developed an antibody to GHRH and, using this to block
GHRH in male rats, showed that GH release can be completely abolished with a
sufficient dose (Wehrenberg et al 1982). With a smaller dose, pulses of GH release
remained, but with reduced amplitude. The involvement of somatostatin was ruled
out by showing the same result with the addition of somatostatin antiserum. In a
follow-up paper (Wehrenberg et al 1983) the same group examined the response to
artificially administered GHRH. They used antibodies to block endogenous
somatostatin and GHRH in conscious male rats. The GHRH antibody was specific to
the rat version, and so they could administer the newly- identified human GHRH and
measure the GH response. Each injection of GHRH elicited a large increase in blood
GH concentration which quickly fell back to basal level. They administered
successive injections of GHRH at 1 and 3-h intervals and showed no consistent
change in GH response amplitude, although the results do show some variation in
GH response. They also showed larger amplitude pulses of GH with higher
concentrations of GHRH up to a maximal level.
These results established that GH release is triggered by GHRH in a dose-
dependent manner. The next stage was to search for the endogenous GHRH pattern
by comparing the response to administered GHRH to normal GH release. The
highly episodic endogenous rhythm of GH in male rats makes it difficult to interpret
the responses to administered substances without first blocking all hypothalamic
control. This problem was tackled by Clark and Robinson (Clark and Robinson
1985b) by moving to female rats, which have a more continuous endogenous GH
6
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release pattern (Eden 1979) and consequently slower growth. GH release in female
rats does show some peaks, but these are irregular, more frequent, and smaller than
in males, with a higher basal concentration. Clark and Robinson administered human
GHRH to normal female rats over 12 days either as a continuous infusion or in 3-h
pulses and measured blood GH concentrations and daily weight gain. Rats treated
with a pulsatile pattern of GHRH showed a pattern of GH release very similar to the
endogenous pattern in male rats, and showed a significant increase in growth
compared with rats treated with a continuous infusion or saline-treated controls.
There was no evidence of endogenous secretion between the artificially-induced GH
pulses, and the rats appeared to become entrained into the new pattern, responding
uniformly to each GHRH pulse. This suggests that, as well as stimulating GH release
from the pituitary, exogenous GHRH was, directly or indirectly, affecting the
hypothalamic systems that control GH release.
The Move Towards Somatostatin Pattern Control
Ferland et al (Ferland et al 1976) had shown that the low basal secretion between
pulses in males can be increased by using antibodies to block somatostatin. This
suggested that somatostatin could be responsible for the low inter-pulse GH release
levels while GHRH triggers the GH pulses, when not inhibited by somatostatin. This
somatostatin control explained the variable responses to GHRH in male rats and it
appeared that the different patterns of endogenous GH release seen in male and
female rats were due to different patterns of somatostatin release.
Clark and Robinson (Clark and Robinson 1985c) made a detailed comparison
between GH release responses to GHRH in conscious male and female rats. In the
first experiment they tested the GH response to a single injection of human GHRH.
GH was measured before and after the injection of GHRH to give a temporal profile
of release. The responses in males and females showed a similar shape, a rapid
increase in blood GH, peaking 3 to 5 min after injection, followed by a uniform
decline back to a basal level. However, the GH responses in males varied much more
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than in females, with some rats almost failing to respond, and some producing large
GH peaks, similar to endogenous GH pulses. None of the females failed to respond,
and all produced smaller, less variable GH peaks.
A second experiment tested the GH responses to multiple injections of GHRH at
varied intervals. At 3-h intervals, rats were given four injections. Only the responses
to the third and fourth injections were recorded. All rats showed a strong, uniform
response to these injections with no evidence of GH release between the two pulses.
Female rats showed smaller amplitude peaks but their GH levels decayed back to the
same low basal levels as the males. The rats again appeared to become entrained into
the new patterns of release, and there was even evidence of a rise in GH level in
anticipation of the later injections. Performing the same experiment with injections at
90-min intervals, the differences between males and females became more apparent.
Females produced fairly uniform GH pulses in response to each injection, but the
males only responded to every second GHRH injection, maintaining a pattern of 3-h
pulses. Some rats responded to the first and third injections and some to the second
and fourth, dividing into two groups 90 min out of phase. At 40-min intervals,
females produced larger peaks after the first injection but continued to respond to
each injection. Males only produced a large GH peak in response to every third or
fourth injection, although they sometimes produced a smaller response to a
consecutive injection before failing to respond for the next two or three.
The results show a refractory period in the ability to respond to GHRH in males.
GHRH has to be continuously infused for as long as 24h before significantly
depleting pituitary GH content (Wehrenberg et al 1986), and so this is unlikely to be
due to a lack of GH available for release, supported by the fact that females continue
to respond to frequent injections of GHRH and males respond to two injections in
rapid succession. It appears that the refractory period in the male may be due to a
cyclic pattern of endogenous somatostatin release controlling the periods when the
pituitary responds to GHRH. In the female, somatostatin appears to be released in a
more continuous pattern, at a level somewhere in-between the peaks and troughs of
the male pattern so that GHRH is never completely blocked, but does not produce as
strong a response as in the male.
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Until this time it had been thought that the 3h endogenous GH pulses were likely
due to a corresponding pattern of GHRH release from the hypothalamus, but it was
becoming clear that pulse frequency was controlled by somatostatin rather than
GHRH. Even if it had been the case that GHRH controlled the pattern, it would have
merely moved the problem of pulse generation away from GH to GHRH. The other
interesting result from this work was that the pattern of response, particularly in
males, can become entrained. The paper made an early suggestion that GH itself may
be involved in some feedback mechanism.
Detailed Profiling of GH Release
The first study to produce a detailed profile of GH release in male rats (Clark et al
1986) used a new system for the automated repetitive micro-sampling of blood. The
system could also simultaneously inject or infuse substances into the rat, and the first
results included experiments administering GHRH and somatostatin to male rats.
The first experiment infused GH into anaesthetised female rats and simultaneously
measured blood GH. The blood GH level rises quickly and then slows to reach a
plateau during infusion before rapidly falling back to zero. Endogenous GH release is
blocked in anaesthetised rats. The next experiment, in conscious male rats, sampled
GH every 12 min for 44 h. This showed the 3h pulses of GH, with amplitude and
frequency maintained throughout the sample period, and no sign of any relation to
periods of light and darkness. Many pulses consist of two peaks, often reaching as
high as lpg/ml.
The final experiment re-examined the effect on the pattern of GH release of a
series of GHRH injections. Male rats were given four 3h injections of GHRH, and
GH release was measured throughout the injections and for 12h afterwards. After the
first or second injection, the GH responses became entrained, responding to each
GHRH injection with a large, single-peaked, GH pulse, and low release between
pulses. The GH release pattern after the GHRH injections stopped is described as
variable and disorganised, but there still appears to be some trace of the trained 3-
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hourly pattern, although with smaller, less well-defined pulses, and a gradual
degeneration. GH release eventually returned to its natural pattern after many hours.
In a follow-up paper Clark et al (Clark et al 1987) produced detailed profiles of
GH release in female rats. If somatostatin secretion in females is less variable, then
the GH release profile should more closely match the pattern of endogenous GHRH
release. Female rats were monitored for up to five days, with blood samples taken
every 12 min. GH release was found to be much more pulsatile than previously
observed, with many large peaks, in some rats similar in size to those seen in males.
These large pulses were more closely studied by sampling at 4 min intervals. The
higher resolution showed that the large peaks rose more slowly than those in males,
taking as long as 25 min to reach the peak level. The pulses were quite different from
those seen in response to single injections of GHRH, which peak within 3-5 min and
are much smaller. These slowly increasing pulses seem likely to be the result of a
longer episode of GHRH secretion or a succession of GHRH pulses.
The frequency and amplitude of the pulses was variable, with no apparent regular
pattern like that observed in male rats. Release did however seem to vary between
more and less active periods, and they suggested that this could be related to the
light-dark cycle. Further experiments tried to establish this, but the variation between
animals leaves the results rather unconvincing. Longer experiments in which the rats
were monitored for five days were particularly concerned with the possible relation
of GH release activity to the oestrous cycle, but no connection was found. The final
experiment compared normal females with ovariectomised rats. Ovariectomised rats
showed larger peaks of GH and multiple peak bursts similar to those in males. They
also more clearly show a distinction between night and day activity with a more
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Figure 1.1 : Typical male and female rat GH release profiles. The males show large regular bursts of
GH release, consisting of two or three large peaks and very low basal release. The females show
smaller, less regular pulses with higher levels of basal release to make up a more continuous overall
pattern of release. They tend to show larger pulses during darkness hours.
Exogenous Somatostatin and GH Release
The paper introducing the new sampling system (Clark et al 1986) also showed
some of the first data on the effect of exogenous somatostatin on GH release. GH
release was measured in conscious male rats before, during and after infusion of
somatostatin, at two different doses. At the lower dose, endogenous GH pulses
remained, but with reduced amplitude. At the higher dose GH bursts were almost
completely abolished. However, when somatostatin was withdrawn there was a large
"rebound" release of GH. The rebound was blocked with GHRH antiserum showing
that it also required GHRH secretion.
It was now clear that the overall pattern of GH release was controlled by
somatostatin rather than GHRH. GHRH stimulates individual bursts of GH release,
but only under the permissive control of somatostatin. Thus, somatostatin must be
low during GH pulses, and high between.
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Clark and Robinson (Clark and Robinson 1987) experimented with different
patterns of exogenous somatostatin in female rats. In the first experiment, rats were
given a continuous infusion of somatostatin at 5 and 50 |ag/h. Similar to the males,
GH pulses were partially blocked at the lower dose, and almost completely abolished
with the high dose infusion. However, as soon as the infusion was stopped there was
a large rebound release of GH, and at the higher dose rate the rebound GH pulse was
larger and showed multiple peaks, similar to endogenous male GH pulses.
Somatostatin has a very short half life in blood (Schoemaker et al 1998) and its
inhibitory effect is very short-lived once infusion is withdrawn.
It had been suggested, based on the comparison between male and female
responses to GHRH pulses, that somatostatin may be released in a sinusoidal pattern
in males. This was tested by infusing the female rats with somatostatin in such a
pattern with a 3h period similar to the cycle in males. This did produce 3-hourly
peaks of GH release, but they were longer than the endogenous male pulses and of
lower amplitude, waves of GH release rather than short bursts. The final pattern of
somatostatin administration used square wave infusions interrupted in a repeated
pattern of 150 min on, 30 min off and was repeated at dose rates of 5 and 25(xg/h.
GH release was suppressed during the somatostatin infusion, with large rebound
peaks of GH release occurring during the interruptions, particularly with the higher
dose. Repeating this cycle of somatostatin administration produced a pattern of GH
release very similar to the endogenous male GH profile.
To measure the effects of these patterns on growth, the experiments were repeated
for longer periods, continuing the somatostatin infusion for 10 days, along with a
control group receiving only saline. The continuous pattern of somatostatin reduced
bone growth. It had no effect on body weight, but this is difficult to interpret since
food intake was increased. The rats treated with the interrupted pattern of
somatostatin showed normal bone growth, with an increased rate of weight gain
despite normal food intake. The interrupted pattern was further tested by varying the
length of the interruption, stopping infusion for 10, 30 and 90 min with rates adjusted
to give the same total dose. This showed weight gain inversely proportional to the
length of the interval. In addition, both the continuous and interrupted patterns of
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somatostatin resulted in increased pituitary GH content over the saline-treated rats
and this may have contributed to the large rebound release. Somatostatin does not
block GH synthesis at the pituitary.
These results suggest that somatostatin may not only be responsible for the periods
of low GH release but may also trigger the bursts of GH release through a rebound
mechanism.
Hypothalamic Control of GH Rebound Release
A small rebound GH release in response to somatostatin withdrawal can be
observed with pituitary preparations in-vitro, but this is much smaller than the
rebound observed in-vivo, suggesting an active hypothalamic component rather than
just the removal of its inhibitory influence. Preliminary results of Clark and
Robinson showed that the rebound is also absent in anaesthetised rats, hinting at the
involvement of GHRH, which is blocked by anaesthesia.
They went on to further investigate this rebound release (Clark et al 1988a). In the
first experiment, male rats were continuously infused with somatostatin for 4h. One
group of animals was injected with a sub-anaesthetic dose of urethane lh before the
end of the infusion. The control rats showed the normal large, multiple peak GH
rebound release, but the rebound release was greatly reduced in urethane-treated rats,
supporting the idea of hypothalamic involvement. The second experiment used the
150 min on, 30 min off, square wave pattern of somatostatin infusion. The infusion
pattern was repeated for 12 h and during the third infusion the rats were given an
injection of either control rabbit serum or anti-GHRH serum. The control rats
continued to produce a large rebound GH release after each infusion of somatostatin
but the rebound was greatly reduced in rats treated with GHRH antiserum. This was
tested further by varying the dose of antiserum and showed a dose dependency
relating the reduction in rebound magnitude to the level of GHRH block.
This was good evidence that the somatostatin-induced rebound release involved
hypothalamic release of GHRH, but it still left the question of whether GHRH
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release was being directly triggered by the sudden removal of somatostatin or
whether the exogenous somatostatin was suppressing endogenous somatostatin so
that GHRH could act when it was removed. Either way, the mechanism would have
to involve the suppression of endogenous somatostatin to allow such a large GH
release as observed in the rebound. There had already been a suggestion from work
with an in-vitro hypothalamic preparation that somatostatin could act centrally to
inhibit its own release (Peterfreund and Vale 1984) and work showing that central
administration of somatostatin paradoxically stimulates GH release (Lumpkin et al
1981).
GH Auto-feedback
GH auto-feedback was originally demonstrated by (Krulich and McCann 1966)
who showed that GH administration could reduce pituitary GH content in rats, and it
had since been shown to suppress the amplitude of GH pulses in conscious male rats
(Tannenbaum 1980) whether given i.v. or i.e.v. However, the mechanism of GH
feedback was unclear. GH did not appear to act at the pituitary (Richman et al 1981),
suggesting a hypothalamic site of action, either increasing somatostatin release or
inhibiting GHRH release, or even both, to inhibit its own secretion.
Clark et al (Clark et al 1988b) investigated the effects of exogenous GH. Blood GH
was sampled for 160min in female rats before giving a 6h infusion of human GH.
The normal pattern of endogenous GH release was strongly suppressed during the
GH infusion. At a low dose, GH release gradually recovered after strong initial
suppression, and at a higher dose there was very little release during the entire
infusion. When the exogenous GH stopped, there was no sudden rebound release but
the normal pattern did recover within an hour or so. In male rats, the lower dose had
little effect on the large endogenous pulses of GH, but at the higher dose GH release




To test the mechanism, female rats were given injections of GHRH at 40min
intervals before, during and after the GH infusion. The rats produced large pulses of
GH release throughout the infusion of human GH, continuing afterwards with little
sign of any suppression even at the larger dose of GH. By contrast, infusion of
somatostatin blocked the responses to GHRH.
Clark et al (Clark et al 1988a) stimulated rebound GH release in male rats by
infusing somatostatin with 30min interruptions every 3h. They also added GH to the
third or fourth infusion and showed that this greatly reduced the amplitude of the
following GH rebound release. Other results had suggested that the rebound was
mediated by GHRH release and so this further supported the conclusion that GH
feedback inhibits GHRH rather than stimulating somatostatin.
The results give further evidence in support of a GH feedback loop, that it can
inhibit its own release, and at concentrations similar to those seen at peaks in
endogenous release. However the mechanism was still unclear. The results in
females contradict other results suggesting that GH stimulates somatostatin release,
since the rats were still able to release GH in response to injections of GHRH.
Indeed, the results here would suggest that GH suppresses its own release by
inhibiting hypothalamic GHRH release. However, it would not necessarily be the
same in males. The more pulsatile pattern of release in the male rats could be related
to differences in the GH feedback mechanism.
Carlsson et al (Carlsson et al 1990) extended the experiment, comparing the
response to injections of GHRH during an infusion of GH, in male and female rats. A
control experiment gave male rats injections of GHRH at 45 min intervals, before,
during and after a 6h infusion of saline. This showed their normal pattern of 3-hourly
responsiveness to the GHRH injections. This was repeated in males and females with
an infusion of human GH. The female rats produced a GH pulse in response to each
GHRH injection, but during the infusion, each of the male rats produced only one
large GH pulse. The spacing relation of the single pulses to those before and after the
infusion, and comparison with the saline controls, suggested that the male rats were
still following a pattern of intermittent responsiveness to GHRH, although with a
prolonged refractory period during the GH infusion. Unfortunately the 6h GH
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infusions were not long enough for any of the male rats to show a second GH pulse
during the infusion, and demonstrate that the intermittent pattern of GH release was
still in place. However, the results show that GH has more of an inhibitory effect
than could come from just inhibition of GHRH release, suggesting an increase in
somatostatin release. A similar experiment without the GHRH injections (Clark et al
1988b) showed a single large pulse after the start of the GH infusion in males. This
was ascribed to a delayed onset of the GH-induced inhibition, suggesting that the
mechanism of GH feedback may involve a long delay.
GH Control of the Endogenous Rhythm
The possibility that there was also some GH-induced somatostatin release in
females was tested by repeating the experiment with lower doses of GHRH.
However, the female rats still showed large GH pulses in response to each injection.
Together these results indicate that the effect of GH feedback in rats varies strongly
between the sexes. GH appears to stimulate the release of somatostatin in males and
inhibit GHRH release in females. The stimulation of somatostatin, only in males,
makes GH an ideal candidate for an endogenous feedback mechanism.
The effect of GH on a more purely endogenous rhythm was tested by Carlsson and
Jansson (Carlsson and Jansson 1990). In their first experiment male rats were given
3-h injections of human GH while blood GH was sampled at 10 min intervals. The
response to the first injection varied depending on how recently the rat had produced
an endogenous GH pulse. Those which had recently released GH pulse showed little
response to the first injection, but the other rats produced large GH pulses. After the
second GH injection all of the rats produced a pulse of GH release. This continued,
with all the rats producing synchronised 3-h pulses of GH release, with no
endogenous pulses between the injections. The results even show that GH levels
were already increasing before the injections. Injections were continued at 3-h
intervals for 24h. When sampling was resumed in the morning, the rats were still
producing GH pulses in synchronisation with the GH injections, but pulse amplitude
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had fallen to about half the size of those seen earlier in the experiment. This fall in
amplitude may have been due to excessive stimulation of somatostatin or inhibition
of GHRH, or desensitisation to GH. The combined dose of exogenous and
endogenous GH would certainly be higher than normally experienced by the system.
After 24h the phase of the GH injections was completely shifted by giving the next
injection after only 1.5h and then continuing at 3h intervals. This resulted in almost
complete suppression of the GH release pulses. However, there was only one more
injection after the phase shift, which one rat did respond to with a GH pulse. The rats
may have eventually synchronised with the phase shifted pattern if the injections had
continued for longer.
In the second experiment the GH injections were given at 1.5h intervals, at half the
dose to maintain the same total dose. Most of the rats produced a large GH pulse in
response to the first injection, but unlike the 3h pattern, they failed to synchronise
with the following 1.5h injections. They continued to produce pulses of GH release,
but at longer intervals than the endogenous male pattern and with gradually
decreasing amplitude.
The synchronisation of GH release with the 3h injections provides good evidence
that GH could function as the feedback trigger for the endogenous male pattern. GH
must somehow be able to trigger a long suppression of GH release, probably by
stimulating a prolonged release of somatostatin. This role for GH is further supported
by the out of phase 1.5h injection appearing to extend the suppression period.
1.3.2 Hypothalamic Structures and Substances
Lower level experiments, examining the anatomy and behaviour of components
within the hypothalamus, are used to define the mechanisms controlling GHRH and
somatostatin release. This will identify and define the functional properties of the
components that can be used to build the hypothalamic model.
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GHRH and Somatostatin Neurons
Hypothalamic peptides which act at the anterior pituitary are released by neuronal
cells which project to the median eminence. Here the peptides are released close to
the portal blood supply which carries them to the pituitary. Using a technique where
axonal release is blocked in order to collect the product synthesised within cell
bodies, and then applying a GHRH immunoreactive test, a large population of
GHRH releasing cells was identified in the arcuate nucleus of the hypothalamus
(Jacobowitz et al 1983) mostly in the ventrolateral region (Sawchenko et al 1985).
The number of cells was found to be in the region of 1500 on each side of the brain.
However, destroying the arcuate nucleus did not completely eliminate GHRH
immunoreactivity (Daikoku et al 1986) and several much smaller populations of
GHRH-containing cells were found in the parvocellular portion of the
paraventricular nucleus, the ventromedial nucleus and in the dorsomedial nucleus.
These are very small populations, however, of around 50 cells and are not thought to
project to the median eminence (Wiegand and Price 1980).
The earliest attempts to investigate somatostatin distribution, in the mid 1970's,
used amino acid extraction techniques (Brownstein et al 1975). The highest
concentration was found in the median eminence but it was also detected in the
preoptic area, cortex, septum, thalamus and in the mid brain. Subsequent
immunoreactivity experiments in the mid 1980's also found somatostatin in many
other areas of the brain. However, the somatostatin found in the median eminence is
localised in nerve terminals (Pelletier et al 1974) and the peptide is also found in
neuronal cell bodies in the periventricular/anterior region of the hypothalamus
(Alpert et al 1976). Electrical stimulation of the preoptic/anterior hypothalamic area
inhibits GH release (Martin et al 1978.) and also causes an increase in the
somatostatin levels found in portal blood (Chihara et al 1979). Selective lesions of
the periventricular area cause a reduction in the levels of somatostatin found in the
median eminence (Critchlow et al 1981). Together, these results suggest that
somatostatin released from the median eminence originates in cells bodies in the
periventricular nucleus of the preoptic/anterior area of the hypothalamus. A small
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population of somatostatin-containing neurons has also been found in the arcuate
nucleus (Kawano et al 1982) but there is no evidence that these cells project to the
median eminence. However, they are well positioned to act on the nearby GHRH
neurons.
These two groups of cells, the GHRH-releasing neurons in the arcuate nucleus,
and the somatostatin neurons in the periventricular nucleus form the major
hypothalamic control sites for GH release, but there are likely to be other groups of
local cells or inputs from other parts of the brain which influence these two groups,
perhaps to coordinate their actions, mediate GH feedback or to provide some other
pattern generation input.
Other Structures and Substances
Apart from GHRH and somatostatin, many other substances have been identified
which affect GH release, neurotransmitters including dopamine, adrenaline,
serotonin, acetylcholine and GABA, as well as hypothalamic or circulating peptides
such as Substance P, neurotensin, opioids, bombesin, galanin, ghrelin, leptin and
NPY. It is unlikely that all of these play an important role in controlling GH release
under normal conditions. Some of them probably play some sort of modulatory role
to cope with special conditions such as stress or hunger. Many of these substances
are likely to originate in the same cells, since many neurons are capable of releasing
a variety of transmitters and peptides. Two substances for which there is particularly
good evidence for a role in normal function are adrenaline and galanin.
The central adrenergic systems appear to play an important role in the control of
pulsatile GH secretion. Administration of the centrally acting 0C2-adrenoreceptor
agonist clonidine increases GH release in rats whereas non-centrally acting agonists
do not have this effect (Day and Willoughby 1980), suggesting that the
adrenoreceptor influence is taking place within the CNS. Spontaneous (Arnold and
Fernstrom 1980) and clonidine-induced (Durand et al 1977) GH release is blocked
by the selective a2-adrenoreceptor antagonist yohimbine and spontaneous release is
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also suppressed by adrenaline synthesis inhibitors (Terry et al 1982) which indicates
an adrenergic rather than noradrenergic endogenous agonist. It is likely that the
adrenergic agonist acts on GHRH release, since GH secretion following clonidine is
blocked by GHRH antisera (Miki et al 1984) but not somatostatin antisera (Krulich
et al 1982).
Galanin is present in GHRH containing cells which project to the median
eminence (Niimi et al 1990) acts to increase GH release. This action is blocked by
GHRH antisera (Murakami et al 1988.) and it has been suggested, based on human
studies, that galanin acts to inhibit somatostatin release (Loche et al 1990). This is
supported by the detection of galanin receptor mRNA in somatostatin, but not
GHRH, neurons (Chan et al 1996). The level of GH increase in response to galanin is
higher in woman than men, and is proportional to oestrogen levels (Giustina et al
1993). Blocking endogenous galanin in male rats significantly disrupts the normal
GH release pattern (Maiter et al 1990). Pulse amplitude is severely reduced and pulse
frequency is increased. The evidence together suggests that galanin may mediate an
inhibitory connection from GHRH to somatostatin.
Neuropeptide Y (NPY) appears to be involved in the negative feedback from GH
at the hypothalamus. GH receptors are expressed on NPY neurons in the arcuate
nucleus (Kamegai et al 1996). NPY has been shown to stimulate somatostatin release
(Rettori et al 1990). Fos expression in response to GH has been detected in
conjunction with somatostatin mRNA in the arcuate and periventicular nucleus
(Minami et al 1992). Activation in the periventricular nucleus was only observed
after a 40min delay. In further study, the Fos expressing cells were matched with
somatostatin and NPY containing cells, but not GHRH (Kamegai et al 1994).
Synaptic connections between NPY neurons and periventricular somatostatin
neurons have been detected (Hisano et al 1990). Note that these results are all in
male rats. The evidence suggests that NPY may act to mediate stimulatory GH




Trying to judge the relative importance of these substances by examining their
potency is difficult because the only output which can be accurately measured is GH
release which many of them control indirectly through GHRH or somatostatin. To
cut down the complexity we must consider them in terms of functions rather than
specific substances.
The main source of control from outside the hypothalamus and pituitary appears to
be the adrenergic input, and this may be a good candidate for providing a basic
rhythm for the GHRH neurons, perhaps in a similar fashion to LH release system
which has a noradrenergic input. However, the apparent significance of adrenergic
inputs can be misleading. Many systems initially cease to function when this input is
removed but then after some time recover their activity, and they often only seem to
require the existence of the input rather than a specific input pattern, suggesting a
permissive role for the adrenergic input rather than any specific functional control.
The current mathematical model of GH release at the pituitary uses just GHRH
and somatostatin as its inputs and it is desirable to maintain this simplification, at
least initially. This leaves just the substances and structures which act in the
hypothalamus to consider. Dopamine does appear to be one of the key players in the
hypothalamus. There is good evidence that GHRH neurons contain tyrosine
hydroxylase (TH), which often indicates dopamine synthesis. Dopamine acts at the
somatostatin neurons in the periventricular nucleus, suggesting that dopamine may
mediate an excitatory link from the GHRH to somatostatin neurons. GABA seems to
mediate an inhibitory connection to the GHRH neurons, and the possible GHRH
release site suggests an auto-inhibitory mechanism. Neurotensin appears to play a
similar role to dopamine, released from the GHRH neurons and exerting a
stimulatory influence on the somatostatin neurons. However, the action of galanin,
providing an inhibitory link from GHRH to somatostatin, is supported by less
circumstantial evidence.
Ghrelin, the recently discovered endogenous version of the artificial
secretagogues, such as GHRP, has a potent stimulatory effect on GH release.
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However, this appears to be specifically related to feeding and weight control and
may not play a role in normal GH release.
GHRH and Somatostatin Interaction
There is evidence that somatostatin neurons may form direct synapses with the
GHRH cell bodies. Fibres containing somatostatin innervate GHRH neurons in the
arcuate nucleus (Daikoku et al 1988), although the origin of the fibres is unclear.
Somatostatin receptors have been detected in a sub-population of arcuate neurons
(Epelbaum et al 1989) and some of these have been identified as GHRH neurons
(McCarthy et al 1992). Subsets of GHRH neurons express mRNA for somatostatin
receptor subtypes, sstl and sst2 (Tannenbaum et al 1998). The density of arcuate sstl
receptors detected is 2-3 fold greater in male rats than in female rats (Zhang et al
1999). The sstl receptor subtype has also been detected in periventricular
somatostatin neurons (Helboe et al 1998). Selectively blocking these receptors
shows that sstl, but not sst2 is essential to normal GH release in male rats (Lanneau
et al 2000). Blocking sstl reduces GH pulse amplitude, without any large
disturbance to pulse frequency. Closer examination of the 15-min sampled GH
profile, however, suggests that blocking sst2 does produce more clearly defined
individual peaks within the GH pulse. In mice, knocking out the sst2 receptor stops
pre-administered GH blocking the arcuate nucleus Fos response to GH or GH
secretagogues (Zheng et al 1997), suggesting that sst2 receptors mediate inhibitory
GH-GHRH feedback.
The main uncertainty is the source of somatostatin acting at these receptors. It is
possible that the somatostatin cells in the arcuate nucleus act as inter-neurons
mediating a link to the GHRH neurons. However, neuro-anatomical tract studies
have found projections from the periventricular to the arcuate nucleus (Toth and
Palkovits 1998), leaving the possibility of periventricular somatostatin neurons
innervating the GHRH neurons. A small proportion of arcuate GHRH neurons also
appear to contact periventricular neurons (Fodor et al 1994).
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It is likely that some of the substances identified earlier are involved in mediating
interaction between the two main groups of neurons. Galanin may mediate an
inhibitory link from GHRH neurons to somatostatin neurons. There is also evidence
that opioid neurons may mediate a connection from somatostatin to GHRH neurons.
Opioids have been shown to increase GH release through an excitatory action on
GHRH neurons (Miki et al 1984) and there is anatomical evidence of connections
between periventricular somatostatin neurons and opioid neurons.
GH Feedback
NPY neurons in the arcuate nucleus appear to mediate stimulatory GH feedback to
the periventicular somatostatin cells. However, GH receptors are also found on
periventricular somatostatin neurons and GH appears to act directly at somatostatin
cells as well as through NPY. Most of the low level results unfortunately come from
just male rats. There has been argument over whether GH acts by inhibiting GHRH
or stimulating somatostatin release and suggestion that this may vary across gender.
GH induces Fos expression in arcuate somatostatin and NPY neurons (above) and
GH receptors have been detected in arcuate neurons (Minami et al 1993).
Comparison with arcuate somatostatin and GHRH cell distribution is so far
inconclusive but they have been colocalized with NPY neurons. The arcuate NPY
neurons appear to innervate periventricular somatostatin neurons and they may also
connect to the arcuate somatostatin neurons to mediate inhibitory GH-GHRH
feedback.
How GH might get into the central system is still a mystery. Large peptides of this




Rats show a particularly strong sexual variation in GH release. Behavioural results
suggest in particular that the effect of GH feedback varies between male and female
rats. In the arcuate nucleus, GHRH mRNA expression is approximately 2-3 times
higher in the male (Maiter et al 1991). Somatostatin mRNA expression in the
periventricular nucleus is also greater in male rats (Chowenbreed et al 1989). There
is not thought to be any difference in the number of somatostatin neurons, and the
assumption is that the greater levels of somatostatin mRNA expression in the males
indicate higher levels of synthesis and release activity in the somatostatin neurons.
Periventicular somatostatin peptide content is higher in males (Murray et al 1999a).
The sex differences are believed to mainly influenced by gonadal factors,
particularly testosterone and oestrogen. Testosterone acts through androgen receptors
on the somatostatin neurons to maintain somatostatin mRNA expression (Argente et
al 1990). Expression of the receptors themselves is sexually dimorphic (Herbison
1995). Oestrogen acts to feminize baseline GH and pulse frequency in male rats
(Painson et al 1992) but its site of action is less well determined. Sexually
differentiated oestrogen receptors are found in conjunction with somatostatin in the
bed nucleus of the stria terminalis but not in the periventricular nucleus (Herbison
andTheodosis 1993).
1.3.3 Electrophysiological Evidence
So far we have mainly considered evidence from experiments designed to detect
the existence and effects of substances when administered to the hypothalamus. The
trouble with the interpretation of such results, is that, in the CNS, there are many
systems within close proximity, which can make it difficult to draw certain
conclusions. Similar substances perform many different roles and their existence and
even apparent effects on a structure are not sufficient to conclude endogenous
involvement in the system being studied. With electrophysiological experiments we
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are taking a step back to a higher level view of activity. Stimulating one structure and
showing an effect at another doesn't give as much detail about the mechanism but it
does provide more certainty that we have discovered a real connection involved in
the system's function.
Unfortunately electrophysiological investigation of the hypothalamic systems
involved in the control of GH release suffers the major drawback that arcuate GHRH
neuron activity is blocked by anaesthesia. In addition, it has never been possible to
record from the periventricular somatostatin neurons because of their anatomical
layout, spread in a thin layer beside the third ventricle. However, this does still leave
two lines of approach; stimulation of the arcuate GHRH neurons, and concurrent
stimulation of the periventricular nucleus and recording from the GHRH neurons. It
is possible to stimulate but not record from the periventicular nucleus because
stimulation does not require such accurate electrode placement.
Stimulating the Arcuate Nucleus
The first of these approaches was used by Dickson et al (Dickson et al 1993) to
investigate the effect of different patterns of stimulation of the arcuate nucleus on
GH release. The idea of testing different patterns of stimulation, with varying
frequency and duration, came partly from a comparison with hypothalamic oxytocin
and vasopressin neurons, which have quite different optimal patterns of stimulation
with relation to the release response. Oxytocin neurons appear to be more dependent
on frequency of stimulation, whereas vasopressin neurons depend more on duration.
In a review paper Robinson (Robinson 1991) suggested that the varied patterns of
GH release across male and female might be comparable to the respective pulsatile
and phasic patterns of release seen in oxytocin and vasopressin neurons.
In the experiments blood GH was measured before and after a pattern of electrical
pulses delivered to the arcuate nucleus of anaesthetised male rats. A 50Hz (5s on / 7s
off) pattern of pulses applied for 5min was used to test whether direct stimulation
could elicit a GH release response. GH was measured 5 and lOmin after stimulation
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and showed a large release, comparable to endogenous pulses in conscious male rats.
For comparison, each rat was given an injection of GHRH at the end of the
experiment which showed a very similar GH release. The effect of stimulation
frequency was investigated by using three protocols; 10Hz (continuous), 20Hz (5s on
/ 5s off) and 50Hz (2s on / 8s off), each giving the same total number of pulses, but at
different frequencies, and repeated for 2min. All three protocols produced a GH
release, but smaller than the large response in the first experiment and with no
significant difference between the three. The next experiment tested the effect of the
number of stimulation pulses, using three 50Hz protocols with an increasing number
of pulses; (2s on / 8s off), (3s on / 7s off) and (4s on / 6s off). This time there was a
significant difference in the GH responses. The first protocol produced a small pulse
of GH release, the second produced a much larger response, and the third produced a
response comparable with endogenous GH pulses. The proportional increase in GH
release was much greater than the increase in the number of pulses, suggesting a non¬
linear relation between neuronal GHRH stimulation and pituitary GH release. This
was tested by comparison with the dose of injected GHRH required to produce the
same GH responses. However, doubling the dose of GHRH did not nearly produce as
great an increase in GH release as doubling the number of electrical pulses,
suggesting that the non-linear relation is at the level of the GHRH neurons.
These results clearly show that GH release can be elicited by direct stimulation of
the arcuate nucleus and since GHRH neurons make up a large proportion of the cell
population in this area it is likely to equate with their stimulation. The fact that this
works under anaesthesia also indicates that the loss of spontaneous release must be
due to suppression of these cells' excitatory inputs rather than their ability to
respond. The GH release in response to the optimal stimulation pattern was of a
similar profile and magnitude to that elicited by a maximal dose i.v. injection of
GHRH and it seems fairly certain that stimulation does cause a release of GHRH.
However, any of the other substances such as galanin, which have been colocalized




Stimulating the Periventicular Nucleus
Anatomical and pharmacological work had suggested that there was a connection
from the periventricular somatostatin neurons to the arcuate GHRH neurons and it
was also believed that the rebound release following somatostatin withdrawal was
mediated by some hypothalamic mechanism involving the release of GHRH. Okada
et al (Okada et al 1991) had shown that GH rebound release could be elicited by
directly stimulating the periventricular nucleus. If this was part of the endogenous
system then it would have to involve some link between the somatostatin and GHRH
neurons. Dickson et al (Dickson et al 1994) proceeded to investigate this by
attempting to concurrently stimulate the periventricular somatostatin neurons and
record from the arcuate GHRH neurons in anaesthetised male rats.
To identify possible GHRH neurons, cells were tested for projection to the median
eminence using antidromic identification. A total of 53 arcuate neurons were
identified in this way and classed as the AD group. Most of these cells were
spontaneously active, but with a mean firing rate of less than 2Hz. Another
comparison group of 29 cells was identified which did not project to the median
eminence and showed bursting type spontaneous activity. These cells had a similar
mean inter-spike interval (ISI) to the AD cells but a much shorter modal IS I,
reflecting the burst type activity. Cells which didn't fit either group were rejected for
use in the rest of the experiment.
Each cell left in the two groups was tested for its response to 5min of
periventricular stimulation at 10Hz. Out of all the cells tested 54% were inhibited
during stimulation, and 15% were excited, while the rest showed no response. There
was no significant difference between the two groups, although a slightly larger
proportion (64%) of the AD cells were inhibited during stimulation. Recording from
the arcuate cells continued after the end of the periventricular stimulation in order to
test for a rebound response. Out of the AD cells which were inhibited during
stimulation, 40% showed a rebound hyperactivation, with a firing rate significantly
higher than before periventricular stimulation. However, the same response was
found in 27% of the bursting group which were inhibited. A further attempt to
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separate the two groups was made by testing their response to stimulation of the
basolateral amygdala. Stimulation in this area has previously been shown to cause
the release of GH without releasing other pituitary hormones and is thought to act by
stimulating GHRH neurons. Of the AD cells, 57% were excited by stimulation of the
basolateral amygdala but there was still no significant difference to the proportion
which responded from the bursting group.
These results give strong evidence for an inhibitory connection from the
periventricular nucleus to neurons in the arcuate nucleus, and it is likely that many of
these arcuate neurons which project to the median eminence contain GHRH. The
strong rebound activation, including some of those which were excited or
unresponsive during stimulation of the periventricular nucleus, is also good evidence
that this may be the hypothalamic mechanism which mediates the GH rebound
release in response to somatostatin, and detecting such a mechanism at this level
gives further suggestion that it may be part of the endogenous system. Despite testing
with several criteria, the bursting cells continued to show similar responses to the
antidromically identified neurons and it is quite possible that these represent a
population of interneurons which are connected to the GHRH neurons.
1.4 Methods
The experimental system for this project is a set of differential equations
implemented as computer software. This produces a graphical display of the model's
output and allows the model's parameters to be immediately adjusted. It also
includes several other features for examining the output graphs, such as measuring




Differential equations are equations which, instead of giving some static absolute
value, define how a value changes with time, or some other progressive measure.
The simplest example is speed, which is the differential measure which tells us how
distance changes with time. In the model, we represent the static state of a system
using a set of variables which represent values such as blood GH concentration,
somatostatin concentration or lower level properties such as a measure of the number
of free pituitary GHRH receptors. Each equation defines how an individual variable
changes, often using previous values of that variable and other variables in the
system. The equations will also include parameters, values which do not change
while the model is running, but which can be changed to alter the behaviour of the
equations and consequently the whole system to some lesser or greater degree.
Parameters can often be related to values such as the strength of a synaptic
connection or may belong to more obscure mathematical constructions.
Computer Implementation
The current version of the model program is coded in C++ and runs on a Windows
based PC. The user interface code makes use of the Microsoft Foundation Classes
(MFC). The original version of the model program was developed in C, but it was
decided that recoding it in C++ would make it easier to adapt and maintain in the
future.
The program displays each of the model variables as a graph against time, and
allows all of the model parameters to be adjusted and the model instantly rerun. The
previous model software, used to develop the pituitary model was an old Fortran
program implemented on a UNIX system. Parameters had to be changed by editing a
text file and the whole program had to be rerun. Displaying the results involved
typing text commands and it became a lengthy process. Making the program easier to
use has made it much easier to experiment with the model and visualise the results.
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In addition to learning the techniques necessary for creating the user interface, it
was necessary to learn how to accurately implement differential equations in a
computer program. Differential equations theoretically model analogue values to an
infinite degree of accuracy and so any computer implementation is always an
approximation. The method which the model program currently uses is the Runge-
Kutta algorithm. This runs fairly quickly and is sufficiently accurate for the type of






This chapter describes the pituitary GH system and the model developed by the
PhD work of Elinor Stephens. The model was chosen from several alternative
designs based on alternative interpretations of the experimental data on the pathways
by which GHRH and somatostatin control GH release. It was based on data from in-
vitro experiments in the pituitary and successfully fitted to quantitative in-vitro data.
As new work for this project, the model has been reproduced and used to experiment
with alternative formulations of possible GHRH and somatostatin input patterns, in
an attempt to work back from what we know about GH release to a more refined set
of possible input patterns from the hypothalamus.
2.2 The Pituitary GH System
The pituitary is essentially a factory which synthesizes and releases hormones
under the control of the hypothalamus. The posterior pituitary forms a delivery
system which releases the two peptide hormones oxytocin and vasopressin which are
synthesized in the hypothalamus and directly transported to the pituitary by axonal
connections, for release into the bloodstream. The anterior pituitary is a more
complex system which manufactures and releases the larger protein hormones.
Hormone synthesis and release at the anterior pituitary is controlled by hypothalamic
peptides which are released by the terminals of hypothalamic neurons at the median
eminence into the portal blood supply, which carries them to the pituitary. This form
of transport means that the pituitary cells receive single combined signals from each
peptide rather than many pulses from the thousands of hypothalamic neurons.
Growth hormone is synthesized and released by anterior pituitary cells called
somatotrophs. These receive two major signals from the hypothalamus, GH releasing
hormone (GHRH) which stimulates release and synthesis of GH and somatostatin
which inhibits the release-triggering action of GHRH to block GH release. Several
other substances act at the pituitary to affect GH release, but usually by modulating
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the actions of GHRH and somatostatin. One exception is the synthetic peptide,
growth hormone releasing peptide (GHRP) which also stimulates GH release,
behaving in a similar manner to GHRH.
2.2.1 The Response to GHRH
GHRH triggers an almost immediate release of GH into the bloodstream in a dose-
dependent manner up to a maximal level. The somatotroph stores synthesized GH,
and it is this stored GH which is preferentially released in response to GHRH rather
than newly-synthesized GH. If the pituitary is exposed to a prolonged infusion or
very frequent pulses of GHRH then the response will desensitise, recovering with
time after the exposure to GHRH. With desensitisation, the GH release response to
GHRH gradually falls to a level which remains above basal pituitary GH release. The
mechanism of desensitisation is still a matter of research. Prolonged exposure to
GHRH in-vitro or in-vivo results in a depletion of pituitary GH stores but this takes a
long time, at high doses, and is insufficient to explain the relatively short term effect
which is observed. What is also likely to play a role, and is perhaps the major factor,
is some type of receptor desensitisation, or down-regulation in the pathway between
receptor and release, and various possibilities for this mechanism form the variations
in the design for the pituitary model.
In addition to triggering release, GHRH also stimulates the synthesis of GH, an
action which is not blocked by somatostatin, so while the release action may
sometimes be inhibited, GHRH will continue to stimulate the synthesis and
subsequent storage of GH at the pituitary. This action is triggered by the same
receptors on the somatotrophs but acts through a pathway which somewhere diverges
from the release pathway. The synthesis action is also much slower than the
relatively immediate release response.
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2.2.2 Cellular Mechanisms of the GHRH Response
The release component of the GHRH response appears to act by triggering an
influx of calcium which causes the exocytosis of stored GH vesicles. GHRH binds to
a G-protein linked membrane receptor which activates adenylate cyclase and causes
a rapid, but transient, increase in cyclic adenosine monophosphate (cAMP). This
triggers the rise in intracellular calcium, mainly by opening voltage activated L-type
calcium channels, but also by causing release from intracellular calcium stores.
Release from intracellular stores is insufficient to cause exocytosis alone but may
regulate genesis and docking of secretory vesicles (Blondel et al 1995). The rise in
intracellular calcium is also thought to inhibit adenylate cyclase activity, causing a
temporary de-activation of the G-protein receptor triggered calcium influx and
limiting the release response to GHRH. However this process acts on a timescale of
seconds and is not a candidate for the desensitisation mechanism. Desensitisation to
GHRH in-vitro takes about 20min and so possible mechanisms must be capable of
acting on this timescale. There is also a lack of cross-desensitisation between GHRH
and GHRP, which further reduces the possibilities, particularly suggesting something
in the triggering pathway rather than depletion of GH stores, unless GHRH and
GHRP trigger release from separate stores, which seems unlikely. The best
candidates for the desensitisation mechanism are receptor down-regulation, down-
regulation of the second messenger pathway, and depletion of readily releasable GH
stores.
GHRH receptor down-regulation has been shown to take place, acting over a
period of hours. All G-protein linked receptors undergo desensitisation after receptor
binding as part of the activation process. Many other similar types of G-protein
linked receptors, such as the LHRH and GH receptors, are internalised after binding,
a process which appears to be necessary for recycling the receptor, and the GHRH
receptors may undergo a similar process. An alternative mechanism for receptor
desensitisation may be decoupling of the activation process, removing the ability of
the G-protein to activate adenylate cyclase.
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There is no doubt that the stores of GH can be depleted and that this will result in a
reduced release response to GHRH, but this is probably not the main mechanism
behind the relatively fast desensitisation which is observed. The fast onset, recovery
and magnitude of desensitisation all suggest a mechanism which is closer to
switching off the release response rather than something that is being gradually used
up, such as the stored GH. However, this possibility can be refined by considering
the process by which the stored GH-containing vesicles are transferred from the
cell's storage compartments to the cell surface, where the vesicles can fuse and
release GH. It is thought that the vesicles do not move freely within the cell, but are
transported by a network of microtubules. This limits the amount of GH which is
close to the cell surface and ready for fast release, giving the idea of a readily
releasable store, which may be used up and replenished more quickly than the cell's
main store of GH. This provides a possible mechanism, but again it would require
that GHRH and GHRP access, at least partially, separate pools of releasable GH.
There is also evidence that desensitisation may take place at the stage of the
second messenger pathway which triggers the cAMP response. The cAMP response
to GHRH stimulation in rat pituitary cells exposed to a chronic infusion of GHRH is
reduced but the same cells continue to release GH in response to cAMP stimulators
or artificial replacements (Ceda and Hoffman 1985). This would be consistent with
the independent desensitisation between and GHRH and GHRP since their activation
pathways are less likely to be shared.
2.2.3 The Actions of Somatostatin
Somatostatin acts quickly at the somatotrophs to inhibit basal GH release and block
the release-triggering action of GHRH, but not the effect of GHRH on GH synthesis.
Somatostatin effectively controls the pattern of GH release by exerting permissive
control over the release action of GHRH. In addition, somatostatin appears to act to
reverse the desensitisation to GHRH, and this may be more than just another effect of
its blocking action. Treatment with somatostatin following exposure to GHRH
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increases the rate of recovery from desensitisation, suggesting that it may actively
reverse desensitisation. Somatostatin treatment before exposure to GHRH also has a
'priming' effect, increasing the response to a subsequent exposure to GHRH
(Dickerman et al 1993).
If a large dose of somatostatin is used to block release from the pituitary, then it
will be followed by a rebound release of GH which does not require GHRH,
although a pulse of GHRH coinciding with somatostatin withdrawal will produce a
much larger rebound pulse of GH. A longer suppression with somatostatin, up to 20
min, will produce a larger rebound response. This rebound action is probably related
to the other actions of somatostatin, either because it inhibits GH release while
synthesis continues, allowing the releasable store to build up, or by its ability to
reverse desensitisation, increasing the GH release second messenger pathway
responsiveness.
2.2.4 Cellular Mechanisms of Somatostatin Action
There are several different G-protein linked receptors for somatostatin on the
somatotrophs. One of these inhibits the action of adenylate cyclase and the others are
believed to regulate ion channels and exocytosis. Somatostatin acts to inhibit
adenylate cyclase, and this is likely to be one of the ways it blocks the action of
GHRH. This results in a reduction in cAMP, but only partially. The effect of GHRH
on GH synthesis is also mediated by cAMP and it is probable that there are at least
two independent cAMP mediated pathways activated by GHRH. Somatostatin only
appears to block one of these. However, somatostatin also blocks the release pathway
beyond cAMP activation. When somatostatin is administered with a cAMP analogue,
the inhibition of GH release remains, even with the elevated cAMP levels. This may
be due to one of the somatostatin receptors working on ion channels. One of the
somatostatin receptors acts to increase potassium conductance, thereby
hyperpolarizing the cell and preventing the influx of calcium, which is required for
exocytosis. This also blocks the release-triggering action of GHRP.
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2.3 Developing the Model
Taking first of all a top-down approach, the first stage in modelling is to outline
what is known about the target system in functional terms. This will form both a
basis for the model, and a target, a set of goals which the model must meet.
However, there may be several possible explanations for each of these functional
components, and if the model is to be based on a simplified representation of the
biological components which are responsible for each functional component of the
system, rather than just replicating their high level behaviour, then the choice of the
biological basis will affect the properties of the component. In fact, modelling comes
into its own at this stage, providing a formal system in which to test alternative ideas
as to how an observed behaviour may arise. The model representation should be as
simple as possible, but in modelling a system at this level, it is important to maintain
a representation which relates to the biology, in order not to miss hidden properties,
and to be able to relate conclusions back to the real system.
2.3.1 The Functional Pituitary GH System
These are the functional components as outlined in Elinor's thesis :
i) GHRH stimulates GH release in a dose-dependent manner
In-vitro, exposing GH cells to varying doses of GHRH for a fixed duration
produces GH release according to a classic sigmoidal dose-response relationship
with the logarithm of the GHRH dose. The magnitude of the response also varies
with the duration of exposure. In response to a single pulse of GHRH, cells produce a
single pulse of GH which varies in magnitude with the duration and magnitude of the
GHRH pulse. The same relationship is observed in vivo in the female rat when given
injections of GHRH, but not in the male rat, where the GH response magnitude
varies, probably because of periodic high levels of somatostatin.
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ii) Dose-dependent desensitisation to GHRH
During an infusion of GHRH, GH cells in-vitro initially produce a large GH
response, but the rate of release rapidly decreases, following a roughly exponential
decline. Responses to succeeding pulses of GHRH depend on the pulse frequency
and magnitude. The first pulse will elicit a large pulse of GH, but if a subsequent
pulse of GHRH occurs too soon after, it will produce a smaller pulse of GH. Larger
GHRH pulses require a longer interval between pulses to get the same GH response.
Hi) Somatostatin inhibits GH release in a dose-dependent manner
When somatostatin is also infused, a GHRH infusion produces a GH dose-
response curve of the same sigmoidal form but with a reduced magnitude. The
response to pulses of GHRH is reduced with somatostatin infusion and the basal
level of GH release between pulses is also lower. The inhibitory effect of
somatostatin is dose-dependent, and a large enough dose can entirely block any
significant GH release.
iv) Somatostatin can prevent desensitisation, and can increase responsiveness to
GHRH
Infusing somatostatin between GHRH pulses reduces the time required between
each pulse to elicit the same large response, apparently accelerating response




v) Rapid removal of somatostatin cause a GHRH dose-dependent rebound release of
GH
When somatostatin infusion is terminated, for a short period GH release increases
to a level above that which occurred prior to somatostatin treatment before falling
back to the basal level. The rebound is larger following a higher dose or longer
duration infusion of somatostatin. The rebound is much larger however if
accompanied by a pulse of GHRH. If GHRH is infused during the somatostatin
infusion then the rebound will be smaller indicating that desensitisation to GHRH
occurs even while somatostatin is blocking GH release. This concurs with the in-
vivo results (section 1.2.1) which demonstrated that somatostatin can block
spontaneous (endogenous GHRH pulses) and artificial GHRH pulse induced GH
release, and that following the end of the somatostatin infusion there is a very large
release of GH which can be suppressed by knocking out endogenous GHRH.
vi) Basal GH release
GH cells in-vitro produce a constant low level of GH release which is reduced by
somatostatin infusion, or by taking away extra-cellular calcium. This suggests that
there is constant activity in the calcium-regulated exocytotic pathway and also some
constitutive activation of the intracellular pathways which trigger GH release in
response to GHRH.
2.3.2 The Underlying Mechanisms
Together, these functional components form the basis and target for the model, but
before these can be translated into a form which can be directly modelled, their
biological mechanisms must be examined in order to decide exactly how to model
them. Most of these components are well-understood processes that can be modelled
using standard techniques, but the processes behind the desensitisation to GHRH and
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somatostatin's effect on this are uncertain. Elinor's thesis re-examines the possible
biological mechanisms for this process and develops several options for proceeding
with the modelling.
a) Depletion of readily-releasable reserves
This is based on the idea that there is a complex process required to get from GH
synthesis to exocytosis, requiring transport from the synthesis site through a system
of microtubules to the readily releasable reserve of docked GH vesicles at the
membrane. The nature of such a system means that the store of releasable GH can be
rapidly depleted but only replenished more slowly. The main argument against such
a mechanism is the lack of cross-desensitisation between GHRH and GHRP. This
would require separate pools of releasable GH or even different types of GH cells
responding to only GHRH or GHRP and there is no evidence that this is the case.
There is some heterogeneity in response between individual somatotrophs, but no
apparent separate populations. Ties between release pools and particular receptor
types are also unlikely since part of the release pathway involves diffusible second
messengers that can not be so precisely targeted. The other option is desensitisation
in the second messenger pathway at some stage which is not common to GHRH and
GHRP, or receptor down regulation. Rejecting the notion of depletion of a releasable
pool will allow the model to treat the supply of GH as essentially unlimited since
depletion of the entire GH reserve requires sustained release for a period well beyond
the time scale of the model.
b) Desensitisation in second messenger system / down-regulation ofGHRH receptor
GHRH and GHRP bind to different receptors and trigger second messenger pathways
that remain independent until voltage-gated ion channels trigger calcium entry and
exocytosis. The lack of cross-desensitisation indicates that desensitisation occurs
independently in the two pathways, prior to where they converge. Elinor's thesis
takes this alternative as the way to proceed with the model, although she still
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develops a model representation of a releasable pool for comparison. This turns out
to produce a form which actually functionally equivalent to the model based on
receptor / pathway desensitisation.
2.3.3 The Model Representation
The release pathway is complex, involving several levels of dynamics; receptor
binding and recycling, a finite pool of G-proteins, saturable second messenger
systems, finite numbers of ion channels and the channel dynamics themselves.
However, attempting to model this in its entire complexity, even if successful, will
still only understand the system at the same low level. From a bottom-up approach
(in complement to the top-down approach described above), the goal of modelling
larger parts of the brain should be to reduce the apparent complexity of the system, to
understand what it is really doing at a functional level. Much of the low-level
complexity in a biological system is necessary to the implementation, but is not
representative of function. Many of these dynamics will be compensating against
each other, or forming together, to produce what may actually be quite simple
dynamics. The reason for examining the system at a low level is to choose the right
simplification rather than to reproduce the complexity. With this goal in mind,
Elinor's thesis develops several alternative models for this part of the system, based
on the Law of Mass Action, the idea that substances and processes can be treated as
continually changing concentrations (variables) and rates of reaction (parameters in
equations) which define how the concentrations affect each other. The model is
intended to work on a timescale of minutes and it ignores processes which are only
significant on a much longer timescale, such as cell growth and GH synthesis.
The model itself consists of a set of variables, each representing some substance or
the state of some component of the system, and a set of differential equations which
describe how these values interact with each other.
The first stage in the process of GHRH triggering GH release is the binding of
GHRH to its receptors. The level of binding will be proportional to the product of the
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concentration of GHRH (the variable r in the model) and the concentration of free
receptors (f in the model). This variable/really represents the ability of the system as
a whole to react to GHRH, but the simplest translation back into biological terms is
to call it the number of free receptors, since these will likely form the major limit on
the response. As GHRH enters the system, and binds to and activates receptors, /
declines proportionally. The level of binding and the subsequent activation of second
messengers is represented by the variable u. This value is then used as a signal to
generate GH release using a sigmoidal relationship. The original design version of
the model also uses a third variable w in this part of the system to represent the
refractory period in the transition from bound activated receptors, u, back to free
receptors, /. This value w could be translated back into some element such as
internalised receptors, in the process of being recycled, or the kinetics of ion
channels with minimum closed and open times. These three variables are tied
together by a principle of conservation s.t. f + u + w = constant. As the level of
activation, u, increases,/is used up. The level of GH release increases proportionally
to u, which then decreases again, increasing w. The cycle is completed as w is
depleted to restore /. This means that the system's capacity to respond and trigger
GH release is conserved and also limited, ensuring saturation in the GHRH-GH dose-
response curve.
Somatostatin inhibits GH release in at least two ways, by activating potassium
channels to hyperpolarize the cell and prevent voltage-gated calcium entry and also
by inhibiting the increase in adenylate cyclase triggered by G-protein linked GHRH
receptors. Both of these processes are essentially limiting the transduction of GHRH
triggered activation into GH release and so this inhibition is represented by making
the u dependent rate of GH release also inversely, and non-linearly, proportional to
the somatostatin level. The non-linear relationship means that there is a maximal
level of somatostatin which almost completely blocks GH release. Somatostatin's
ability to accelerate the resensitising process is modelled by making the rate of




This basic design for the model still leaves the construction of the actual equations
and final options about how to implement the functional properties. During the
original development of the pituitary model, several versions were produced before
settling on a final refined version of the model.
The prototype design version of the model uses six variables; the GHRH level (or
concentration), r, the somatostatin level, s, the GHRH-GH release system variables,
/, u and w, and the GH level, li. GHRH and somatostatin are modelled by simple
equations that contain just an input component, specified from outside the model and
a decay component representing clearance in the pituitary bloodstream.
Model 1
The first stage of designing the equations was to develop a function which would
give the non-linear relation between the variables u and S and the processes they
control, GH release and resensitisation. The following model equations were






1 + e (-s-s0)/S0
These give a non-linear form (similar to those illustrated in figure 2.1) which is
controlled by a threshold parameter, uo or so and a rate parameter, So or Sj. Most
processes where one substance controls another have some sort of threshold,
otherwise insignificant levels of a substance would have a disproportionate effect on
the model's behaviour. The non-linear increase in activation represents the smaller
increase in effect with the same increase in the substance at already high levels. The
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equation is scaled to give values between 0 and 1. By changing the steepness
parameter the function can produce a gradual increase in activation or act as a sharp
switch when the value exceeds the threshold.
Figure 2.1 : Activation curves for receptor recycling Ofc(.y) and GH release inhibition ®r(s)- These
example curves are from the final version of the pituitary model, but use the same form as ®(u) and
®(j) in the first prototype version. Parameters are So = 0.029, 5o = 0.3 (top left); si = -0.56, 5| = 0.3
(bottom left). The right hand curve shows the effect of using a smaller 6 value to increase the gradient
and produce a more switch-like activation, parameters si = -0.56, 5] =0.1. (Note : These parameters
and equations refer to the final version of the model, not the version 1 prototype in this section.)
The activation value (P(u) is used for the rate of GH release and the rate of transfer
from u to w. The activation value 0(s) is used for the transfer from w to /,
representing the effect of somatostatin on the recycling process, and also on the
transfer from u to w, increasing the rate of w's depletion, to inhibit GH release. This
gives the following set of differential equations for the GHRH-GH release system :




— = k\rf ~ (*4 + k5®(s))u - k6$>(u)
at
dw
— = (^4 + k5<&(s))u-(k2 + k3<i>(s))w + k6<S>(u)
dt
~ = k9<t>(u)-kl0h
At this stage the model (figure 2.2) can be simplified because of the principle of
conservation that dictates that/+ u + w =fT, where fT is a constant which defines the
maximum potential for activation. This means that only two of these equations are
required, and if the equations for u and/are kept then w is defined by w = fr - u -/.
The rate parameters are set so that when the somatostatin level is low and u is high
then the rate of GH release will be greater than the somatostatin-controlled transfer
from u to w. The low level of somatostatin will also mean a slow transfer from w to/
so that when GHRH triggers transfer from/to u and subsequent GH release,/will
fall causing desensitisation to GHRH. Conversely, when somatostatin is high, u will
fall quickly, suppressing GH release, and transfer from w to f will be faster,
accelerating resensitisation. GH release itself is modelled simply as the activation
due to u, a{u) modified by a rate parameter and a decay component.
This first version of the model was tested by adjusting the parameters to produce a
roughly realistic response between input levels of GHRH and somatostatin and GH
release. The model produced the desired basic behaviour but not the desired
dynamics. The main problem was that u is depleted as fast as it triggers release and
so it never gets much above its threshold value, uo, causing very low levels of GH
release. It was also considered at this stage that modelling somatostatin inhibition by
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Figure 2.2 : Model prototype 1. Pathway begins with binding of r and/, depleting/and increasing u.
Variable u is depleted by two routes, one dependent on somatostatin, and the other proportional to GH
release. Release will only occur when u is high enough to defeat depletion due to the somatostatin
dependent term, allowing <P(s) to control release. The 0(.v) term in the transfer from w to f allows
somatostatin to accelerate resensitisation.
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k, rf [k2 + k2®(s)] u
[kA - k5 <D(s)]
Figure 2.3 : Model prototype 2. Pathway begins with binding of r and/, depleting/and increasing u.
There is now a direct somatostatin dependent route back to /. Transfer from u to w is inhibited by
somatostatin so that the new direct route is preferred when <t>(s) is high. Release is directly
proportional to u. Model function is similar with k5 = 0 and so this term can be removed, since the &3




The first change was to shift the somatostatin-controlled resensitisation component
so that it transfers directly from u back to/. This gives two pathways, and returning
to the biological interpretation, creates two possibilities for a bound GHRH receptor.
It could fail to activate the whole pathway, either because of failing to associate with
a G-protein or failing to activate adenylate cyclase (which can be inhibited by
somatostatin), and end up just being recycled. Alternatively, it successfully triggers
the whole release pathway, and follows the path back to / through w. The balance
between these two paths is controlled by somatostatin, so that a high level of
somatostatin causes more transfer directly back from u to/, causing w's depletion and
inhibiting release. The second change in this version of the model is just to get rid of
the component that depletes u at the same relative rate to release. The rate of transfer
from u to w and u to/, not controlled by somatostatin is then just proportional to u,
rather than the release rate. The new equations are given below :
— = -kprf + (k2 + k3<S>(s))u + k6w
dt
— = kxrf - (k>2 + k3<i>(s))u + (k4 - k5<&(s))u
dt




In this version somatostatin increases the rate of the immediate recycling route and
also decreases the rate of transfer through the full release pathway, controlled by
parameter ks. The model still behaves in the same manner with k5 = 0, taking away
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the negative effect of somatostatin on the release pathway, and so it can be simplified
by removing this component. The positive somatostatin component, increasing direct
receptor recycling, implements inhibition in a less intuitive manner, but also fills the
role of accelerating resensitisation, although at the expense of u. However this indeed
turned out to be the downfall of this version of the model. No combination of
parameter values was able to produce the desired behaviour and it was the clear that
the major flaw was transfer from w to/not being dependent on somatostatin. When
the level of GHRH is increased and release is triggered, increasing w, then
somatostatin has no way to accelerate the restoration of/ Any changes to parameters
to allow quicker resensitisation, essentially by limiting the transfer to w, also caused
insufficient desensitisation, allowing prolonged high levels of release. The value for
u tended to stay near its maximum, requiring the threshold for activation due to u to
be set very near this maximum value and to be made very sensitive.
The conclusions after testing this version suggest two solutions to the problem
with w's profile. The version of the model here requires the rate of transfer in and out
of u to be similar, so the level shows little variation, but what could be measured
instead is the rate of flow rather than the actual level. The first suggested way to do
this would be to have a time delay in the transfer from u to w, but the software which
was being used to implement the model didn't allow such a feature. This would stop
m's content being immediately returned to/, enforcing desensitisation but it would do
so in quite a rigid fashion, depending on the length of fixed delay rather than the
amount of GHRH input. The second suggestion was to differentiate between freshly
bound contribution to u and older content of u but again this presented the problem
of a fixed arbitrary point, dividing between 'new' and 'old' making the model unable
to produce a similar type of response to different lengths of GHRH pulse.
48
Chapter 2






k,rf [k2 + k2 0(s)] u
[*4 (1 - ®(.v)) + k5 CD(S)] rf
[kg (1 - ®(s)) + kw ®(5)] rf
kjj h
Figure 2.4 : Model prototype 3. Pathway begins with binding of r and/, depleting/and increasing u.
Binding is reversible, allowing a direct, partially somatostatin dependent, route from u back to f. The
rate of transfer from u to w, and GH release, is now proportional to the rate of binding. The
construction with two opposing ®(.v) terms is intended to force preference for the direct route when




The third version of the model replaces the transfer from u to w and also GH
release with a construct proportional to the rate of binding (the product of r and f)
which has two components, proportional and inversely proportional to somatostatin,
balanced by their parameters so that the direct recycling route is preferred in the
presence of somatostatin, and the release route otherwise. This allows somatostatin to
directly inhibit transfer from u to w and GH release and uses the rate of u's increase
rather than its absolute level. It also matches the rate of release to the transfer
between u and w. These changes gave the set of equations below :
-j- = -kxrf + (k2 + k2<t>(s))u + k6w
~T~= kprf - (k2 + k^(s))u + *, (1 - - k5<S>(s)rf
at
^- = k4(l-<P(s))rf + k5®(s))rf -k6wat
dh
— = kg (1 - 0(s))r/ + k10<&(s)rf - kxxh
dt
To correct the problem of somatostatin-independent resensitisation after GHRH-
triggered release an extra reverse connection from w to u was added, creating a path
for somatostatin-controlled transfer back from w to/, through u. After adjusting the
parameter values this version of the model was able to successfully produce the
desired behaviour, comparable to the real system. With these parameter values, w
stayed at a very low value, effectively not being used and indicating that it could
actually be entirely removed from the model.
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2.3.5 The Final Model Design
Working with these prototypes highlighted a particular problem with designing a
model in this manner. Although it makes sense intuitively to use variables to
represent stages in the process, in the real system there are time delays, so that the
components do actually store something for a time and record what is going on.
However, with just the differential equations and instantaneous change, the variables
tend to stay at either a high or low level, not really giving any representation of their
inputs and outputs. The solution to this was to use the rate of increase rather than the
variable itself, the main example being using the rate of binding, rf, instead of u. The
model can still have components which directly use a variable, but they shouldn't be
set up to produce too much concurrent input and output activity. The final version of
the model also removes w, effectively just cutting it out of the system. The
component u takes over the representation of the desensitised, activated state. The
principle of conservation remains, and this means that the model can be further
simplified by replacing u withfr-f
The model's central process is the reversible binding which transforms r +/into u.
The bound receptors are continually recycled at a rate proportional to u, with a slow
constant component and another faster path controlled by somatostatin. The model
still uses the original activation equation for somatostatin, but the one for u has been
replaced by the binding rate. GH release triggered by GHRH is composed of two
components proportional to rf. One is constant, giving a level of release which isn't
blocked by somatostatin and will normally be very small. The other, larger release
component is inversely proportional to somatostatin, allowing somatostatin to block
release in a dose-dependent manner. The biological interpretation of this final form is
that somatostatin blocks GH release at the final stages of the pathway, preventing
depolarisation and calcium-dependent exocytosis of GH. In addition to GHRH-
triggered release, there is some constitutive activation in the GH release pathway,
which produces basal GH release, and is also sensitive to inhibition by somatostatin.
To simulate this in the model a small constant, c, is added to the GHRH level, r.
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The final problem with the model was that the level of GHRH was being
controlled by the reverse link in the transfer from u to f and r. This was causing
significant depletion of the GHRH level if somatostatin was increased when GHRH
was already high, due to the replenished/, causing more binding with r faster than r
was being replenished. In the real system the amount of GHRH is much larger than
the number of available receptors and so the GHRH level should never be
significantly depleted by binding. This was fixed in the model by just taking away
the components of the GHRH equation which modified the level of GHRH with
binding and receptor recycling.
The behaviour of this final simplified version of the model is no less complex than
prototype version 3, maintaining all the functional properties, along with the
improvements, and the model successfully produces all the behaviour from the
original specification. The final form of the pituitary model's equations, those used
for the further work to go on and develop a model of the complete system, are
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Figure 2.5 : Final pituitary model design. Pathway begins with binding of r and /, depleting / and
increasing u, at a rate increased by c to represent constitutive activation. Binding is reversible,
transferring from u back to / at a rate accelerated by somatostatin. Release is proportional to the
binding rate with a smaller non-somatostatin dependent component (k4) and a larger component (k5)
inhibited by high somatostatin levels. Conservation between / and u s.t. f + u = fT allows u to be
replaced by 1 - fT.
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2.4 Fitting to Real Data
In the second part of the previous thesis the model was fitted to real data to
calibrate its parameters to give a quantitative, as well as qualitative, match to real
data. Two types of in-vitro experiment were used to fit the model; perifusion, which
measures the model's response to discrete pulses of input substances such as GHRH,
and static incubation, which measures the total amount of release in response to long
infusions of GHRH and somatostatin, usually to get dose-response relationships.
2.4.1 Perifusion Experiments
In these experiments an in-vitro preparation of isolated pituitary cells from male
rats was contained in a dish with a constant flow of perifusate, a mixture of the
substances used to keep the cells alive and whatever might be released from the cells.
At one minute intervals a sample of the perifusate was removed to be assayed for GH
in order to produce a temporal profile of the GH response to various substances
added to the preparation, particularly GHRH and somatostatin and also GHRP.
To fit the model to the perifusion data, a special formulation of the model's
equations was developed which used a reduced number of parameters and could be
directly compared with the in-vitro experiment's inputs and outputs. This was fitted
to the experimental data using non-linear regression and the fitted parameter values
were translated back into estimated parameter values for the original model. On the
whole good fits were achieved, but for some parameters, particularly those
describing the rate of resensitisation, it was not possible to get consistent values
across all of the experimental data which was being used. There were also problems
due to the limitations of the in-vitro preparations, such as leakage of GH due to cell
damage, increasing the apparent basal release to a level more significant in relation
to the level of release during stimulation than it would be in-vivo. The final fitted
values however are a good representation of the system. The uncertainty in the
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values of some of the parameters is not great enough to have a large effect on the
model system's behaviour.
2.4.2 Static Incubation Experiments
These experiments test the response of a preparation of GH cells to an infusion of
some substance such as GHRH in order to measure the total amount of GH released
in response to a particular concentration of the stimulating substance. The results are
used to produce a dose-response curve mapping the GH response to a range of
concentrations of GHRH, with and without the presence of somatostatin. This is in
contrast to perifusion experiments which record the GH response on a temporal axis.
The dose-response curve for GH in response to GHRH is sigmoidal with the
logarithm of the GHRH concentration. The magnitude of the GH response in the in-
vitro experiment depends on factors such as the number of cells and their condition
after cell dispersion, and so the result can only give a relative measure of the range of
GH release in response to GHRH, rather than an absolute measure of the maximum
level of GH release. For the fitting a specialised formulation of the model was used
to match the form of the infusion experiments with a reduced set of parameters,
similar to the form used for the perifusion experiments. Experimental data from
several different sources was used and the units had to be scaled to a common
measure for GH and GHRH. It was possible to get good fits to the data but not with a
unique set of parameter values and the only way to get a unique set of parameters
values was to fix the parameter describing the rate of resensitisation. Testing the
quality of fit over a large range of values for this parameter produced very similar
scores, indicating that the infusion experiments don't preserve enough information
about the system to determine this parameter. However, it was possible to combine
the fitted values from the infusion experiments with the better constrained values




2.4.3 Finalising the Parameters
Once a set of fixed parameters had been derived for the formulation of the model
used for fitting, these values were used to produce estimated values for the
parameters of the full model (table above). In further work subsequent to the thesis,
(Brown et al, unpublished), the parameters were tested with more experimental data
and managed to get a good fit with values which were identical or only slightly
different to the previously fitted values. This confirmed that the model together with
the fitted parameter values is a good qualitative and quantitative representation of the
real pituitary GH release system. The quality of the model's fit to the data is also
evidence to back up the model's biological basis and the significance of the
mechanisms on which it is based. The pituitary model now gives a firm base on
which to build and test ideas about the rest of the system, the hypothalamic networks
which generate the patterns of GHRH and somatostatin release.
2.5 The Pituitary Model
The first objective of this thesis project was to reproduce Elinor's pituitary model,
produce a new software implementation and then to reproduce and extend her results,
in the direction of preparation for modelling the hypothalamic systems. This section
first presents the equations for the final form of the pituitary model with some
description of their function and the parameters which control them. The second part
describes the first results using the pituitary model, reproducing those in Elinor's




2.5.1 The Pituitary Model Equations
To further simplify the model's equations, the total number of GHRH receptors,
previously/r, has been scaled to 1, replacing the measure of the absolute number of
receptors with a proportionate measure. The number of free receptors is represented
by the variable /, and this simplification allows the number of bound receptors
(previously u) to be just 1-/, instead of using the separate variable, or/7--/, reducing
the number of parameters. The other three variables are r, the GHRH concentration,
s, the somatostatin concentration, and h, the GH concentration. Each of these
variables has its own differential equation to describe the way it changes with time
and in response to other substances in the system, incorporating all the components
which increase or decrease the level of that substance. The concentrations of GHRH
(r) and somatostatin (s) are modelled by simple equations which represent release
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lr and Is are parameters which give the respective release rates for GHRH and
somatostatin. These function as inputs to the model which can be set to any value
and usually follow a pattern defined by an input protocol. The values k6 and k7 give
the rates of clearance in the blood stream which are modelled as proportional to the
current concentration, giving exponential decay, a standard form for modelling
clearance.
The effect of somatostatin on the processes of receptor recycling and GH release is
modelled by calculating a level of somatostatin activation, <!>(/) which is a non-linear




The best way to explain this equation is show what it looks like (figure 2.1). The
level of activation varies between 0 and 1. After s reaches a certain value, controlled
by so, the activation value will increase quickly and then level off at a plateau. The
same equation is used for recycling and GH release, but with different threshold and
gradient parameters, so and 8o, and s\ and 8i, respectively. The final version of this
equation has the modification of using the log of the somatostatin concentration,
instead of using it directly. In many biological systems the effect of a substance
varies as its log rather than linearly, i.e. at low concentrations a small increase has a
large effect, but the same increase at a larger concentration has less effect, and so the
base 10 log of s is used instead as just s itself. The adds an extra layer of non-
linearity to the activation equation.
The number of free GHRH receptors,/, is modelled by :
~T~ = ~k\(r + c)f + (k2 + £3<J>(s))(l - /)
at
The first part of the equation represents the rate of receptor binding, modelled as the
product of the number of free receptors if) and GHRH concentration (r) at rate k\.
This reduces the number of free receptors and so is negative. The extra value, c, is
added to the GHRH concentration in order to represent constitutive activation of the
release pathway which produces basal release. The second part of the equation
represents receptor recycling (resensitisation) which is modelled as the product of the
number of bound receptors, (1 -f), and the sum of the normal rate, &2, and the rate due
to somatostatin k^(s).
The final equation models the system's output, the rate of GH release :
dh
— = [kA + k5 (1 -O(s))] [r + c]f- ksh
dt
This represents GH release as the product of the rate of receptor binding, (r + c)f and
a sum which allows release at rate £4 independently of somatostatin and extra release
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at rate k.5, which is modified by somatostatin activation. Normally k.5 is much larger
than k4 making the somatostatin-blockable component much more significant.
2.5.2 The Model Parameters
The parameters used here are based on those in an unpublished manuscript (Brown
et al unpublished). This presented the thesis and carried out some further work,
mainly to refine the parameter values and adding improvements such as using the log
of somatostatin in the somatostatin activation equation. The model's final set of
parameters were generated based on values estimated from real data and by
experiments fitting the model to real in-vitro experimental data, described later. The
only change to the parameters made for developing the hypothalamic model was
using a much longer half life for GH, by reducing the value of k%, so that the model
could be matched with in-vivo experiments rather than the in-vitro experiments used
in the previous work. This is a fairly high level model using an abstract
representation of the real system and so many of the parameter values cannot be tied
to direct equivalent real experimental measures and as such do not use particular
units of measure. The default set of parameters is presented in the table below :
Parameter Name Description Default Value
It GHRH release rate 10
Is somatostatin release rate 10
k\ GHRH binding rate 0.1
k2 receptor recycling rate 0.002
h som controlled recycling rate 0.018
k\ GH release rate 9
som controlled GH release rate 71
k() GHRH clearance rate 5
k2 somatostatin clearance rate 5
h GH clearance rate 0.07
c constitutive activation level 0.01
So recycling som act. threshold 0.029
Si GH release som act. threshold -0.56
80,81 somatostatin activation gradients 0.3
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The clearance rate parameters, ke, h and k%, are scaled to give half lives in minutes so
that the model is scaled to one minute per model time unit. The default values for the
release rate parameters, Ir and Is are just arbitrary values chosen to give levels of
GHRH and somatostatin at a recognisable level, in the range of 0 to 100 units.
Properly scaling these to match the real system is very difficult because of the
variations in effective concentrations in-vitro and the lack of in-vivo measurements.
The GHRH binding rate works relative to this arbitrary GHRH level and the
proportional 0 to 1 range for/. The two pairs of parameters k^ and &3, and k4 and k5
are scaled to match the arbitrary somatostatin level but can be compared to each
other, both pairs using a small independent rate and a larger somatostatin controlled
rate. The constitutive activation parameter, c, is scaled relative to the GHRH level
and the somatostatin activation equation parameters, so and si, are similarly scaled
relative to the somatostatin level. This activation level can never go to a negative
value but the negative value for si makes sure that even very low levels of
somatostatin have a significant inhibitory effect on GH release.
2.5.3 Input Protocols
The inputs to the model take the form of patterns of GHRH and somatostatin.
These are controlled by the release rate parameters, which give the magnitude of the
inputs, and protocols which give the timing, describing a series of pulses, or longer
periods of switched on release, separated by periods of no release. For GHRH these
usually consist of short pulses, simulating the likely endogenous pattern, and
somatostatin release usually consists of longer periods of on and off activity, but in
the current implementation any square wave pattern can be defined. The form of
these protocols is illustrated in the results below (figure 2.8).
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2.5.4 First Experiments With the Model
These experiments use the final version of the model with the default parameters
taken from the most recent work with the pituitary model, but reproduce the early
experiments in Elinor's thesis demonstrating the model's fulfilment of its
behavioural requirements in simulating the pituitary GH release system. Before
generating these results the new implementation of the model was validated by
reproducing the experiments in the thesis with the original parameters and the new
version successfully produced identical results, which are not shown here.
Response to GHRH Alone
For the first tests the model was given varied patterns of GHRH input, with no
somatostatin input, to test the relationship between GHRH and GH release. The first
experiment in figure 2.6a shows the model running with no GHRH input at all. GH
quickly climbs to its basal level of release, controlled by c, which then declines very
slowly until settling at a steady level. The plot of/shows GHRH sensitivity falling
from its initial value of 1 to an equilibrium level at approximately 0.65. If/is set to a
lower initial value then it will climb to the same equilibrium level, with GH release
slowly climbing in parallel. At this point the level of GH release, which is partly
controlled by /, has reached a point where response desensitisation and
resensitisation are occurring at the same rate to maintain a steady state in the model,
with the GH level at 7 units. Although / mainly represents free GHRH receptors it
also measures the system's general ability to respond to release stimulation and so
constitutive activation is allowed to reduce/in the same manner as GHRH, although
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Figure 2.6 : a. no GHRH,/falls to equilibrium level, low level basal GH release; b. GHRH infusion,/
rapidly depleted then slowly recovers after infusion, large pulse of GH release which falls with rapid
desensitisation before settling at minimal level.
The second experiment tests the response to a long constant exposure to GHRH
(figure 2.6b), comparable to an infusion. This produces a very large peak of GH
release which rapidly declines as the model system becomes desensitised, with /
falling very quickly to almost 0, maintaining a low level due to the recycling process
and sustaining the GH release level at 23 units. When the infusion stops, the GH
level drops to almost 0, slowly recovering back to basal level as/resensitises.
In the third experiment the model was tested with pulses of GHRH (figure 2.7a).
Each pulse produces a corresponding GH pulse, which decline with successive
pulses of GHRH as the system desensitises, until reaching a steady response level.
With higher frequency pulses of GHRH (figure 2.7b) desensitisation is more rapid
and the eventual steady response level is lower. The size of the GH response varies
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directly with the height of the GHRH pulse and with the GHRH pulse duration, in an
almost indistinguishable manner, partly due to GH's long half life, which masks the
difference between effects on pulse height and duration. The GH pulse size is really
just sensitive to the total amount of GHRH, at least within a limited time range.
Similarly, larger magnitude or longer GHRH pulses cause more rapid desensitisation.
These experiments demonstrated the model's ability to reproduce dose-dependent
GH release response and desensitisation to GHRH, and also basal GH release. The
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Figure 2.7 : a. pulses of GHRH at lOOmin intervals,/reduces with each pulse, with some recovery in
the intervals, GH pulses correspond to GHRH with smaller peaks as caused by desensitisation,
levelling out at an equilibrium steady response; b. pulses of GHRH at lOmin intervals, / falls more
rapidly with less time for recovery in the shorter intervals, corresponding rapid pulses of GH release
showing the faster desensitisation to a lower steady response level.
In the first of these tests, the model was given an infusion of somatostatin with no
GHRH input (figure 2.8a) to compare with figure 2.6a. Initially, with no
somatostatin, GH climbs to its basal release level and then slowly declines as/falls
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towards its equilibrium, but when somatostatin is added basal GH release is blocked,
falling to almost 0. At the same time, somatostatin increases the rate of
resensitisation and / climbs until it reaches a higher equilibrium level at
approximately 0.9 units. When somatostatin is withdrawn again GH rapidly climbs
back up to basal level, rising above this in a small rebound, and then slowly declines
back to basal level as/falls back to its lower equilibrium at 0.65.
GHRH GHRH GHRH
Somatostatin Somatostatin Somatostatin
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Figure 2.8 : a. 500 min infusion of somatostatin,/maintained at high level, basal GH release blocked;
b. mixed pattern of 1 min duration, 50 min interval GHRH pulses and somatostatin infusions 250min
off, 250min on repeated, pulses of GHRH without somatostatin produce progressively smaller GH
pulses with desensitisation, somatostatin infusion blocks basal GH and accelerates resensitisation,
following GHRH produces another large rebound GH response, very small GHRH triggered GH pulse
during somatostatin infusion, somatostatin still maintains / but at lower level; c. same pattern of
GHRH as b without somatostatin infusions, first burst of GHRH produces similar large response but




The second experiment with somatostatin mixes GHRH pulses with somatostatin
infusions (figure 2.8b). A similar test in figure 2.8c shows for comparison the same
pattern of GHRH without any somatostatin. Without any somatostatin, each GHRH
pulse produces a corresponding GH pulse, which become smaller as the system
desensitises. After a gap in the GHRH pulses there is little recovery in response to
the next train of GHRH pulses. However with an infusion of somatostatin between
the trains of GHRH pulses, basal GH release is inhibited and the response to the
following train of GHRH pulses is much greater. When somatostatin is infused
during the train of GHRH pulses the GH response is greatly inhibited, producing
very small regular pulses of GH release. Somatostatin also maintains sensitivity to
GHRH while it is inhibiting release, even though GHRH continues to trigger
desensitisation with the release response inhibited. Reducing the dose of somatostatin
reduces the level of inhibition of GH release and also reduces its effect on
resensitisation (figure 2.9).
These tests demonstrate the dose-dependent somatostatin inhibition of GH release,
its ability to prevent desensitisation and increase responsiveness to GHRH and also
the small rebound effect on GH release when somatostatin is rapidly removed. The
model has successfully satisfied all the functional criteria in order to reproduce the
pituitary GH system. The results demonstrate the competitive roles between GHRH
and somatostatin, controlling the level of GH release and the system's ability to
respond. Somatostatin is very important in controlling the pituitary GH response,
both in making sure that the intended GH pulses are large enough and in enforcing
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Figure 2.9 : a. repeat of figure 2.8b, Ir = 10, Is = 10; b. reduced GHRH dose, Ir = 5, smaller pulses of
GH release, / shows less desensitisation; c. reduced somatostatin dose, Is - 1, larger pulses of GH
release with reduced inhibition of GHRH action, / shows less recovery during somatostatin infusion,
lower GH rebound after somatostatin withdrawal.
2.5.5 Scaling the GH Level
Fitting the model to in-vitro data was able to scale the model's dynamics, but only
in a relative manner, leaving the model's output, GH release following an arbitrary
scale. The level of GH release cannot be scaled using in-vitro data, because this data
itself treats the GH level on a relative scale, with the level of GH release depending
on the characteristics of the in-vitro preparation, and not matching the in-vivo
system. However, now that the model has been fitted at a relative level it should be
possible to use the results from in-vivo experiments to at least roughly scale the
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model's GH output to real units comparable with the in-vivo experiments. The
scaling will always be approximate since the levels of GH release vary between
different experiments, and between individual animals. However, it should be good
enough to improve the ability to compare the model's output with real data.
The technique for scaling the GH level will be to compare the response to GHRH
and the maximal level of GH release, using the pituitary model to simulate in-vivo
experiments where animals are given injections or infusions GHRH. The GH
response is sensitive to the duration of the GHRH pulse and the comparison will be
limited by how well the model's input protocols can be compared to injections. The
minimum duration for a pulse in the model is lmin and this may be too long to
directly compare with an i.v. injection lasting seconds. However, injections are likely
to be performed fairly slowly, and a minute possibly is a realistic timescale.
Since the model has already been fitted on a relative scale, it may be sufficient just
to compare the maximal level of GH release in response to GH. It should be possible
to determine this value for the real system from in-vivo experimental data and also
with the model. It may also be possible to use this to scale the model's GHRH levels
to real units by comparing the dose in infusion experiments which should be easier to
match between the model and real data than injections.
Experimental References
The first paper used for fitting (Wehrenberg et al 1983) tests the GH response to
varied dose injections of GHRH and also 30min infusions. The maximum GH
response was achieved with a 1 nmole (1 pg) dose of GHRH, with GH reaching a
peak level of approximately 9pg/ml. With the 30min infusion of GHRH at
0.5nmole/min GH reached a peak level of just under 10pg/ml after lOmin before
declining back to under 2pg/ml within an hour. A different experiment in (Clark et al
1985) figure 2 produces a similar maximum level for GH release. Here they test the
GH response to high dose injection of GHRH in male and female rats, demonstrating
the variation in the peak GH response level, probably mainly due to varied
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somatostatin levels. The maximum response is the same 9pg/ml. The same paper
presents the response to multiple injections of GHRH over a longer timescale and
here the peak GH levels are considerably lower, no higher than 4pg/ml. The reason
for this is mainly the delay between the injection and the first blood sample, usually
lOmin, and comparing with figure 2 shows that allowing for the delay, this gives a
similar level of release.
Figure 2.10 : Dose response curves plotting the peak level of model GH release against the base 10
log of the GHRH input rate (Ir). Both curves show the sigmoidal form which matches the GHRH-GH
dose-response curve in the real system, but increasing the initial value for/produces a large increase
in magnitude.
Comparing with the Model
The model was first used to produce its own GHRH-GH dose-response curve. For
the first version of this the peak GH response was measured with lmin GHRH
pulses, varying the GHRH release rate, Ir. The first complication which arises is the
initial value for/, since this measures the ability to respond to GHRH and will have a
large effect on the amount of GH released. To make a comparison, the experiment
testing varied dose rates for GHRH was repeated with initial / values 0.3 and 0.7.
The resulting dose-response curves are presented in figure 2.10. Peak GH release
with initial/ = 0.3 was 258 units and with initial/= 0.7 the GH peak was 545 units.
This second value for / (0.7) is similar to its equilibrium level during basal GH
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release. After a 90min infusion of somatostatin in the model,/can be as high as 0.88,
which gives a GH peak at 680 units. Setting/to its maximum value gives an absolute
maximum GH response peak of approximately 750 units. With all the values for/, a
GHRH release rate of 500 units was sufficient to get close the maximal GH level.
Testing the GH response to 30min infusions of GHRH produced the same maximal
GH levels and this matches the result in (Wehrenberg et al 1983) where the infusion
produces a similar GH peak (slightly higher, but within the error range) to the high
dose injection.
There is no way to measure/in the real system, but we can assume that the biggest
responses to GHRH in the experimental results correspond to a fairly high/, and so
the model results with / = 0.7 or 0.88 are probably a better match to the highest
responses in the real system. According to the error bars some of the experimental
results may have been GH peaks as high as 12pg/ml. Considering this, a rough match
between the data and the model could be that 500 model units = 10pg/ml, or 1 model
GH unit = 20ng/ml. If the in-vivo results indicate an average absolute maximum level
of GH release at 10pg/ml then the scale might be 1 model GH unit = 15ng/ml.
However, since levels of release vary a great deal between results, and these
represent the highest levels detected, for the results in this thesis a scaling of 1 model
GH unit = lOng/ml is used. These results also indicate a match between GHRH
levels, comparing lr with in-vivo data, to give 1 model lr unit = lng of GHRH.
2.6 GHRH and Somatostatin Inputs
The first set of proper new experiments with the pituitary model is an attempt to
reproduce the endogenous pattern of GH release in the male and female rat by
controlling the input protocols for GHRH and somatostatin in the pituitary model.
The aim is to discover what sort of patterns of release the hypothalamic network
needs to produce based on the assumption that the pituitary model is an accurate
representation of the real system. It is likely that there will be several plausible input
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patterns, but experiments at this level can at least be used to constrain the target for
hypothalamic modelling.
2.6.1 The Target Release Pattern
One of the first points to consider is the basis on which to compare data from the
model and the real system. In modelling a whole system at this level it is more
important to reproduce the characteristics of the real data rather than exact
quantitative details. The exact form of the GH bursts and the magnitude of the pulses
varies between experimental subjects and so, together with the relatively low
temporal resolution of much of the data, the only definite characteristic is the general
form of the release pattern, although closer analysis can still give clues to the
functioning of the system and the line between what can be considered a quantitative
or a qualitative detail is often blurred.
GH release in the male rat occurs in 3-hourly bursts of several large pulses of GH
over roughly 1 to 1.5 h (the period of apparent pulse activity varies in different
results). The burst usually consist of around two to four distinct peaks of varying
height but of similar duration. Between the bursts there are very low levels of
release, often below the threshold of detection. The blood GH concentration in
female rats does show some peaks but these are irregular, more frequent, and usually
smaller than the distinct pulses seen in males, making up a fairly continuous release
of GH in the female with a higher basal concentration. Figure 2.11 gives examples of
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Figure 2.11 : GH release profiles in male and female rats. The top profiles are sampled at lOmin
intervals. The black bar indicates the period of darkness. The bottom profiles and sampled at 12min
intervals. Male rats show a multi-peaked pulse of GH release approximately every 3h. The form of the
pulse is irregular but usually shows 2 or 3 distinct peaks, with a tail at the end the pulse where GH is
no longer being released, indicating exponential rate blood clearance (half life approx. lOmin). Inter-
pulse GH levels are very low or undetectable. The female rats show a much less regular pattern of GH
release, with no distinct pulses. The profile, however, does show distinct peaks and periods of higher
release. Minimum GH levels are higher than the male. The overall effect is a more continuous release
of GH compared to the male. Modifiedfrom (Clark et al 1987) and (Clark and Robinson 1988).
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2.6.2 Likely Patterns of Hypothalamic Release
Under the modulation of somatostatin's inhibitory effect, GHRH governs the
amplitude of GH pulses, and individual pulses of GH correspond to single pulses of
GHRH. Somatostatin is released in long periods of sustained release which disappear
during the GH pulses. The periods of somatostatin release also seem to start and stop
fairly quickly; experimenting in-vivo with an infusion of somatostatin in a sinusoidal
pattern did not reproduce the normal pattern of release (Clark and Robinson 1987)
and the endogenous somatostatin pattern is thought to be closer to a square wave
form. GHRH seems to be released as shorter pulses corresponding to the pulses of
GH. The limited evidence that exists, (Plotsky and Vale 1985), suggests that there is
less GHRH release during the periods of somatostatin release, and vice versa. The
more continuous pattern of GH release in the female is thought to reflect a fairly
constant level of somatostatin, at a magnitude somewhere between the highest and
lowest level in the male.
2.6.3 Testing Release Patterns with the Pituitary Model
The pituitary model provides a controlled system in which to test these ideas. The
first set of experiments tests three possible patterns based on pulses of GHRH and
longer bursts of somatostatin, which all generate a pattern of GH release which
roughly resembles the male pattern. The first of these uses just pulses of GHRH with
no somatostatin (figure 2.12a). This reproduces the basic pattern, but has relatively
small pulses of GH compared to basal release, which itself is higher than the almost
undetectable level observed in male rats between GH bursts. The second experiment
(figure 2.12b) shows the same pattern of GHRH, with continuous somatostatin
release between the GHRH pulses. This produces much larger GH pulses as
somatostatin primes and resensitises the system between bursts of release, also
suppressing basal GH release. In the third experiment (figure 2.12c) the pulses of
GHRH are maintained with no quiet periods. This produces the basic pattern of GH
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pulses but with small pulses of release between the large pulses, which themselves
have smaller GH peaks, with the system not being left to resensitise. The patterns of
input in the second experiment produce the most efficient pattern of release for
growth and also the one that most closely resembles the real male pattern. This input




































Figure 2.12 : a. lmin pulses of GHRH at 20min intervals in 2 bursts of 4 pulses, corresponding 4
peak bursts of GH, with small peaks; b. same pattern of GHRH with alternate 90min infusions of
somatostatin, / is charged up to a higher level, corresponding 4 peak burst of GH with larger peaks,
comparable to in-vivo release with model units scaled at 1 unit = 10pg/l; c. same pattern of
somatostatin with continuous GHRH pulses,/charges but continues to be depleted by GHRH, 4 peak
bursts of GH with some release between bursts.
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Testing Varied GHRH Pulses
Some more refined testing can be done to compare the output of the pituitary
model with the form of the GH pulse in experimental data, in particular looking at
the number of individual peaks and their relative size. The information on the exact
form is fairly rough however, due to the rarity of published endogenous release
profiles and the limitation of the temporal resolution, determined by the frequency of
GH blood sampling. The number of peaks within the GH pulse is also masked by the
half life of GH in the bloodstream, which between different results, ranges from 10
to 15 min. GH blood profile data which has been processed through a deconvolution
model to remove the effect of the decay rate (approximately reproducing the original
release rate) (Hartman et al 1991) often shows more peaks than appear in the original
data.
Examining GH profiles from male rats (figure 2.11) suggests that the GHRH
pulses are frequent enough to trigger another pulse of GH before the previous one
has died away. Estimating the duration of the GHRH pulses is difficult because the
length of the GH pulse is dominated by its decay rate. Experimentation with the
model suggests that a longer GHRH pulse has more effect on the height than on the
width of the GH pulse. The number of peaks in real data is usually at least two, but
can be three or four, and these may represent a larger number of individual GHRH
pulses. Repeating the experiment in figure 2.12b with a longer GH decay rate of 15
min shows less of a fall between the GH pulses but the individual peaks are still
more distinct than in real data. However, the model can also be used to simulate the
effect of sampling by limiting its temporal resolution, and the same data at a 12 min
sampling rate is displayed in figure 2.13a. The GH bursts shows fewer, less distinct
peaks and the apparent relative height of the peaks, between the two bursts, is also
different, being purely down to the luck of exactly when the sample is taken. In an
interesting paradoxical result, increasing the number of GHRH pulses actually
reduces the apparent number of GH peaks as demonstrated in figure 2.12b. Adjusting
the exact timing of the sample points also has a significant effect on the sampled GH
profile (figure 2.13b). These limitations of the sampled data in comparison with the
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model suggest that, in the real release profile, there must be reasonable gap (at least
as long as the sample period) between the real GH peaks within the pulse, since
individual peaks do often appear in the sampled release data. In the model, very
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Figure 2.13 : a. as figure 2.12b, with lOmin, 12min and simulated real sampling (10-min sample with
10% assay error, 30s sample period and random start point), 12min sampling shows loss of peaks in
GH burst; b. similar to figure 2.12b with 2 bursts of 5 GHRH pulses at 15-min intervals, 10-min
sampling shows only 3 peaks, shifting sample timing for second burst by 2 min changes the heights of
the peaks, simulated real sampling shows less regular forms for the peaks and varied heights
If the true pulse rate is faster than the sample rate then the sampling won't be able
to pick up individual peaks and troughs, merging the peaks together. However, this
also depends on the regularity of the pulses, with the effect being more random with
less regular spacing, as is likely to exist in the real system, and this was also tested
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using the pituitary model by adding the ability to randomly generate the spacing of
GHRH input pulses, following a Poisson distribution and controlled by a minimum
refractory period. The first test of random GHRH pulses (figure 2.14) performs an
equivalent experiment to figure 2.12b. The pattern of GH release is similar to the
equivalent test with regular GHRH pulses, but with correspondingly less regular
peaks of GH release within the burst, more comparable to the irregular pattern
observed in real data (figure 2.11). In figure 2.14 the model was also used to test the
effect of random pulse timing on the sampled GH profile. The two bursts of GH
pulses are similar but in the sampled data the height and number of pulses varies due
to the random pulse timing interacting with the sampling of the data.
Simulating Real Sampled GH Profiles
Comparing the model's normal display of GH output with the sampled version
illustrated the dramatic effect that sampling has on the GH release profile. Since this
sampled nature is common to all data on real GH release, this becomes a very
important factor in interpreting real experiments. Several other factors, as well the
actual sample rate, effect the final measured GH profile. The actual assaying of each
sample has a fairly high error rate, relative to the GH level in the sample, so that each
point has a 10% uncertainty. Samples are also not based on just one discrete time
point but are collected over periods of around 30s. The goal here is to extend the
model's simulation of sampling to include these additional factors by implementing a
more sophisticated version of sampling.
The first stage of this was to implement the 30s sample periods. The model runs at
a temporal resolution of 8 points per minute, 7.5s. per point, so a 30s period would
use 4 of these points. The method is for each sampled measure to take the average of
four model time points. This is then adjusted by a uniform random component of up
to 10% of the sample measure, to simulate the error in the assay. Finally, the start
point for sampling is randomised, so that this is independent of the GHRH input












Figure 2.14 : Randomly timed GHRH pulses, with alternating somatostatin infusions, similar to
figure 2.12b. GHRH pulses with 10-min mean interval + 10-min refractory period. Graphs on the right
show the same GH release data, 10-min samples, simulated real sampling (10-min sample with 10%
assay error, 30s sample period and random start point)
Testing these additions to the generation of sampled data shows that none of them
has as dramatic an effect as the original addition of basic sampling, but they do work
to reduce the regularity in the form of the model's artificial data. In order to test the
individual effects each of the new processes was first tested alone, in addition to
basic sampling at 5-min intervals. The 30s sample periods had very little effect on
the form of the profile, but they did slightly increase the height of the GH peaks, by
increasing the influence of the real peaks on the sampled measurements. Adding the
10% errors also had no effect on the general form, but did change the height and
form of the individual peaks, making some appear wider or thinner than others, with
less regular slopes coming off the peaks. Making the start point for sampling random
had a larger effect on the heights of the peaks, although not enough to change their
height order. It also sometimes affected the form of the peaks when by chance two
sample points were fitted between the highest points. Increasing the sampling
interval to lOmin reduced the effect of the sampling periods and the randomised




peaks. This is as expected, since the magnitude of the change in the profile due to the
sampling intervals will dominate, having a much larger averaging effect than the 30s
sample periods. The sample periods only have a more significant effect on the shape
of the pulses when they are made as long as the sample intervals. Figure 2.13 shows
the same data used for the previous sampling results, processed with all the new
sampling features. The general form of each burst is still similar because they are
each generated by regularly spaced GHRH pulses and the sampling is still evenly
spaced, even with the random starting point. Figure 2.14 shows the new sampling
applied to data produced with randomly timed GFIRH pulses. Here, the new
sampling features have a more significant effect on the sampled GH profile,
changing the number of distinct peaks, and their height order.
Varied Somatostatin Input Patterns
Within the assumptions of the pituitary model, the only alternative to the pulsatile
form of the GH burst being controlled by GHRH is a more complex pattern of
somatostatin release during the period of high GH release activity. Somatostatin
would still need to remain high during the periods of low release in order to create
the periods of very low or undetectable release observed in the male rat, but it could
conceivably follow a more complex pattern during the GH burst, something closer to
the previous pulsatile pattern of GHRH. To test this the model was run with a pulsed
pattern of somatostatin alternating with a constant infusion, along with varied
patterns of GHRH input. In the first test GHRH is input as a constant infusion during
the pulsed phase of somatostatin, illustrated in figure 2.15a. This produces a huge
release of GH (note the scale in the figure), much larger than previous experiments
with the model, due mainly to the priming by the infusion of somatostatin and the
very long exposure to GHRH. Although the GH level isn't scaled to directly compare
with real data, in-vivo experiments do show a release response to pulse type
injections which is on a similar scale to endogenous release, and this very large level
observed here in the model is likely to be beyond the range observed in the real
78
Chapter 2
system. Its form with a very large initial pulse followed by much smaller ones also
varies from real data where following GH pulses within the burst are often of a
similar size to the first one. Therefore although this reproduces the gross level
behaviour of GH bursts it is unlikely to be representative of the real system. The
sharp peaks of GH release observed in real data cannot be reproduced in the model
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Figure 2.15 : a. GHRH infused during a pulsed phase of somatostatin (lOmin duration, 10-min
interval), this produces a very large release of GH, over 4000ng/ml, much larger than GH peaks
observed in-vivo\ b. pulses of GHRH (lmin duration, 15-min interval) during a similar phase of
pulsed somatostatin, this produces a burst of GH release with a much closer resemblance to in-vivo
data, showing irregular GH pulses which depend on GHRH timing relative to the somatostatin pulses
In the second test GHRH is input as pulses similar to those used in previous
experiments. This produces a GH burst, but its form depends heavily on the
frequency and timing of the GHRH pulses. If the GHRH pulses are synchronised
with the periods of low somatostatin release then they produce regular large pulses of
GH but if they correspond with the high periods of somatostatin then the burst
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consists of very small GH pulses. Changing the timing of the GHRH pattern so that
the pulses do not synchronise with somatostatin (figure 2.15b) produces more
interesting, less regular bursts of GH with some GHRH pulses producing GH pulses



































Figure 2.16 : Simulating GH release in the female rat; a. pulses of GHRH at regular 20 min intervals
during a constant low level infusion of somatostatin (/, = 2); b. similar constant low level somatostatin
release with randomly timed GHRH pulses, produces a pattern of GH release which resembles release
in the female rat, closer pulses of GHRH produce larger GH peaks
Producing the Female Release Pattern
Release in the female rat consists of smaller, less regular pulses of GH forming a
more continuous level of GH release with no distinctive periods of completely
blocked GH release, as in the male. This is thought to correspond to a more
continuous pattern of somatostatin release, at a lower dose than the high points of
somatostatin release in the male. To test this in the model, the somatostatin release
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rate was reduced to sr = 2 (compared to 10 for the male) and given as a continuous
infusion along with pulses of GHRH. Regular pulses of GHRH (figure 2.16a)
produce a corresponding pattern of small GH pulses, partially inhibited by the low
level release of somatostatin. The difference in pulse height compared with the male
is similar to the real data but the pulses are much too regular. Figure 2.16b shows the
same test using randomly timed GHRH pulses. This shows a much closer
resemblance to the real data, with varied intervals and heights of the GH pulses.
2.7 Conclusions for the Hypothalamic System
Experiments with the pituitary model support the evidence from behavioural
experiments suggesting that the pattern of GH bursts is likely to be controlled by an
alternating level of somatostatin, with the peaks of GH release triggered by
individual pulses of GHRH. Exposing the pituitary model to such a pattern of input
produces a GH release profile which closely resembles real data. One of the most
important points demonstrated here is that the pattern of release requires GHRH to be
suppressed at the pituitary and in the hypothalamus. Using this fitted model, and also
from in-vitro results, the inhibition by somatostatin at the pituitary is not strong
enough to completely block GH release when pulses of GHRH are still being
released from the hypothalamus. GHRH release itself must be blocked, and release
inhibition at the pituitary is also essential in order to block basal release between the
GH bursts. The very low levels between bursts are essential to GH signalling.
The simplest control mechanism for the central blocking of GHRH would be
somatostatin itself since it already needs to follow such a pattern, or alternatively
some common mechanism which controls the GHRH and somatostatin release
patterns. The requirement to synchronise the two, and the unnecessary added
complexity makes independent control mechanisms unlikely. Therefore the




The main alternative presented here to the pattern of alternating infusions of
somatostatin and the bursts of GHRH pulses is the more complex pattern of
somatostatin controlling the form of the GH burst. This was able to produce a pattern
of GH release which looks similar to real data. The main argument against this is that
it is a more complex solution requiring more sophisticated central interaction
between somatostatin and GHRH. Whether extra complexity is required will depend
on how easily and robustly the simpler pattern of release can be generated.
Using randomly timed GHRH pulses has no major effect on the overall pattern of
GH bursts but it does produce a GH profile that resembles the less regular patterns of
release observed in real data. If the system required a regular pattern of GHRH then
this would be more difficult to produce and the system would be less robust. One of
the main questions for developing a hypothalamic network will be the source and






This chapter describes the development of the hypothalamic model. The first stage
of this was the specification, defining the output which the new components need to
produce, and gathering existing knowledge about the system on which to base the
new components The second stage of development was to use the specification, the
defined output and what we already know about the system, essentially the pieces
which are available to build it from, to come up with a basic design for the system.
This basic design was then translated into a mathematical form and taken into the
third stage, which consisted of a cycle of implementing, testing and experimenting
with the model's design, with the goal of matching the structure and behaviour of the
real system. Analysis of the model system's components and its behaviour as a
whole can then be used to make predictions for the real system and suggest further
experimental work with results predicted by the model.
3.2 The Specification
The outputs of the hypothalamic system are the patterns of GHRH and
somatostatin release, and these form the inputs to the pituitary model that goes on to
generate GH release. The likely form of these outputs has been developed by
examining the results of in-vivo behavioural experiments with the real system, and by
using the pituitary model to experiment with different patterns of GHRH and
somatostatin. Based on the tests which validated its qualitative and quantitative
properties, the assumption is to be made that the model is an accurate representation
of the pituitary system, and its structure and parameters can be treated as fixed.
While this may not be ideal, it is necessary to have the system as well defined and
specified, essentially restricted, as possible in order to make the design and testing a
tractable process.
The second part is the existing structures and what we know about their behaviour
and interaction, similar to the functional components presented for the pituitary
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system. Gathering this information was the main goal of the research review in
chapter 1 and the information will be summarised here in a form ready for
developing the model.
3.2.1 The Model's Output
The model's first desired output is the endogenous pattern of release in the male
rat, but it should also be easily adapted to produce the less regular and more
continuous pattern of release in the female rat, which is thought to be a similar
system, modified by different exposure to sex hormones, particularly oestrogen.
Initially, the target outputs for the new hypothalamic components will be the patterns
of GHRH and somatostatin release defined during experiments with the pituitary
model, short pulses of GHRH and square wave periods of sustained somatostatin
release.
The aim is to create a self-contained system which is capable of generating the
desired output without any external input which isn't already suggested or defined by
existing knowledge about the real system. Defining an external input which contains
part of the output pattern effectively just shifts part of the problem away from our
system, and fails to provide a complete solution to how the system functions. It may
turn out to be the case that some external input is required, but exhaustively
attempting to make the system work without any such input will provide better
evidence for its existence.
3.2.2 Existing Components
These are the well defined functional and structural components derived from
what we already know about the system with a decent degree of certainty :
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i) GHRH is released by a group ofneurons in the arcuate nucleus
Evidence from in-vitro and in-vivo experiments indicate that pulses of GH
correspond to pulses of GHRH, and so the form of GH release suggests GHRH is
released in sharp pulses, lasting a few minutes. Relatively short, sharp pulses must
require synchronisation between the GHRH neurons.
ii) Somatostatin is released by a group ofneurons in the periventricular nucleus
The true pattern of somatostatin release is also unknown, but periods of high
somatostatin release probably match periods of low GH release in the male rat.
Hi) Somatostatin has an inhibitory effect on the GHRH neurons
More recent work has focused on the negative effect of somatostatin on GHRH
mRNA expression, but the best evidence for this connection is the
electophysiological studies. The electrical connection suggests a very direct and fast
acting inhibitory effect on GHRH neuronal activity and release.
iv) GH inhibits its own release
Administering GH in-vivo has a dramatic inhibitory effect on its own release and
on an unusual timescale. The effect takes in the range of an hour to develop, and it
takes one to two hours for normal release to recover after the infusion. The properties
of the inhibitory effect also vary between male and female rats. In both, an infusion
of GH suppresses its own release, but the female rat, unlike the male, continues to
respond to injections of GHRH. The male would normally show a more varied
response to GHRH injections because of its periods of high somatostatin release, but
after administering exogenous GH the period of unresponsiveness is longer than
usual. This appears to suggest inhibition of GHRH in the male and female and also
prolonged somatostatin release in the male, but interpretation is complicated by the
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interactions between GHRH and somatostatin, making it difficult to distinguish
direct and indirect effects.
v) GH stimulates the somatostatin neurons
The only evidence for the dynamics of this is what we can extract from the effect
of GH on its own release. It appears to be able to trigger a prolonged release of
somatostatin, lasting longer than the original pulse of GH. The effect also appears to
be delayed and it is thought to take up to an hour between the original GH release
and the corresponding increase in somatostatin levels (Chihara et al 1981). This
suggests an effect on the releasable pool of somatostatin, rather than direct electrical
stimulation.
vi) Other connections
There is some evidence for a connection from the GHRH neurons to somatostatin
neurons, possibly via some other transmitter. Acetylcholine has been co-localised
with GHRH and has an inhibitory effect on somatostatin in-vitro, providing a
possible inhibitory link. Similar evidence exists with galanin, but similarly
circumstantial evidence also suggests an excitatory link mediated by dopamine.
Much of the behavioural evidence also suggests GH acting at the GHRH neurons
to inhibit release, particularly in the female rat and probably also in the male. In
particular, the large GHRH-dependent rebound observed following somatostatin
withdrawal is blocked by GH infusion in the male and female.
The main outside input for which evidence exists is an adrenergic input to the
GHRH neurons which appears to be necessary for GHRH release, perhaps providing
the electrical activity to stimulate release from the GHRH neurons.
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3.3 The Basic Design
For the first stage, the components of the system specified above were laid out
together to form a picture of the system (figure 3.1). The main structural components
are the GHRH neurons, the somatostatin neurons and the pituitary GH release
system. This first design includes the links for which good evidence exists, the
inhibitory link from somatostatin to GHRH and the GH feedback link to the
somatostatin neurons.
3.3.1 System Function
The next stage was to consider how this system might produce the target output
pattern, beginning with the GH release profile in the male rat. Individual pulses of
GHRH trigger the individual peaks of GH release. This means that there needs to be
something to generate the individual pulses of GHRH, either some periodic
inhibitory input or a pulsatile excitatory input. One candidate for this is the
adrenergic input. The apparent form of the GHRH pulses, based on the
corresponding GH release, suggests that this input should be a series of short pulses.
An alternative mechanism for triggering pulses of GHRH is the somatostatin
withdrawal rebound. When somatostatin is infused in-vivo, blocking GH release, and
then suddenly withdrawn, there is a large rebound release of GH which is triggered at
least partly by GHRH release. The mechanism of this rebound is still not understood.
One idea is that exogenous somatostatin may inhibit endogenous somatostatin,
leaving GHRH unopposed upon its withdrawal (Clark et al 1988), but another idea is
that the rapid fall of somatostatin induces GHRH release, suggesting a mechanism
which could play a role in normal function. The large rebound release may not play a
role in the endogenous system but in the attempt to reduce the use of outside inputs






Figure 3.1 : Basic knowledge about the GH release system. This shows all the components and
connections for which good evidence already exists and forms a starting point for designing the
model.
The overall output repeats in a cycle, and so in the absence of any outside
generator producing this pattern, the system needs to have its own cycle. Assuming
that somatostatin controls the overall pattern of release, there needs to be a feedback
input to somatostatin. The obvious choice for this is GH itself. GHRH release
triggers GH release which would then stimulate somatostatin release, which in turn
would inhibit GHRH release from the hypothalamus and GH release at the pituitary,
switching off the feedback signal. Eventually the somatostatin stimulated by GH




This is a model of the system at a functional rather than mechanical level, and
major simplifications will be made in representing the system's components. In the
pituitary model GHRH and somatostatin are each represented by a single variable
which measures the level of the peptide in the system. We are thus assuming that
each group of neurons can be treated as single unit. This works for several reasons,
the main one being the timescale of the model. The model works on a scale of
minutes, whereas neurons work on milliseconds and so activity is averaged out. We
know that the neurons do synchronise because this is necessary in any system to
produce pulsatile output. The other major reason is the way in which electrical
activity is transduced into hormone release. Although individual action potentials
trigger individual releases of peptide, the release from individual neurons all diffuses
into a common transport channel to the pituitary, and so the GH releasing cells
experience overall GHRH or somatostatin activity rather than the actions of single
cells.
3.4 Building the Model
Turning the basic design into a working model formed into two generations of
model development. The first generation formed a process of learning how best to
formalise the types of connections in the system, exploring the properties of the
mathematical constructions and refining them to get the system functioning correctly.
The second generation, which formed the final basic version of the model, rebuilt the
model, using more biologically representative components, such as the Hill
equations, to create a more refined model which better matches the quantitative




The state of the system is stored as a set of variables that represent measures such
as hormone blood level or number of free receptors, each related to some component
of the system. The functions of each component may be broken down into more
variables but this will only be done with the aim of reproducing the component's
behaviour, rather than just its mechanism. The basic GH model (figure 3.1), has four
variables, representing the blood concentrations of GHRH, GH and somatostatin, and
the number of free GHRH receptors at the pituitary, variable / from the pituitary
model. To maintain the model's simplicity, the same variables for GHRH and
somatostatin are used to represent the hypothalamic components and their actions at
the pituitary. This makes the assumption that the level of activity in the
hypothalamus can be matched directly to the level of peptide released into the portal
blood.
Each variable has a corresponding differential equation, and these equations
contain parameters which relate to some measure such as a threshold or synaptic
strength, or may belong to a more abstract mathematical construction. The model
also contains other equations, such as in the pituitary model, which calculate
values such as level of receptor (and associated downstream component) activation.
Hill Equations
A standard form for modelling the effect of one substance on some component of a
system is the Hill equation. In the later version of the model, these equations model
the actions of peptides on neurons. In general, these equations model the effects of
ligand-receptor binding and allow a variable threshold for activation and variable
steepness using the Hill coefficient, which measures the degree of cooperativity of
the binding. If binding is cooperative, then the binding rate is affected by the current
level of bound complex, so if the effect is positive, the binding rate will increase as
the level of bound complex increases. If the effect is negative then the binding rate is
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reduced. This controls the gradient with which the level of binding increases. These
equations give a biologically realistic, but simple, way of getting a measure of
activation where there is a substance binding to receptors. The equations produce a
value ranging from 0 to 1, with a higher value indicating a higher level of binding, or




where I is the level of ligand present, th is the threshold, and n is the Hill coefficient.
Storage Variables
For this model a type of variable has been developed which represents a measure
of the ability to release a substance, or 'releasability'. This is deliberately vague
because it is intended to represent functional properties rather than a particular
mechanism. The real biological substrate could be something like vesicle
mobilisation or the number of activatable receptors. The idea is that they allow a
substance to charge up the ability to release something without directly triggering its
release. They form a 'memory' that allows a substance to trigger an effect which
takes place over a longer timescale or at a different time point to when the original
trigger substance was experienced. This was originally developed to model rebound
effects. The storage variable could be charged up during inhibition while its release
was blocked, and then allowed to drain quickly after inhibition to produce a large
rebound spike. It has also been used to model the effect of GH on somatostatin, by
getting GH to charge up a somatostatin release variable so that the relatively short




Even fairly complete models of self-contained systems usually need some sort of
external input to control them, or at least to provide some driving activity. When the
system of equations is run in software, the variables are progressively calculated at
discrete time points. Inputs are usually given to the system by perturbing the
variables, changing them to a specified value at a specific time point, or they can just
be added to existing activity. A whole series of inputs can be defined in order to form
a pattern, such as a series of spikes, and this whole pattern of inputs is known as the
protocol. Each variable can have its own protocol, but usually only a few of them
will be controlled in this way.
3.5 Comparing Model Output to Real Data
In the early stages of developing the model, assessing the model's output will be
based more on the qualitative rather than quantitative features of the real data,
focussing on reproducing the system's behaviour, and basic features of the release
pattern. As development progresses (particularly the second generation version of the
model and chapter 4) this will shift towards more exactly matching the quantitative
features of the real data. The direct output comparison combines with the goal of
designing the model in a manner which fits what we know about the biological
systems, it's biological plausibility. The criteria for comparing model output are
given below :
• GH pulse cycle duration - approx 180min in male rats
• GH pulse duration - the duration of high GH release in each pulse
• GH pulse height - peak GH release levels within each pulse
• number of GH peaks with each pulse
• inter-pulse GH levels - very low in the male rat
• width of individual GH peaks
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The reference data for the normal pattern of real release is shown in figure 2.11. This
illustrates GH release in male and female rats at lOmin and 12min interval sample
rates. There is a large variation in the form of individual GH pulses, and between
animals, though most pulses follow the 180min cycle. GH pulse duration is
approximately 90min, with a similar period of inter-pulse low GH release. Peak
height in this data corresponds to 800ng/ml although other data (not shown)
sometimes shows peaks as high as 1200ng/ml. The sampling process tends to
underestimate peak GH levels. Inter-pulse GH levels are very low, often zero,
although with occasional very small GH peaks. Each GH pulse usually consists of 2
or 3 distinct peaks. The first is often the largest, although not always. Looking at the
top male profile in the figure, sometimes there is a large drop between peaks making
them very distinct (the third GH pulse) and sometimes the drop is smaller (the first
GH pulse) giving a more flat top to the GH pulse. Measuring the width (or duration)
of GH peaks is limited by the sample rate, but the one or two sample points within
each peak indicate that they are approximately 15 to 20min long.
To make a direct comparison with the real data, the model's GH output is
subjected to a similar sampling process. Figure 3.5b shows the first example of
model data which resembles the real data. The pulse cycle length matches real data.
There are a similar number of GH peaks within each pulse, and the peak height and
width is similar to real data. The main variation, which is more difficult to formally
quantify, is the more regular form of the model data, with little variation between the
shape of each GH pulse, compared to real data. The period of low inter-pulse GH is
also slightly shorter in this model data, with GH pulses lasting approximately
lOOmin.
Figure 3.7 shows two sets of model data compared for their match to real GH
release data. The second set of data (figure 3.7b) is stated as being a better match
because it shows higher GH peaks and also 3 rather than 2 peaks within each GH
pulse. It does however have the trade-off of having a shorter inter-pulse low GH
period, compared to the better match in figure 3.7a. Such a comparison becomes
subjective, depending on which particular set of real data is used for reference, due to
the variation within real data.
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Figure 4.2 introduces random input pulse timing to better match the variation
observed in real data. The gives a better match to real data just by better covering the
range of different forms observed in real GH pulses. Figure 4.2c in particular shows
a good match to the GH pulses with a small drop between individual peaks.
In the final stages of model refinement the judgement becomes more difficult with
more subtle difference between sets of model output. Here various possibilities are
presented rather than being definitely compared, such as figure 4.7. The difference
here is mainly in the number of peaks within each GH pulse. However, Figure 4.7a
shows more distinct peaks than would normally be observed in real data, making
4.7b the better match to real data.
3.6 The First Generation
The pituitary model used four variables each with a corresponding differential
equation, three representing the concentrations of GHRH (r), somatostatin (5) and
another giving a measure of free pituitary GHRH receptors if). The hypothalamic
model was built onto the pituitary model by adding to and modifying the existing
equations.
3.6.1 The Model Equations
The first part of the system to be considered was GHRH. At this stage, the system
was considered at a very simple level, not looking at the detail of the GH pulses and
their multiple peaks, and the mechanism which seemed capable of triggering the GH
pulse was the somatostatin withdrawal rebound. To produce a rebound, a new
variable, g, was added to represent the ability of the GHRH neurons to immediately
release GHRH, or 'releasability'. This component would charge up to a maximal
level, at a rate inversely proportional to the current store, and be depleted as GHRH
was released. Inhibition of GHRH release by somatostatin would allow it charge up
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to a high level so that sudden removal of the inhibition would produce a large pulse
of GHRH release, assuming that there would be some existing level of basic activity
which would trigger release with inhibition removed (figure 3.2). The function of g is
described by the following equation :
= [el]
at
GHRH releasability, or charge, increases at a rate controlled by parameter l\, relative
to the existing charge g, to produce saturation at a maximum value of 1. The value
falls at a rate proportional to g controlled GHRH, at a rate by parameter l2.
The second part of the system to be designed was the somatostatin-GHRH
inhibition. A measure of the inhibition (ract) was added to be used with the GHRH
equation. This is shown below :
1
v =
1 + e\p[sigl log10 (s) - sig2 ]
This gives a standard negative sigmoid curve with gradient and threshold controlled
by sigi and sig2 respectively. Depending on the gradient, controlled by sig\, this
allows a fairly sudden block of GHRH when somatostatin reaches a high enough
level. It also means that there will be little GHRH release until somatostatin falls
back below the threshold. The modified GHRH equation, integrating the two new
components, takes the form :
^T = ractVr+h8)~Krat
This changes the original equation by allowing ract to block the input component and
adding an input from g, controlled by the rate parameter 13. This allows an input
based on the charge, g, to increase GHRH release independently of the artificial
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input, Ir. Modifying the whole input by ract allows a total block of release, rather than
just blocking individual inputs.





The new component 0(/i) is a measure of activation due to GH, similar to <£>(s) in the
pituitary model. It is given by the following equation :
<F(/i) =
1 + exp[-(log10 (Ji) -h0)/ Sh\
This equation is best explained by referring to the illustration for 0(V) (figure 2.1).
The level of activation varies between 0 and 1. After h reaches a certain value,
controlled by ho, the activation value will increase quickly and then level off at a
plateau. The gradient of the change is controlled by dh, with a smaller value giving a
steeper change. Parameter y'2 scales the activation value from <F(/i) to give a release




Figure 3.2 : The first generation model. GHRH pulses are triggered by charging a releasable pool (g)
which allows a large rebound release of GHRH when somatostatin inhibition is removed. The pool
continually charges and is depleted as GHRH is released. Somatostatin release is driven by an
excitatory feedback from GH. For this to work, a delay had to be added so that the GH pulse wouldn't
immediately inhibit itself. Pulse input was added to GHRH in order to produce multiple peaks with
each GH burst, removing the need for the rebound mechanism.
3.6.2 Testing the Model
This version of the model was built by developing the somatostatin-GHRH
interaction and rebound, then adding GH feedback. The model program allows
artificial input protocols to control GHRH and somatostatin levels in a way that
simulates in-vivo experiments. This allowed the individual components of the model
to be tested in isolation rather than having to work together immediately. The model
uses the final version of the pituitary model The only modifications are the
97
Chapter 3


























0 100 200 300 400 500
Time (minutes)
Figure 3.3 : Using somatostatin withdrawal rebound to generate a GHRH pulse. 90min somatostatin
infusion allows g to charge while inhibiting GHRH release. Upon withdrawal, GHRH is released, with
g rapidly discharging to leave basal level of GHRH release at low level equilibrium (sigi=20,
sigi=0.l, /i—0.05, l2=0.5, /3=20). The discharge of g at a rate proportional to the remaining pool leaves
a tail on the GHRH pulse, prolonging the GH pulse. Peaks in real GH profiles (fig 2.11) tend to be
shorter, indicating sharper GHRH pulses.
To test the GHRH rebound and somatostatin-GHRH inhibition mechanism, the
model was run with an input pattern of somatostatin defined as two 90min infusions,
separated by 90-min. The process began by setting the parameters to values which
produced roughly male rat levels of GH release and then went on to vary these values
to test their effect on release with the other parameters already set.
The first parameters set were the threshold and gradient for ract, somatostatin's
inhibitory control over GHRH. For the rebound to work, somatostatin at its level
between GH pulses must almost entirely block GHRH release, and so the threshold
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and gradient were set so that ract was close to 0 during the somatostatin infusions.
Values sig\ = 10 and sig2 = 0.1 were used to give an ract value of 0.06 with high
somatostatin. The charge component of GHRH release was switched on and the
parameters set so that the 90min somatostatin infusion would be sufficient to charge
g to its maximum level, and the rebound pulse produced a large GH pulse (approx
5ng/ml). Initial values were l\ = 0.05, h = 0.5 and /3 = 20. The first problem was that
the somatostatin-triggered inhibition was insufficient to totally block GHRH release,
leading to levels of GH release during the somatostatin infusion higher than those
observed in the male rat. To counter this, sig\ was increased to 20, and this produced
a sufficient inhibition of GHRH. The resulting rebound produced a sudden increase
in GHRH release which quickly decayed as the releasable store was depleted (figure
3.3).
Increasing I2, the rate at which GHRH uses up the releasable store, reduced the
size of the GHRH release pulse, making it sharper and reducing its height with a
corresponding effect on GH release, but did not significantly effect the overall form
of the GH profile. In addition to the sharp rebound pulse, the GHRH store
mechanism also produced a level of basal GHRH release, due to the constant
charging. The level of this was controlled by the balance between l\ and I2, with a
small value for 6, relative to I2, keeping it at a low level.








The combination of somatostatin inhibition of GHRH, and rebound release,
worked well but requires a very sharp effect of somatostatin on GHRH, so that the
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block works more like a switch, rather than a gradual dose-dependent inhibition. The
rebound produces a large, sharp pulse of GHRH which is able to trigger a large GH
pulse. However, this system is unable to produce the multiple peaked GH bursts as
seen in real experiments. The single peak pulse of GH is also not as sharp as the GH
peaks in real data (figure 3.3). In a further test of the rebound mechanism, the
artificial somatostatin input was replaced with more realistic, gradually decaying
levels of somatostatin. The system was still able to function but the somatostatin-
GHRH inhibition had to be made steeper still in order to get a pulse of GHRH
release rather than a gradual leakage (not illustrated). A sharp pulse of GHRH is
required to get a pulse of GH release, as opposed to a gradual increase and decay in
the GH level.
3.6.4 Adding GH Feedback
The next stage was to add GH feedback and remove the artificial control of
somatostatin. This was done very simply, by adding a GH component to the
somatostatin equation, using an activation function similar to the one used in the
pituitary model to represent the effect of somatostatin on GH release and receptor
recycling. The activation function uses two parameters controlling its threshold and
steepness, ho and 4- These were given initial values ho - 8 and 4 = 0.5, after testing
the activation level against typical GH levels. These values give a very sharp change
in activation, with a threshold at a GH level of 8 units. This low threshold makes the
effect on somatostatin more dependent on the duration of GH release, rather than the
level of release, so long as release is above the threshold level. Without the sharp
gradient, there is too much somatostatin release during the GH burst caused by basal
GH release, and making the threshold too high reduces the period between the GH
bursts by making a shorter period of GH release trigger somatostatin.
To produce the first pulse of GH to trigger feedback, the model was tested with an
input protocol giving one 90min infusion of somatostatin. With parameter ji
(controlling GH feedback) still set to 0, this produced a single pulse of GHRH and
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corresponding GH release, decaying back to basal level and then remaining there.
Increasing j2 just caused an immediate increase in somatostatin, leading to a smaller
GH pulse and a higher level of constant GH release following, as the increased
somatostatin level maintained a low level of GHRH release through the rebound
mechanism. Higher values for j2 obliterated the GH pulse leaving just a constant low
level release of GH, which reduced in level after j2 became large enough to cause a
sufficient increase in somatostatin to make the inhibitory effect on GHRH more
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Figure 3.4 : a. GHRH rebound combined with GH-somatostatin feedback with no delay, somatostatin
infusion followed by withdrawal triggers first GHRH pulse, immediate somatostatin release truncates
GH pulse, somatostatin declines and system goes into equilibrium producing low level GH release; b.
GH-somatostatin feedback with 30min delay, after delay GH triggers somatostatin release which
recharges g and triggers another GHRH pulse, and cycles; c. as b. with 80min GH feedback delay to
produce pulses of GH every 180min, comparable to pulse cycle in the male rat. A 2min delay is
sufficient to produce small pulses (not shown) (j2 =10).
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This first version didn't work because as soon as GH levels rose, somatostatin
levels increased and blocked most of the GH pulse (figure 3.4a). The feedback was
too fast, and so a delay was added by allowing the activation function to use a value
for h from an earlier time point. This makes sense, because in the real system it is
likely to take some time for GH, which is released peripherally, to feedback to the
CNS. The delay was initially set at 30min. This immediately fixed the problem of
feedback truncating the peak of the GH pulse. Parameter j2 was increased until
feedback produced a high enough level of somatostatin release to inhibit GHRH
release and trigger a rebound pulse. Beginning with the form in figure 3.3, higher
values gradually reduced the length of the single GH pulse as the delayed GH
triggered somatostatin release inhibited the long GHRH maintained tail. Between j2 =
8 and j2 = 9 pulses of GH began to appear, as the somatostatin level became high
enough to allow GHRH releasability to charge. Pulses continued in a regular pattern,
following a cycle lasting 95 min (figure 3.4a). Increasing the delay to 80 min
produced longer pulses of GH and a cycle lasting 180 min, comparable the GH
profile in male rats (figure 3.4c).
For the first time, the model was able to produce regular pulses of GH without any
outside input, just a single GHRH pulse (or somatostatin infusion) to start the cycle.
After one or two pulses the model settled into a regular pattern of GH release, not
dependent on the original triggering input. The only parameters which had a
significant effect on GH pulse frequency were ho (the GH-somatostatin feedback
threshold) and the delay value for h. A longer delay or lower threshold reduced GH
pulse frequency. Pulse amplitude was affected by the ract parameters, sigi and sig2
and also 5/,. When somatostatin inhibition of GHRH is less steep (a smaller value for
sig0, the pulse amplitude is reduced until pulses are completely lost.
In male rats there is a high level of variation in GH pulse amplitude between
animals, but they all show the same regular pattern of 3-hourly GH pulses. This
suggests, that as with the model, the effect of GH on somatostatin is more dependent
on the duration of release, rather than the absolute amount.
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3.6.5 Adding an Input to GHRH
The final change to this version of the model was to alter the GHRH equation so
that GHRH release requires GHRH available for release, and another input. This
would allow a more complex pattern of GHRH release rather than just single
rebound pulses. It is also a good biological model; the charge (releasability) variable
could represent the amount of GHRH ready for release and the input could be




The positive component is now the product of GHRH charge (g) and input activity
(T). GHRH input protocols were used to provide the input component, consisting of
a train of short pulses, similar to the artificial GHRH input used with the pituitary
model. The pulses were each of lmin duration with 15min intervals. All the other
parameters were left at the values set previously, including a delay of 80min. There
was no effect on the overall pattern of GH pulses, with the length of the pulses and
the quiet period between them remaining the same, but the input pulses now
produced multiple peaks within the GH pulses and made them look much more like
real pulses of GH release (figure 3.5a). This further supports the idea that there is
another component involved in generating the pattern of GHRH pulses, perhaps a
further interaction with somatostatin or GH or an outside pulse generator such as an
adrenergic input.
Adding input pulses removed the need for a GHRH rebound pulse, and removing
the rebound component made very little difference to the form of the GH pulses
(figure 3.5b). Using the rebound form of the GHRH equation summed with artificial
input produces GH bursts with a much higher peak at the start of the pulse,
combining the effect of the rebound with regular input. However, following the
principle of keeping the model as simple as possible, it was decided to remove the
rebound mechanism at this stage. On its own it is insufficient to produce a pattern of
103
Chapter 3
GHRH of the form required to match real data and combined with a pattern of
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Figure 3.5 : initial 90min somatostatin infusion; a. lmin duration, 15min interval, input pulses trigger
release from GHRH releasable pool (g), corresponding multi-peak pulses of GH release; b. GHRH
release directly defined as lmin duration, 15min interval pulses, produces similar multi-peaked GH
pulses; bottom traces show GH release scaled at lmodel unit = 10 ng/ml, sampled at lOmin intervals,
with 10% error, 30s sample period and random start point, sampled GH profile often shows first peak
as largest when this is not the case in unsampled data.
3.6.6 Conclusions
Although this version of the model did work, in that it was able to produce the
basic pattern of GH pulses, the relations between somatostatin and GHRH and
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between GH and somatostatin were rather unrealistic, using switch-like activation
curves, although it is possible that a sequence of non-linear relations in the biological
system could produce an overall switch-like relation. The GH pulse patterns also
showed a shorter quiet period than seen in the real male release pattern, and a long
delay was required to produce a pattern of GH pulses following the same timescale
as the male rat. The next stage was to go on to develop more biologically plausible
interactions and attempt to more accurately reproduce the real pulse patterns.
3.7 The Second Generation
The first change to the model was to replace ract and O(h) with Hill equations to
model the hypothalamic effects of somatostatin and GH. Like the old equations,
these give a value that ranges from 0 to 1, with a higher value indicating a higher
level of binding, or activation. This is the new equation for ract:
1 5
r, = 1 -
s*+th*
The parameter th\ gives the threshold for activation (really the level for half maximal
receptor binding, but with a reasonably steep coefficient it essentially forms a
threshold) and n\ is the Hill coefficient giving the steepness with which the level of
binding increases. The Hill equation is subtracted from 1 since it is being used for
inhibition. The binding of somatostatin in the hypothalamus is thought to be highly
cooperative (Wagner et al 1998) and so n\ - 4. The new simplified equation for
GHRH, removing the releasability component, is given below :
— = r I -k r
,. act r 6
at
Figure 3.6 shows the model's output at this stage, the first generation with the GHRH
releasability component removed and the original ract replaced with the new Hill
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equation version, using parameters n\ = 4 and th\ = 1. The changes so far make no
major difference to the model's behaviour, but use a more biologically plausible






















Figure 3.6 : The first generation model with Hill equation somatostatin-GHRH inhibition, 15min
interval input pulses. The first GH pulse shows smaller peaks because of no previous somatostatin
release to charge pituitary GHRH sensitivity (/). The reduced gradient of the somatostatin-GHRH
inhibition leaves small pulses of GHRH and corresponding GH during periods of high somatostatin.
Model behaviour is otherwise unchanged. The small inter-pulse GH peaks do not show in the sampled
data.







This has a similar form to the new ract equation, with the threshold parameter th2, and
the Hill coefficient «2- The behaviour of these two equations is not radically different
to the old versions but they are more robust, in that they are less sensitive to the
parameter values, and don't require such extreme values to work well. They also
more closely represent the biological mechanisms and are known to give a good fit to
the activation profile in ligand-receptor binding. The main difference in behaviour
from a basic sigmoid equation is that the gradient of the Hill equation depends on the
threshold as well as the coefficient. As the threshold increases, the level of activation
increases more slowly, unlike the basic sigmoid where increasing the threshold just
shifts the curve without changing its shape.
The second stage in advancing the model was to develop a more sophisticated
connection between GH and somatostatin. A new charge (releasability) variable, sr,
was added for somatostatin. The idea was to develop a mechanism that would allow
GH to trigger a prolonged period of somatostatin release, potentially longer than the
actual period of GH release, without having to use very long delays. Instead of
directly affecting somatostatin release, GH charges up somatostatin releasability.
The new equation for sr is :
ds
= Snhacl-Sr2lsSr
Somatostatin releasability increases at a rate proportional to GH receptor activation
(Jiact) controlled by the parameter sri- The level of charge decreases with somatostatin
release at a rate controlled by sr2. The difference from the equivalent equation for
GHRH (el, page 95) is that the charge and discharge rates are not proportional to the
current level of charge. Relative rates give a non-linear rate of change relative to
peptide release, which is unlikely to be the case in the real system. A more linearly
varying charge variable also makes it easier to achieve the sharp changes in release,
such as sudden pulses, which are required by the model. The new component was
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integrated into the somatostatin equation by making the release rate the product of sr
and input activity (Is) to give the new equation below :
— = I sr -k7s
dt s r 1
This form allows the decoupling of the direct connection between GH and
somatostatin release, allowing GH to charge up the store, which is turned into
somatostatin release at a rate not directly dependent on GH release activity. Release
is split into two components, the availability of the substance and the triggering
electrical signal, which for somatostatin is defined as a constant level of activity so
that it releases as soon sr is charged. Using the constant level could allow the model
to be further simplified, with just a constant instead of the input activity, but
maintaining the use of the input protocol will allow more flexibility for later
experimentation.
3.7.1 Testing the New Model
The input protocols were set up to give regular lmin pulses of input to GHRH at
15min intervals and constant stimulation to somatostatin. The GHRH pulses were
sufficient to trigger the first GH pulse. The GH feedback delay was initially set at 30
min. The two parameters for hact were set at n2 = 2 and th2 = 20. Setting a lower
threshold allowed too much somatostatin release with low levels of GH, resulting in
very small GH peaks. Increasing the threshold had a direct effect on GH pulse
amplitude, reducing the somatostatin level during the GH pulse and increasing the
size of the GHRH pulses. The remaining parameters to be tested were sri and sr2,
controlling the rates of charge and discharge of the somatostatin store. To set these
the model was initially run with hypothalamic control of somatostatin disabled, so
that somatostatin was purely controlled by the input protocols, set up to give a
normal pattern of GH release. The two values were likely to act relatively to each
other and so sri was given an initial value of just 1, since this appeared to produce a
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reasonably scaled level of charge. The value, sr2 was then adjusted so that the level of
charge from one pulse of GH would gradually fall back to 0 with somatostatin
release between the GH pulses. This gave a value of 0.005 and these two values were
set for testing the full model.
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Figure 3.7 : a. Full second generation model. GH release triggers charging of somatostatin store (sr),
constant activation releases somatostatin at rate proportional to sr, gradual decline in somatostatin
produces smaller GHRH pulses and corresponding GH peaks at start of GH pulse, less obvious in the
sampled data. Note the larger scale somatostatin axis compared to previous figures. (n2=2, th2=20,
delay=45, ,yrl=l, sr2=0.005), pulse cycle = 185min; b. parameters adjusted to better match real data
and give squarer somatostatin release by increasing sr2 (n2=2, th2=30, delay=60, s>i=l, .vr2=0.01), pulse
cycle = 180min.
The full version of the model was immediately able to produce pulses of GH
release (figure 3.7a). GH pulse cycle length was 150min. The GH pulses were fairly
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small in height and so th2 was increased to 30 to return them to an amplitude more
comparable with real data. This slightly reduced the cycle length to 145min.
Increasing the GH feedback delay to 45min gave a cycle length of 185min, matching
the GH pulse cycle in the male rat, and with a much shorter delay than was required
with the first version of the model. Somatostatin release now had a more wave like
form, climbing steeply in response to each GH pulse in the previous burst and then
falling more gradually until low enough to allow GHRH pulses to trigger the next
burst of GH release. The gradual fall in somatostatin resulted in smaller pulses of GH
at the start of the burst, with the GHRH pulse still partially inhibited. This could be
improved by increasing n\, and increasing the sharpness of somatostatin's inhibitory
effect on GHRH. Increasing the threshold, th\, actually made the effect worse,
probably since it would also reduce the sharpness of the activation curve. Another
way to return somatostatin to more sudden changes in level, giving a squarer wave
form, was to increase the rate of sr discharge, sr2■ Increasing this to 0.01 gave a much
steeper fall in somatostatin and produced much bigger GH peaks but at the cost of
reducing the cycle length, to give a cycle of 150 min with a 45 min GH feedback
delay. Getting back to a 180 min cycle length required a GH feedback delay of 60
min (figure 3.7b). This produced a pattern of GH release which appeared a good
match to the release profile in male rats (figure 2.11).
Controlling the Somatostatin Release rate
The main problem with the new mechanism is the direct relation between the level
of somatostatin release and the amount stored. In simple systems, if all the releasable
store is stimulated then the release rate will be directly proportional to the amount
stored, but this is very wasteful, releasing somatostatin at a rate far higher than is
required to inhibit GHRH and GH at the pituitary. A better mechanism might be to
limit the release rate to a maximum. To do this a new activation component, Hill
equation sract, was added to the somatostatin equation so that the release rate was
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limited to a value from 0 to 1, determined by the level of activity, ls and the
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This was integrated into the equations for somatostatin and sr by replacing the direct
use of sr, as shown below :
ds
= I<Srart h-j S
dt ' "" 7
ds
-J- = SrAc,-SrJsSrac,at
Parameters th3 and n3 were set to give release with any level of sr and a steep switch
between the maximum and zero release when sr is drained. A typical result is
illustrated in figure 3.8a. Adding this mechanism further decouples the length of the
GH pulse from the delay between them and creates sharper changes in somatostatin
release, giving a squarer wave form. This reduces the problem of gradual change in
the somatostatin level causing smaller pulses of GH at the start of the burst. The
length of the delay between GH bursts becomes much more dependent on the rate of
sr charge and discharge, allowing a longer pulse cycle length with a smaller GH
feedback delay.
Setting a Maximum For the Somatostatin Store
A simpler way of limiting the amount of somatostatin, and one that should
increase the biological plausibility of the mechanism, is to put a maximum on sr.
This was implemented by limiting the rate at which GH can increase the amount of
charge, using the following new equation for sr:
~T~ = SrAct (Onux ~Sr)! ^max ) ~ Srl1sSr
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Figure 3.8 : a. Decoupling somatostatin release rate from sr using Hill equation to limit release. This
makes the period of high somatostatin much more dependent on ,sH and sr2 and less dependent on the
length of the GH pulse, allowing long pulse cycles without using a larger feedback delay, it also
causes higher somatostatin release during the pulse period, reducing GH pulse height (jri=l,
ir2=0-005, «3=2, th2=1, delay=30), pulse cycle = 190min. b. Similar to figure 3.7b, with sr limited to a
maximum level, note the smaller scale for somatostatin, limit reduces somatostatin release and
produces squarer wave form (n2=2, th2=30, delay=60, ,571=1, 572=0.008, srmax=5), pulse cycle =
180min.
The new component limits sr to a maximum value defined by the parameter, srmax. It
makes the charge rate proportional to the difference between the current charge and
the maximum. This reduces somatostatin output to levels sufficient to provide
maximal inhibition of GHRH without releasing larger quantities than is necessary
(figure 3.8b). It also forces the pattern of somatostatin into a squarer wave form by
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cutting off the large peak. The maximum level of somatostatin release matches the
value specified by srmax, in a similar manner to parameter j2 in the first version of the
model. Reducing somatostatin release slightly reduces the length of the quiet period
between GH pulses, but otherwise the GH release pattern is unaffected. The
reduction in cycle length can be compensated by reducing the rate of sr discharge, sr2.
With srmix = 5, the cycle length can be returned to 180 min by reducing sr2 to 0.008
(from the previous value of 0.01), very slightly reducing the height of the GH peaks.
3.7.2 Conclusions
The new version of the model was able to produce a pulsatile pattern of GH
release, and using ligand-receptor activation relationships, more closely based on
biological mechanisms. Using the more sophisticated GH-somatostatin feedback
mechanism allows the model to reproduce the long period of GH release inhibition
without having to use such a long absolute delay, and also suggests a possible
mechanism to be tested in the real system. Adding the extra layer of complexity, with
the activation equation controlling the somatostatin release rate, essentially returns
the model's behaviour to the state before using the somatostatin store, with a square
wave pattern of somatostatin release. The difference is that the period of high
somatostatin release is now controlled more by the charge and discharge parameters
rather than the GH feedback delay. The main argument against this new system is
that it requires a more complex system in the hypothalamus. However, examining
real data also suggests that the period of high somatostatin release is closely related
to the length of the GH burst, suggesting that there is a close causal relation between
the two, unlike in this new mechanism. Using the releasability component allows the
model to produce a pattern of GH release which matches the real data using a
shorter, and probably more realistic, GH feedback delay, and so for the final version
of the basic model it was decided to compromise, and keep the somatostatin
releasability component, limited to a maximum level, but without the extra activation
component, sract. The model is of course maintained in a manner which allows the
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switching of these components for later experiments if further results cast doubt on
the decisions made at this stage. The idea of dividing somatostatin release into
releasability and input activity has worked well and suggests work for real
experiments, perhaps in-vitro work investigating the effect of GH on somatostatin
cells to find out if GH pre-treatment increases release in response to an electrical
stimulus. Little is known of the real mechanism by which GH increases
hypothalamic somatostatin release.
Whether the model really needs the more complex GH feedback mechanism
depends on interpretation of the delay. The GH pulse in data from male rats usually
lasts at least an hour, and so the delay between GH release and increased
somatostatin release must be at least 60min. However, the question is of how this
delay is made up. It seems unlikely that the 60min or more can be just the amount of
time it takes GH to reach the periventricular neurons. It is more likely that there is
some more complex mechanism which delays the response between GH reaching the
periventricular nucleus, and somatostatin release.
The final basic version of the model is illustrated in figure 3.9. The final set of










The two essential hypothalamic components are the somatostatin-GHRH inhibition
and the GH-somatostatin feedback. Together these allow sudden changes in GH
release and create a cycle which generates a pulsatile pattern of release. There is
good evidence that these exist in the real system, but no detail on the dynamics of the
interactions, giving any information on timing, thresholds, or response curves for the
interaction of these substances. To model them, parameters have been chosen by
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trying to stay within a biologically plausible range and by comparing the model's
output with real data. The other component which had to be added to the model was
a pulsed input to the GHRH neurons, in order to produce the multiple peaks within
the GH burst. Evidence from the real system gives two possibilities for the source of
such an input, an adrenergic input, similar to that used in the LH Model (Brown et al
1994) or a feedback connection from GH to the GHRH neurons. These two sources
suggest input with quite different properties, one driven by the model and the other




Figure 3.9 : Final version of the basic model. Somatostatin inhibits GHRH and GH release. GH feeds
back with a delay to charge the pool of releasable somatostatin. A GH pulse causes high level
somatostatin release which continues until sr is drained and somatostatin allows GHRH release again,
triggering another GH pulse.
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The basic version of the model produces an output profile which closely resembles
GH release in the male rat and provides a base on which to experiment with other
components which may exist in the real system, with the aim of getting a more exact
fit to the real data and making the system more robust. The system should also be
capable of reproducing in-vivo experiments, and can perhaps aid their interpretation.
Another important test of the system will be the ability to reproduce the female
pattern of GH release. This will need to be combined with adding a random
component to the GHRH input activity and so this is left to the next chapter,
although initial tests during the model's development have suggested that the current




Experimenting with the Model
Chapter 4
4.1 Introduction
This chapter takes the basic version of the full GH system model and uses it as a
base with which to experiment with the system, testing the effect of new components
and using the model to simulate in-vivo experiments. The aim here is to further refine
the model, to get a closer fit to real data and also to begin doing genuine
experimentation, testing less well defined knowledge and identifying new ways in
which to explore the real system.
The first part of this chapter investigates the GHRH input pulses which were
added in order to produce the multiple peaks within the GH burst. The aim will be to
define what criteria these need to fulfil in order to match the peaks observed in real
data. It will be desirable to have the specification of this external input as loose as
possible, in order to avoid this input being used to drive the model's output pattern. It
will be essential to this analysis to use the sampled version of the model's GH
output, since the pattern of GH release can appear quite different when the temporal
resolution is reduced. If the model is to reproduce the quantitative as well as
qualitative features of real GH release then the only fair way to compare them is
using the simulation of how GH is measured in real experiments.
The first change to the model will be to make the timing of GHRH input pulses
random, in a similar manner to experiments with the pituitary model. A further
development of this will be to attempt to reproduce the less regular pattern of release
observed in the female rat. The entirely new components which will be tested with
the model are those suggested by experimental data, which may play a role in the
normal system. Testing these will indicate what sort of functional role they could
play and on the basis of this, how likely they are to exist in the real system.
Using the model to simulate existing in-vivo experiments will be a further
important test of how well the model represents the real system. If the model is able
to reproduce the real experimental data then it should provide a useful tool to be able
to add to the interpretation of these results. It will be possible, under the assumption
that the model is an accurate representation of the system, to explain the mechanism
behind the system's response to experimental intervention.
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4.2 GHRH Input Activity
The aim here is to test the nature of the external GHRH input by experimenting
with how much it can be varied in the model and still produce a pattern of GH
release which resembles real data. The first part of this will be to experiment with the
frequency of the input pulses. The current 15 min intervals are very long compared to
what might be expected from some general non patterned driving input. Most
electrical signals in the brain are of a much higher frequency and, assuming that there
is an outside electrical input to the GHRH neurons (and this would seem likely to be
the case since blocking possible inputs blocks out GH release) then it is unlikely to
follow such a regular form, or such a slow rate. The second part of the testing will
add a random factor to the input pattern intervals. However, before attempting either
of these the next important step is to examine the sampled form of GH output with
the full version of the model.
4.2.1 The Sampled GH Profile
The sampled profiles here use the extended sampling process developed in
chapter 2, including 30s. sample periods and 10% proportional error in each sample
measure, to simulate the measuring of the GH profile in real experiments. Sampling
has the effect of reducing the number of peaks which appear in each GH burst and
also effects the size and shape of the GH peaks. Applying sampling to the model's
GH output produces a profile which much more closely resembles real data. The
main differences between real GH bursts and the un-sampled model profile are the
sharpness and frequency of individual peaks, and the smaller peaks of GH release
which appear in the model, but not in real data. Running the model data through the
sampling process hides the smaller peaks, reduces the number of peaks and makes
them less sharp, producing a profile very similar to the real data. Figure 3.8 shows
the model data along with a sampled version (15min GHRH pulse intervals). In real
data, the GH profile is the only evidence for the form of GHRH release and the effect
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of sampling complicates the interpretation. There are likely to be more individual
GHRH pulses than the number of individual GH peaks which appear. The next goal
with the model is to test what range of GHRH pulse frequencies could be responsible
for the sampled profile which appears.
4.2.2 Varied GHRH Pulse Frequencies
For these tests the basic version of the GH system model was used with the
parameters specified at the end of chapter 3, varying the GHRH pulse frequency by
controlling the input activity specified by the input protocol. The simulated sampling
uses lOmin sample intervals, in common with typical real data. The pulse interval
was gradually increased (reducing the frequency) beginning with just a lmin interval
between the lmin duration GHRH input pulses, each triggering a corresponding
GHRH pulse during the periods of low somatostatin. Similar experiments with the
pituitary model have already suggested that the interval needs to be quite long in
order to get individual peaks because of the lOmin half life of GH in the
bloodstream.
For GHRH pulse intervals of up to lOmin, nothing but very small individual peaks
appear in the sampled (lOmin sample intervals) GH burst (figure 4.1a). This is as
expected, given the sample interval. At 12min GHRH intervals, well defined two
peaks bursts begin to appear (figure 4.1b), and then at 14min intervals some of the
bursts show three peaks, beginning to more closely resemble real data. When the
pulse interval increases to 18min, 4 peak sampled bursts appear (figure 4.1c) and the
number of peaks stays at 4 until the interval increases to 2lmin and it falls back to
three, as the number of peaks in the un-sampled GH profile reduces, falling to two
peaks after the interval increases to 3 lmin.
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Figure 4.1 : Varied GHRH input pulse intervals and sampled profile; a. 7min pulse intervals, only
small peaks within sampled GH pulse; b. 12min pulse intervals, 2 distinct peaks within sampled GH
pulse; c. 18min pulse intervals, 4 distinct peaks within sampled GH pulse, now matches unsampled
data, larger input pulse interval also creates smaller chance for sampling to detect peak height in
unsampled data, producing smaller peaks in sampled profile.
Two competing processes cause this climb and then fall in the number of peaks
appearing in the sampled profile. In the first place the number of peaks increases as
the intervals become big enough for the samples to pick up more individual peaks. At
the same time the number of peaks in the un-sampled profile decreases, in line with
the reduced number of GHRH pulses. When the interval becomes big enough for
sampling to pick up all the peaks the falling number of GHRH pulses takes over
control of the number of peaks appearing in the sampled profile. Real GH profiles
using lOmin samples (figure 2.11) show two or three distinct peaks in each GH burst.
On the basis of the current model, this suggests that the interval between GHRH
pulses is likely to be in the range of 15 to 30 minutes.
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4.2.3 Random GHRH Pulse Intervals
Although the basic model is able to match the general form of the GH bursts in
real data, including the number of peaks, the length of the burst and the quiet period,
the form of the model's output is too regular to exactly match real data, where the
spacing of bursts, their duration and the number and height of peaks varies. It is also
an important test of the model's robustness that it should still be able produce the
pulsatile pattern of GH release without depending on a regular form for the input
activity.
input pulses
0 100 200 300 400 500
Time (minutes)
100 200 300 400 500
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100 200 300 400 500
Time (minutes)
Figure 4.2 : Random input pulse intervals; a. 15min mean interval, sampled pulses show 2 or 3
distinct peaks; b. 5min mean interval, sampled pulses show no distinct individual peaks; c. lOmin
mean interval + 5min refractory period, sampled pulses show 2 or 3 distinct peaks, also shows
truncated peaks which show a similar form to real data (figure 2.11).
To do this the model software's control of the input protocols was adapted so that
so that instead of specifying a fixed interval between each input pulse, the interval
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could be specified as a random component defined by a mean and a fixed refractory
component (which can be zero). The random component is generated using the
Poisson distribution, the standard form for randomly timing an individual event. The
model was set up using the final set of parameters for the basic model, defined in the
table at the end of chapter 3. With these parameter values and GHRH input pulses of
lmin duration at 15min intervals, the model produced a regular pattern of pulsatile
release matching the general form of the GH profile in male rats (figure 2.11).
For the first test the mean interval length was set to 15min, matching the previous
regular protocol, with no refractory period (figure 4.2a). The first important result is
that the pattern of 3h bursts of GH release was maintained. There was some variation
in the time between bursts, ranging from 170min to 190min, but the general form
showed little change. With the randomly timed GHRH pulses, each GH pulse had a
different form, with peaks varying in height and numbers, sometimes three peaks and
sometimes just one large single peak, very similar to some of those observed in the
real release profiles. The random GHRH pulses also reduced the number of GH
pulses with smaller GH peaks at the start of the pulse, which are usually not observed
in the real data.
Experiments continued by varying the mean interval length. Using a short mean
interval of 5min showed similar problems to the short interval tested with regular
pulses. The sampled GH bursts tended to show only one large peak (figure 4.2b). The
random spacing did reduce this problem, with a few pulses showing three small (very
little drop between) peaks. Increasing the mean interval increased the number of
pulses with two or three peaks, although the variation observed between interval
lengths was less well defined than with the regular intervals. Pulses continued to
resemble the form of real data with mean pulse intervals as high as 50min, although
increasing the mean interval over 30min tended to produce some occasional pulses
with very small peaks. Adding a refractory period produced better results at lower
mean pulse intervals, taking away the very short intervals causing larger single peaks
in the sampled profile. Using a lOmin mean interval with a 5min refractory period
produced a good match to real data (figure 4.2c). One particular feature which is
observed in the real data profiles, particularly the 12min sampled figure, is square
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tops to some of the sampled bursts, which appear to be truncated peaks. In the
sampled model data these tended to be observed more commonly with lower mean
pulse intervals, of lOmin or 15min.
The model has proved that it does not need a regular pattern of GHRH input in
order to produce regular bursts of GH. Using the random pulses the model now
produces a match to real data as close as can be judged given the resolution of real
data. The form of the sampled model bursts provide a good match to those observed
in real profiles, and using the estimated scaling of 1 model GH unit to lOng/ml of
real GH, the height of the pulse gives a good match to real data where pulses are
observed as high as 1200ng/ml. The model demonstrates that the sampled peaks are
likely to be smaller than the true peak levels of GH release, with sampling in the
model producing as much as a 40% reduction in the height of GH peaks. Random
pulse timing extends the range of mean pulse intervals which can produce the
number of peaks observed in real data but still suggests a similar range to that
predicted with regular GHRH pulses, perhaps 10 to 30min.
4.3 The GH Profile in the Female Rat
The pattern of GH release in the female rat is much less regular than the male,
losing the well defined 3h pulses. The levels of release never drop as low as the
periods between pulses in the male and GH peaks tend to be lower, although data
from some female animals does show peaks with heights comparable to those
observed in males. The pulses of GH observed in the sampled female profiles appear
to follow a similar frequency to those observed in the male bursts, and it is thought
that the underlying pattern of GHRH activity is similar, with the sexually
differentiated patterns being produced by varied patterns of somatostatin release.
Evidence suggests that the sex steroids testosterone and oestrogen affect the control
of somatostatin, perhaps modulating the effect of GH feedback. The model can be
used to test this, by using the parameters controlling the somatostatin store and GH
feedback to attempt to reproduce the female pattern of release. However, earlier
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experimentation during the development of the model also suggested an alternative
point at which the effect of somatostatin could be varied between the sexes. Varying
the inhibitory effect of somatostatin on the GHRH neurons can produce a pattern of
release similar to the female, and so this will also be tested here.
The testing here was done using the standard set of parameters, with randomly
timed GHRH input, using a mean pulse interval of 15min added to a 5min refractory
period.
4.3.1 Varying GH Feedback Activation
The first parameter tested was tlil, the Hill equation threshold for GH feedback.
Reducing this value makes the GH peaks smaller and lengthens the GH burst cycle
but maintains the regular pattern of bursts. Increasing its value has the corresponding
opposite effect, increasing the height of GH peaks and shortening the cycle length,
but also maintains the regular male pattern of release. The effect of changing the
Hill coefficient, ti2, was similar. Reducing the value made the GH pulses much
smaller until GH release completely stopped. Increasing the value increased the
height of GH peaks and slightly reduced the pulse length, but again maintained the
regular pulse pattern. Changing these parameters affects the relation between the GH
levels and the somatostatin store, and by extension, somatostatin release. With a
lower threshold, or higher coefficient, the activation curve (the relation between the
GH level and its effect) becomes steeper so that somatostatin release becomes closer
to a square wave, giving very low levels between the high periods of somatostatin
release, which creates the higher GH peaks. However the effect of these parameters
on the regular pattern of release is constrained by there still being the absolute delay
in GH feedback, in these experiments set at 60min. Part of this delay may be due to
the mechanism by which GH triggers somatostatin release, after GH has reached the
somatostatin neurons. This may be modulated in the female, but there is still likely to
be some significant delay, and reducing the delay on its own shortens the pulse cycle
length but still maintains regular pulses.
124
Chapter 4
Attempting to reproduce the female release pattern by changing the parameters
controlling the somatostatin store, sr\ and sr2, is much more successful. Either
reducing sr\ (the charge rate) or increasing sr2 (the discharge rate) reduces the levels
which sr charges to and in turn reduces somatostatin release to levels below the
threshold required to block GHRH pulses. In combination with random GHRH input
activity this creates a more random pattern of GH activity, still with some GH pulses
but following a less regular cycle, and without the periods of very low GH release.
Regular pulses are lost after syi is reduced to 0.2. Making it smaller makes the release
pattern progressively less regular until release matches the pattern of GHRH input
activity. Changing sr2 has a similar effect. Regular GH bursts are lost at 0.2 and with
higher values, GH bursts disappear entirely, leaving just random pulses of GH
release. Figure 4.3a shows an example pattern of release similar to the female rat,
produced by reducing sr 1 to 0.05.
Another way to achieve the same effect is to reduce srmax, the parameter
controlling the maximum level for the somatostatin store. Reducing this to 0.5 (its
normal value is 5) reduces the level of somatostatin release, producing a less regular
pattern of GH release, with smaller GH pulses, tending to maintain a constant low
level of somatostatin release (figure 4.3b). This last feature is in contrast to changing
.syi and sr2 which tends to maintain a more wave like pattern of somatostatin release,
and has less of an effect on GH pulse heights. In real data, the difference between
GH pulse heights in males and female varies between different papers. The
consensus appears to be that GH pulses are usually smaller in females, but some data
shows pulses which are as large as those in males, particularly during darkness.
However, producing the female pattern by reducing sri does reduce also pulse height,
although by a smaller proportion, and this isn't good enough evidence to choose
between the two methods on the basis of which provides a better match to real data.
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4.3.2 Varying Somatostatin - GHRH Inhibition
The two parameters tested here were n\ and th\, the coefficient and threshold for
the Hill equation controlling somatostatin's inhibitory effect on GHRH release.
Increasing n\ increases the steepness of the switch between full inhibition and no
inhibition of GHRH. Higher values increase the height of GH pulses and slightly
reduce the GH pulse cycle length. Reducing n\ to values below 0.7 breaks the regular
pattern of GH release, but also greatly reduces the height of GH peaks with
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Figure 4.3 : Reproducing the female release pattern; a. jrl reduced to 0.05, regular pulse activity lost,
still some peaks similar in magnitude to males; b. ,srmax reduced to 0.5, more level pattern of low
somatostatin release, regular pulses lost, GH peaks smaller than in males; c. th\ (som-GHRH
inhibition threshold) increased to 0.7, regular pulses lost, GH peaks smaller than in males, high level
somatostatin release continues but in a less regular pattern.
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Reducing the threshold, th\, initially increases GH pulse height and increases the
pulse cycle length. However, after reducing thi to 0.2, the effect reverses and as thi is
reduced further, GH pulse heights and the pulse cycle length are reduced until pulses
become so small that they disappear. The regular pattern of release is maintained
throughout. The cause of this is the minimum level of somatostatin release, between
periods of high somatostatin, which is about 0.2 units. This is maintained by basal
GH release having a small effect on sr.
After increasing th\ to values above 5, the regular pattern of GH bursts is lost, with
GH peaks reduced in height. The effect progresses as th\ is increased to higher values
until the pattern of GH release matches the pattern of random GHRH input. GH
pulses are reduced in height but less so than when the female release pattern is
produced by reducing n\. There are still occasional large peaks of GH release. Figure
4.3c shows an example pattern of release produced with th\ =7.
4.3.3 Conclusions
The experiments here have demonstrated that the model can easily be modulated
to produce the female pattern of release. This an important validation of the model,
on the basis that the GH systems in male and female rats are likely to be similar, with
a sex hormone controlled modulation capable of switching between the two patterns
of release. The model has also demonstrated two alternative methods of producing
the female pattern, suggesting two possible sites of modulation in the real system.
The main difference with the method of altering somatostatin's inhibitory effect on
GHRH is that there is a larger reduction in GH pulse height along with the loss of the
regular burst pattern. The variation between sets of real data is too great to use it as a
basis to differentiate between the two. It may however be possible to test this further
by simulating in-vivo experiments which show varied results between male and
female rats, and this will be attempted later in this chapter.
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4.4 Testing a Reciprocal GHRH-Somatostatin Connection
One of the apparent problems with the current model, from a design point of view,
is the sensitivity of GHRH to the gradual changes in the somatostatin level, which
are produced by the mechanisms which prolong somatostatin release. At the moment
the model solves this problem by making the activation curve in the equation which
defines the inhibitory effect, very steep, acting as a switch. This may be biologically
feasible if the system combined several layers of non-linear relations, but is generally
not an ideal solution and not very robust.
What is required is functional bistability in the GHRH neurons. This can be
created by controlling the functional properties of the group of neurons on their own,
or as part of a larger system. Reciprocal connections to another group of neurons can
often produce such properties. There is circumstantial evidence that such connections
between the somatostatin and GHRH may exist. Substances that are contained in the
GHRH neurons have been found to act at the somatostatin neurons, with different
results suggesting both excitatory and inhibitory effects. The model gives the
opportunity to test what effect on the system such a connection might have. It is
obvious within the current system that an excitatory connection from GHRH to
somatostatin will not produce any useful or interesting behaviour. Any increase in
the GHRH level would trigger somatostatin release which would then immediately
suppress GHRH, so that GHRH would never be able to increase to a significant
level. The behaviour of an inhibitory connection however is less predictable, and so
this makes an interesting component to test with the model.
4.4.1 Implementing the Inhibitory GHRH-Somatostatin Connection
The new connection was implemented in a similar manner to the inhibitory
somatostatin-GHRH connection, using a Hill equation to give a measure of





The new parameters, th4 and n4, give the threshold and binding coefficient. This was
integrated into the control of somatostatin, so that it can modulate release activity,
using the following new equation :
ds
— = snctIsr -k7s
dt
The Hill coefficient, n4, was set at an initial value of 2, similar to the GH feedback
equation. The threshold parameter, th\ was set at 1, a fairly low level of GHRH
release. In the model software the new component was set up so that it could be
switched on and off in order to easily to make a direct comparison of the model's
behaviour with and without the new component.
4.4.2 Testing the New Component
The model was initially run with regular 20min GHRH pulse intervals. Its
immediate effect was to increase the size of GHRH pulses and the corresponding GH
peaks, particularly the smaller ones which had previously been partially inhibited by
somatostatin (figure 4.4a). There was no effect on the overall pattern of GH bursts.
Adding random pulse intervals to GHRH input, showed similar effects, with slightly
larger GH pulses, and a few more single peaked pulses appearing in the sampled GH
pulses (figure 4.4b).
The new component creates bistable behaviour in the GHRH neurons. When
somatostatin partially inhibits GHRH, but GHRH is still above the threshold to
inhibit somatostatin (r/z4), then somatostatin is inhibited and the GHRH pulse
becomes much larger. This results in either full size GHRH pulses or GHRH entirely
inhibited by somatostatin. This makes the model more robust, with less variation in
GH pulse size, but does not add anything functionally to the model. The resolution of
real data and the rough scaling of the model's GH level to real GH release is not
sufficient to judge such a subtle variation by comparing the effect with real data. The
important test is whether this new component allows the inhibition of GHRH by
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somatostatin to be made less steep. When the parameter controlling this activation
curve, m, is reduced from 4 to 2 the pattern of GHRH release takes on a more wave
like form, with smaller pulses at the start and end of the GH burst. Adding the new
component allows n\ to be reduced to 2, with larger pulses of GHRH maintained. In
terms of comparing the sampled GH profile with real data, the GH pulses with the
new connection tend to be taller with steeper sides (figure 4.4c), which appears to be
a closer match to the real data.
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Figure 4.4 : GHRH-somatostatin inhibition; a. regular 20min interval GHRH pulse input, GHRH
pulses over threshold inhibit somatostatin, removing their own inhibition, producing bistability in
GHRH, GH pulses are taller and more regular; b. random 15min mean + 5min refractory period pulse
input, GHRH pulse heights more regular, taller more regular peaks in GH pulses (cf figure 4.2c); c. as




The new component is based on evidence from real data, and added to the model it
does play a useful role in the system, making GHRH activity robust and allowing a
more biologically plausible relation in the inhibitory effect of somatostatin on
GHRH, requiring a simpler biological mechanism. The new connection has no
negative effect on the model's behaviour although at the same time, it doesn't add
anything to the model functionally and if the main goal is to keep the model simple
then this new connection should probably be left out. However, its role in making the
system more robust and providing a use for some of the experimental evidence is
strong enough to suggest possible experiments with the real system, looking for such
a connection.
4.5 GH-GHRH Feedback
When it originally became apparent that GH feeds back to inhibit its own release,
there were two possible ways in which it could do this, by inhibiting GHRH, or by
exciting somatostatin release. Evidence for both of these connections exists at the
anatomical level. Testing exogenous GH along with injections of GHRH and
somatostatin also suggests that both of these connections exist, and probably vary
between the sexes. The main reason for not including the GH-GHRH connection in
the model this far was that it was not required to produce the basic pulsatile release
pattern, for which the GH-somatostatin connection is essential. It is essential to have
high somatostatin release as well as low GHRH between the pulses in order to get the
periods of very low GH release. The motivation for adding the GH-GHRH
connection at this stage is to find a more self contained method of producing the
pattern of input required by the GHRH neurons. In order to match the appearance of
real GH profiles, the model needs input pulses that are separated by much longer
intervals then would normally be expected from a triggering input coming from
another part of the brain. A possible candidate for producing this pulse interval might
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be an inhibitory input triggered by GH. The interval between GH peaks appears to
match their duration, determined mainly by the half life of GH in the bloodstream.
4.5.1 Implementing the GH-GHRH Feedback Component
The new component uses a similar form to the mechanism by which somatostatin
inhibits GHRH. A new Hill equation, hract, gives a measure of the GHRH inhibition




The new parameters ns and ths give the Hill coefficient and threshold and were
initially set to the same values as those used for GH feedback at the somatostatin
neurons to give ns = 2 and th5 = 30. The new equation is integrated into the GHRH
equation so that it can directly modulate release activity :
= CcMact1 r ~ k6r
at
Similarly to the new GHRH-somatostatin connection, the new component was set up
in the model software so that it could be switched on and off for comparison. The
model was tested using the standard set of parameters, and without the GHRH-
somatostatin connection.
4.5.2 Testing GH-GHRH Feedback
The goal for the new connection is to be able to replace the pulsed external input
to GHRH. Even if it is capable of producing the required pattern of modulation, it is
likely that there will still need to be a level of input activity, perhaps a constant high
input similar to that used with the somatostatin neurons in the model. In the first
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instance the new connection will be tested with the normal pattern of GHRH input to
see how it can work with the current form of the model. The aim is that it should be
able to override the external pattern of input pulses and change the form of the GH
bursts.
a b
Figure 4.5 : a. GHRH input at constant level, pulsatile GH release continues with reduced cycle
length (152min); b. first attempt at using GH-GHRH feedback, after delay GH peak inhibits GHRH
producing two peaks within each GHRH pulse and corresponding GH release (n5=2, r/i5=30,
delay2=15) (pulse cycle=158min)
For the first test the new component was set up with parameters as specified
above, running the model with regular input pulses to GHRH. The only effect of
adding the new connection was to reduce the size of the GH pulses. With an
immediate feedback effect the individual pulses just work to inhibit themselves.
Testing with a constant level of GHRH input, instead of regular pulses, still produces
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the pattern of 3h pulses of GH release, but the pulses consist of one long period of
sustained release with no individual peaks. The obvious problem is that there needs
to be a delay in GH feedback, similar to the delay used for feedback at the
somatostatin neurons. This makes sense biologically as a similar process that is
responsible for at least part of the somatostatin delay is also likely to affect feedback
to the GHRH neurons. However, if the GH-GHRH feedback effect is to be used to
form the local structure of the GH pulses then the delay will need to shorter,
probably in the same 15-30min range determined for the external input pulses. The
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The new value, hdeiay2 gives the value for h (the GH level) at a previous time point,
specified by the parameter delay2. This was initially set to 15min. In the first test
with the delay, the model was given regular GHRH input pulses at matching 15min
intervals. This produced a similar result to using no delay, with the delayed inhibition
effect working on the following GH pulse, although it did have some effect on the
relative heights of the individual peaks, tending to make the later ones in the burst
smaller. It was clear at this stage that attempting to test the new component alongside
the existing input pattern added too much extra complication and so the input pattern
was set give a constant high input, the same as that used with somatostatin.
For a first control test, the model was run with constant GHRH input and no GH-
GHRH connection. The model continued to produce a pulsatile pattern of GH
release, but GH pulses consisted of just one large peak of GH release, with a shorter
pulse cycle length of 152min (figure 4.5a). GHRH release corresponding to each
pulse consisted of just a single period of constant high release, lasting for
approximately 60min. For the next step, the GH-GHRH connection was added in,
with parameters «s=2, th5=30 and delay2=15. This immediately had some success,
producing a smaller second peak in GHRH release, and a corresponding small
second peak in the GH pulse (figure 4.5b). The pulse cycle was slight increased to
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158min. The change in GHRH inhibition was too gradual to produce sharp pulses of
GHRH release and so the parameters for GH-GHRH feedback were adjusted to try
and produce sharper inhibition of GHRH. Reducing t/z5 to 20 and increasing n5 to 4
produced two distinct pulses of GHRH for each pulse and a much more distinct
second peak within the GH pulse. The cycle length was again slightly increased to
162min. This improved further by increasing ns to 8, producing a very switch like
inhibition of GHRH and a larger second peak in the GH burst, though still smaller
than the first. The cycle length increased to 164min. More changes to the parameters
did not produce any significant change in the form of the GH pulse.
a b
Figure 4.6 : a. steeper gradient on GH-GHRH inhibition produces sharper GHRH pulses, producing
well defined individual peaks within each GH pulse (/i5=16, ths=30, delay2=5); b. increasing GH-
GHRH feedback delay reduces the number of peaks (n5=16, th5=30, delay2=15)
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The next stage was to test the effect of changing the delay length, delay2. This
began with parameters 715=8 and ths=20. Decreasing delay2 to 5 min produced 3 peak
bursts of GH release, but the peaks were small and the pulse cycle length was
reduced to 150min. Further increases in 725 made the individual peaks much larger,
with the second peak usually the largest in the un-sampled data, and also increased
the cycle length. After increasing 225 to 16, the middle peak began to dominate the
pulse, with the third peak becoming smaller until it disappeared at 724 =22. At the
same time the reduction in the third peak reduced the effect on somatostatin feedback
and reduced the pulse cycle length. At 725=16, r/25 could be increased to 30 to produce
larger to GH peaks and a longer pulse cycle (164min), but further increases in th5
moved the peaks closer together and reduced the pulse cycle length.
Increasing delay2 to lOmin (725 = 8 and ths = 20) returned the pulse to two distinct
peaks of GH release, although, unlike the 15min delay, the second peak tended to be
the largest. Increasing 725 and reducing t/25 produced a very large second peak and a
corresponding long cycle length of over 170min. Increasing delay2 to 20min
produced a GH pulse with only a very small second peak and shorter cycle length
(148 min with 725=8 and ths=30).
For further testing, the two Hill equation parameters were fixed at 725= 16 and th5 =
30 since these values produce GH pulses with a good resemblance to real data with
each of the values for delay2. The model's GH output with these parameters and
delay2=5 and delay2=15 is illustrated in figure 4.6. With both delay2=5 and 15min
the pulse cycle length can be returned to over 180min by reducing sr2 to 0.004 or by
increasing the GH-somatostatin feedback delay to 75min. The sampled model GH
profiles with the GH-GHRH feedback connection using these parameters give a good
match to real data, except for having too regular a form to the GH pulses, which in
real data vary in the number and heights of GH peaks. One way to solve this problem
is to replace the constant level of GHRH input with frequent randomly timed input
pulses, such as a mean 5min interval with no refractory period. With no GH-GHRH
feedback this produces correspondingly frequent GH pulses, which in the sampled
data appear as a single long peak of GH, but the feedback component can act to
enforce longer, fewer, more distinct pulses of GH, with GH bursts ranging from two
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to four peaks in the data (delay2 = 5) processed through lOmin sample intervals
(figure 4.7). Using higher values for delay2 (10 or 15) produces GH bursts with
usually two, and occasionally, three peaks.
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Figure 4.7 : Mixing short mean interval (5min) random GHRH pulses with GH-GHRH feedback; a.
5min feedback delay, produces 2 to 4 peaks within each pulse; b. 15min feedback delay, usually 2 and
occasionally 3 peaks within each GH pulse
4.5.3 Conclusions
Given the useful role that the GH-GHRH feedback component plays in the model,
and the physiological evidence for such a connection, it seems likely that this may be
a part of the real system. Experimenting with the model's sampled output in
comparison with real data indicates that there needs to be an average interval
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between GHRH input pulses (or release triggering activity in general) of at least
15min. Even if the system does not rely on this input being regular, it is unlikely that
there could be an external input that could fulfil this criteria without having a specific
pulse generator. Adding the new feedback component to the model gives the system
its own pattern generator for GHRH activity and makes it more self-contained, one
of the original goals of the modelling. However, the irregularity of real GH release
profiles still suggests that the model needs a random element in driving the GHRH
pulses. The irregular pattern is evident even on a very long timescale and the
relatively small errors in sampling are not sufficient to reproduce this pattern. Adding
a high frequency randomly timed input to GHRH, which is regulated by the GH-
GHRH feedback connection, allows the model the produce a more irregular pattern
of GH release which gives a closer resemblance to real data.
The parameters used with the new connection use very high Hill coefficients,
values which specify a much sharper change in the activation level than would
normally be produced by a simple biological mechanism. The high values are
required in order to reproduce the fairly sharp peaks observed in real GH release
data. These require sharp pulses of GHRH, and a more gradual change in GH
feedback inhibition cannot produce these.
4.6 Simulating Real Experiments
An important test of the model, after reproducing normal function in the system, is
to be able to reproduce the results of in-vivo experiments where substances are
administered. If the model is able to reproduce these results then it will provide more
validation of the model and also help to interpret the real experiments. If the model
does not match the results then the conclusion will depend on the particular instance,
but it may suggest that the model's behaviour needs to be altered to better represent
the real system. The experiments to be used here include those where the three
substances, GHRH, somatostatin and GH itself, are manipulated, either by injection
or infusion, or blocking endogenous content using antibodies. The first stage in doing
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this is to alter the model so that the artificial addition or removal of these substances
can be simulated.
4.6.1 Implementing Artificial Substance Control
For the purpose of simulating in-vivo experiments, the input protocol system was
updated and extended. A separate GHRH input pulse protocol was added, to replace
use of the general GHRH input protocol, and the original GHRH protocol was
returned to a form where it can control the GHRH variable independently of other
influences. The new GHRH equation is given below :
4r
, r , r
— = racthraJr-Kr+Ir2
The input pulse protocol controls the value Ir and the general GHRH input protocol
controls Iri, with its own input rate parameter. Since development of the full
hypothalamic model, somatostatin has been given a constant input and so this was
replaced in the somatostatin equation by just a constant value, the somatostatin
release rate parameter (here denoted sp). It is uncertain whether exogenous
somatostatin acts at the hypothalamus or just at the pituitary, and so the model was
set up to allow testing of both alternatives. Simulating action at just the pituitary was
more complex because the model needs to maintain separate levels for exogenous
and endogenous somatostatin, summing the two for pituitary actions. To do this, a
new variable was added to the model, se, using the same form as the somatostatin
equation in the pituitary model. The input value Is was left in the main somatostatin
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The final change was to add a similar general input protocol for GH, controlling the
new value Igh- This gave the following new GH equation :
^ = [kA + k5 (1 - d>(s))] [r + c]f-kth + Ighat
The general input protocols use the same form as the original versions in the pituitary
model, but because they are summed with other components, they no longer entirely
control input to their variables. Instead, they add some quantity, specified by the
input rate parameters to the variable at specified time points, defined by the input
protocol. In this way they perform the same function as an artificial injection or
infusion.
Experiments which add antibodies for a substance to the system can be simulated
by increasing the substance's clearance rate (reducing half-life) in the model. This is
fair way of simulating this effect in the model since this is essentially what the
antibodies do, eliminating the substance after release, rather than blocking release in
the first place.
4.6.2 Simulating GHRH Injections
For these experiments the model was set up using the standard set of parameters
and tested using three different forms for GHRH input; regular GHRH input pulses,
random input pulses and GH-GHRH feedback. In the real experiments where GHRH
injections are given, the exogenous GHRH is usually at a concentration sufficient to
produce a maximal GH response, and usually produces larger GH pulses than those
normally observed. The GHRH input rate used for GHRH input pulses in the model
is currently Ir = 10. This is sufficient to produce large GH pulses but is not maximal.
According to the scaling experiments with the pituitary model, the large lpg
injection used in in-vivo experiments is equivalent to a 1000 unit input rate in the
model. The GHRH-GH dose response curve follows a logarithmic scale and so 1000
units produces roughly five times as large a GH response as 10 units, without the
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presence of somatostatin. During normal function of the model, with somatostatin in
the system, giving an artificial pulse of GHRH and increasing lr2 from 10 to 1000
units only produces a 200% increase in GH pulse height. The effects of sampling
further reduce the difference in pulse height. These differences in pulse height appear
to match those observed in real data (Clark and Robinson 1985a) and so for
experiments with the model GHRH input was kept fixed at 10 units, and injections
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Figure 4.8: a. 180min interval GHRH injections (/r2-1000), synchronised with exist GH pulses,
produces large GH peak which dominates existing pulse; b. 180min injections 90min out of phase
with existing GH pulses, release initially disrupted, then after two injections, release synchronises
with injections
For the first test, the model was given 3h injections of GHRH, timed to either fall
during normal GH pulses or during the low GH release periods. With regular GHRH
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input pulses (15min interval), the injections during the GH bursts created a much
larger pulse of GH release, dominating the pulse and appearing as a single peak in
sampled data (figure 4.8a). Injections timed to fall between normal pulses initially
produced irregular GH output but after the first two pulses there was a normal GH
pulse and then all following pulses synchronised with a large GH peak in response to
the injection and smaller pulses of GH release generated by normal GHRH activity
(figure 4.8b). The effects using randomly timed GHRH input pulses were similar.
Testing with constant GHRH input and GH-GHRH feedback also produced similar
results, although with a smaller increase in GH peak height and retaining multiple
GH peaks within the GH burst. The longer duration GHRH pulses produced by GH
feedback control drain/ (pituitary GHRH sensitivity) to a lower value so that there is
less capacity to produce larger pulses of GH release. The lower ability to respond to
GHRH is also why the pulses retain their multiple peaks, with the injection triggered
peak unable to dominate. Replacing the constant GHRH input with frequent random
input pulses produced similar results to those without GH-GHRH feedback, although
still with more pulses showing multiple peaks.
These results are a good match to the equivalent real experiments (Clark et al
1986) where 3h injections of GHRH produce GH pulses with a large central peak
and, if given out of synch with endogenous activity, cause the system to train to the
new pattern. This was one of the most important pieces of evidence for feedback in
the system, and the model's ability to reproduce this is an important validation for its
design. In other experiments (Clark and Robinson 1985c) GHRH was injected at
more frequent intervals and produced a more varied response, with the system
continuing to follow the pattern of 3h responsiveness, although sometimes producing
smaller responses to the injections falling between the dominant release periods.
For the next test the model was run with injections of GHRH at 90min intervals.
Testing with no GH-GHRH feedback and regular GHRH input pulses produced a
pattern of extended GH bursts, separated by a very short quiet period. The pulses
continued to follow the three hourly pattern but the large extra pulse of GHRH, out
of synch with the main pulse produced an extra peak of GH release, making the pulse
much longer (figure 4.9a). The timing of the pulses entrained to peak with every
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second injection. The peaks were also smaller than the large ones observed with the
injections at 180min intervals. Somatostatin remained high during the second GHRH
injection in each pulse cycle but the inhibition at the pituitary was insufficient to
block release by the large dose GHRH injection. In real experiments there is a large
GH response to every second injection, with the alternate ones producing only a very
small pulse of GH. This difference could be due to the fitted somatostatin inhibition
in the pituitary model being too weak compared to the real system and so the dose
rate of the GHRH injections was reduced. This reduced the size of the second peak,
but still did not produce the very small response observed in real data. Testing with
random GHRH input pulses produced similar results. The same test was repeated
after adding GH-GHRH feedback back into the model but this still produced the long
pulses with a GH peak in response to both GHRH injections within the 180min cycle
periods.
Adjusting the Pituitary Model
In the pituitary model the GH equation has a release component which is relative
to the GHRH level but not modulated by somatostatin. This component is scaled to
produce much lower levels of release than the somatostatin modulated component,
but with the very high levels of GHRH the model is exposed to, simulating the
injections, this component produces a large release of GH. Before the model was
tested with injections of GHRH, all of the GHRH in the system was also inhibited by
somatostatin in the hypothalamus. The injections are not subject to this inhibition and
this is the first time that the model has had to be able to suppress GH release using
just somatostatin inhibition at the pituitary. Inhibition at the pituitary was tested
during the model's development, but not with such high doses of GHRH. The real
results (Clark and Robinson 1985c) show the system producing almost no response
to the large dose injections of GHRH, when they fall during the period of high
somatostatin release, suggesting that high levels of somatostatin at the pituitary
should be sufficient to almost entirely block GH release. On this basis it was decided
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to experiment with the pituitary model's parameters which control GH release,
particularly k4, which gives the level of release which is not modulated by
somatostatin.


















Figure 4.9 : a. 90min interval GHRH injections (/r2 = 1000). Some disruption before pulses
synchronise with injections, then large response to both injections in each 180min pulse cycle,
creating extended pulse with short low GH release period. Second injection in pair falls during high
somatostatin, but insufficient inhibition at pituitary (&4=9); b. non-somatostatin modulated GHRH-
triggered GH release reduced (Ar4=2), much smaller response to second injection in each pair, similar
to result in real experiment, but smaller peak GH in pulse.
To test this, k4 was reduced from 9 to 2 units and the model was tested first with
no injections of GHRH. The heights of the GH peaks were slightly reduced, but the
pattern of GH bursts and the peaks within them was not changed. GHRH injections
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were then added and the model produced a pattern of release with a much closer
resemblance to the real data. The GH response to the second injection in each pair
was much smaller, making the response to the injection during the main pulse larger,
with the reduced second peak no longer causing depletion of pituitary GHRH
sensitivity and higher somatostatin levels (figure 4.9b). The model was tested further
using injections of GHRH at 40min intervals. With the normal pituitary model
parameters 3h GH pulses were lost, with the model producing regular single GH
peaks in response to each injection (figure 4.10a). It was necessary to reduce k4 to
0.5 and also to strengthen somatostatin's inhibition of GH release at the pituitary by
reducing deltal from 0.3 to 0.2. This produced a good match to the real experimental
results (figure 4.10b).
Conclusion
Overall the model worked well in reproducing these experiments but it has forced
the pituitary model to be re-examined at a late stage. The current model is unable to
reproduce the real system's ability to block the response to high dose injections of
GHRH. The non-somatostatin modulated component in the pituitary model's GH
release equation allows too high a rate of release, and it appears that this part of the
pituitary model needs to be changed, in order to give a better simulation of the real
system. Before this point in testing, where GHRH was also subject to central
inhibition in the hypothalamus, the model did not require such strong inhibition at
the pituitary and so if this change, reducing the value of parameter k4, had been made
earlier, it would not have had a significant effect on the previous results. Testing this
here, with the model's normal behaviour showed only a small reduction in the height
of GH peaks, with no change to the overall pattern of release. The case for blocking
GHRH at both the hypothalamus and the pituitary remains, since the two levels of
inhibition produce a more switch like change in GH release levels, and also block
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Figure 4.10 : a. 40min interval GHRH injections (7,2=1000). Normal GH pulses lost, GH peak in
response to each injection (&4=9, 8t= 0.3); b. pituitary model parameters adjusted to reduce non-
somatostatin modulated GHRH triggered GH release (&4=0.5) and increase somatostatin inhibition of
GH release (§!= 0.2). Large GH response to only every fourth injection, smaller response to preceding
injection, similar to result in real experiment
4.6.3 Simulating Somatostatin Infusions
Giving a high dose (50pg/h) infusion of somatostatin almost entirely blocks GH
release in the male and female rat (Clark et al 1988a), with only occasional
detectable levels of GH in blood samples. With a lower dose infusion (lOpg/h),
which is likely to be closer to endogenous levels of release, there is some response to
high dose (lpg) injections of GHRH, but still producing very small pulses of GH
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release, no higher than lOOng/ml. The lowest dose somatostatin infusion in the
experimental results referenced here is lpg/h, given to male rats (Clark et al 1988a).
At this dose there is still GH release, although at reduced levels, and without the
distinctive pulsatile pattern, almost resembling the female pattern of release.
Following the somatostatin infusion there is large rebound release of GH,
producing a very high GH peak. This rebound is almost entirely knocked out when
animals are given anti-GHRH serum and must be to be due to either an increased
ability to respond to GHRH, or a large release of GHRH triggered by hypothalamic
action of somatostatin. The latter was the basis for using the rebound to trigger
release in the first version of the model, but it is probably the least likely of the two
explanations. It would require that exogenous somatostatin is somehow transported
into the hypothalamus, which although possible, is considered unlikely. But the best
argument against this is that a large release of GHRH alone, such as the high dose
injections of GHRH, is insufficient to produce the very large rebound. The sensitivity
to GHRH at the pituitary and the ability of somatostatin the increase this factor
makes this the more likely explanation.
The aim here is to attempt to reproduce these results with the model, and to use the
model to further suggest which mechanisms are most likely to be responsible for
these effects. Some of the experimental results are from female rats and this will
provide a test of the different methods used to reproduce the female pattern of release
with the model.
For the tests here the model was set up with GH-GHRH feedback switched on
(delay2=5, ^4=16, t/i4=30), with random input pulses (mean interval 5min, no
refractory period). The first experimental data for comparison is figure 1 in (Clark et
al 1988a). This shows the GH rebound in male rats given a 4h high dose (50pg)
infusion of somatostatin. The model was set up to reproduce this experiment with
742=50, high enough to almost totally block GH release. For the first test the model
was switched so that the exogenous somatostatin only acted at the pituitary (figure
4.11a). This immediately demonstrated the same problem with non-somatostatin
controlled GH release, as seen with the GHRH injection experiments. Parameter k4
was reduced to 1 and this solved the problem, producing very low levels of GH
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release during the somatostatin infusion (figure 4.11b). However, there was no
apparent rebound GH release following the somatostatin infusion. Although GH
release is blocked during high somatostatin, pulses of GHRH continue to reduce
sensitivity to GHRH. Switching the model to allow exogenous somatostatin to act at
the hypothalamus and block GHRH release, as well as GH release at the pituitary,
allows the sensitivity to GHRH to charge up at the pituitary.
b c
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Figure 4.11 : a. somatostatin infusion only acting at pituitary, high dose unable to block GH release
(k4—9, /i2=50); b. pituitary non-somatostatin modulated GHRH triggered GH release reduced (&4=1,
7,2=50), now get almost total block of GH release during infusion, but no large GH rebound release
after withdrawal; c. somatostatin infusion acting at pituitary and hypothalamus, GH release
completely blocked during infusion, large rebound GH release following infusion.
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This successfully produced a large rebound release of GH following the somatostatin
infusion (figure 4.11c), with a good resemblance to the real experimental data.
The second real experiment to be simulated is figure 5 in (Clark et al 1988b). Here
female rats were given a similar long infusion of somatostatin, but also with
injections of GHRH. The results are similar, a GH peak in response to each injection,
with the first injection following the infusion producing a much larger rebound GH
pulse. The model was set up to produce female release behaviour by reducing .syi to
0.07 and with exogenous somatostatin set to act at the hypothalamus. Figure 4.12a
shows the model at this stage, producing a female release pattern. Parameter th4 was
reduced to 20, to give more distinct pulses of GH with the lower levels of GH
release. For the next test an infusion of somatostatin was added, timed to match the
real experiment. This successfully produced a rebound release of GH following the
infusion, similar to the model simulating the male rat (figure 4.12b). Finally, GHRH
injections were added (at maximal dose, input rate = 1000) matching the real data's
timing (9 injections at 45 minute intervals, with 2 injections before the somatostatin
infusion). The model produced slightly larger responses to GHRH during the
somatostatin infusion than the real experiment but the pattern of GH release was
otherwise very similar, with a larger GH peak at the end of the infusion followed by
two smaller responses to the following injections (figure 4.12c). The tests here were
repeated with the alternative method of producing female behaviour by reducing
srmax to 0.5, but the results were very similar.
These successful results further validate the model's ability to reproduce the
behaviour of the real GH system. They also give evidence to suggest that artificially
administered somatostatin acts at the hypothalamus, since the model is unable to
reproduce the rebound otherwise. Without hypothalamic action, GHRH release
continues to desensitise the pituitary's response and there is no priming effect from
the prolonged high levels of somatostatin to produce the large GH rebound. It was
attempted to use the model to test the alternative idea of the GH rebound being due
to a GHRH rebound, but because the model was already producing a rebound effect
with exogenous somatostatin allowed to act centrally, there was no way to test this
properly. Disabling the components which allow the pituitary generated rebound
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would change the model too much. The fact that the pituitary system is already
capable of producing the rebound (in conjunction with hypothalamic GHRH release)
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Figure 4.12 : a. female release pattern produced by reducing sr charge rate (,srl = 0.07); b.
somatostatin infusion (with hypothalamic action) (7V=50), all GH release blocked during infusion,
period of very low somatostatin after infusion with rebound GH pulse; c. 45min interval GHRH
injections (/r2=1000), very small GH responses during infusion, period of low somatostatin and large
GH rebound pulse in response to first injection after infusion, good match to real experiment (Clark et
al 1988b figure 5); (&4=1)
4.6.4 Simulating GH Infusion and Injections
Infusing human GH in the male rat produces an inhibition of GH release, with
only very small responses to GHRH injections. There is however usually a delay on
. . .




the order of lh before the rat stops responding to GHRH after the start of the infusion
(Carlsson et al 1990 figure 2a). The model was used to attempt to reproduce this
experiment. Pituitary model parameters were set up to allow somatostatin to almost
fully block GH release (£4=0.5, <5i=0.2). GH-GHRH feedback was switched on with
random 5min mean interval GHRH input pulses. The model was given 45min
interval maximal dose injections of GHRH timed to match the real experimental data
(figure 4.13a). GH pulses synchronised to the injections, producing large 2 peak GH
pulses and only a very small response to injections during high somatostatin release.
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Figure 4.13 : Simulating GH infusion and GHRH injections in male rat; a. 45min interval GHRH
injections, produces large 2 peak GH pulses; b. 6h GH infusion, timed to match real experiment, get 1
injection response during infusion and then only very small GH responses to each injection, normal




Next, the 6h GH infusion was added, timed to match the real experiment. The first
GHRH injection after the start of the infusion still produced a large GH response, due
to the 60min GH-somatostatin feedback delay. For the rest of the infusion, and for a
period afterwards, matching the delay, GH release was almost entirely blocked with
only very small responses to each GHRH injection. After the delay at the end of the
infusion, the injection response recovered (figure 4.13b).
The result with the model is a very good match to the real experiment and suggests
the result is due to the infused GH inhibiting endogenous somatostatin release after a
long delay. In the real experiment, the second GHRH injection after the start of the
infusion (approximately 60min into the infusion) still produces a GH response,
suggesting that the feedback delay in the real system is at least 60min.
The final experiment tested with the model, gives male rats injections of hGH,
following varied time patterns (Carlsson and Jansson 1990). Injections give a closer
approximation of endogenous GH release. They showed, that in a similar manner to
GHRH injections, endogenous GH secretion, after 2 or 3 pulses, synchronises with
the 3h injections. They also showed how the pattern could be disturbed by shifting
the phase of the injections or doubling the frequency to 90min intervals. The model
set up with the new pituitary parameters (&4=0.5, <Si=0.2), GH-GHRH feedback
(5min delay) and random 5min mean interval GHRH input to test all three of these
results. The GH injections in the model were simulated by short 3min infusions at
input rate 7g/l=10, set to give a comparable response to the real experiments. In the
first test, the model was given 4 180min interval GH infusion. The first GH infusion
was followed by a large GH peak after a slight delay. Following GH pulses gradually
synchronised until the GH pulse was already rising slight before the GH infusion
(figure 4.14a). This is a good match to the real experimental result (Carlsson and
Jansson 1990 figure 2). The next test gave four infusions, with the second pair 90min
out of phase with the first pair. The first two produced similar GH responses. There
was no response to the third GH infusion and there was GH pulse already rising at
the fourth infusion (figure 4.14b). The real data shows similar results, but a smaller
response to the fourth infusion and then very little GH release for the rest of the
experiment (approx 4h). The model in contrast produced a large GH pulse 3h after
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the last infusion and then returned to the normal release pattern. In the final test the
model was given 7 GH infusions at 90min intervals. The first infusion produced a
fairly large GH pulse response. Following that, there was a small GH pulse following
every second GH infusion, and no response to the others. The results in the real data
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Figure 4.14 : a. 180min interval short (3min) GH infusions. GH pulses gradually synchronise with
infusions, later pulses already rising before the infusion; b. second pair of GH infusions 90min out of
phase, no response to third infusion, early response to fourth infusion, followed by another large GH
pulse, not observed in the real data, probably random coincidence of two GHRH pulses in quick
succession; c. 90min interval short GH infusions, GH response to first infusion, followed by small
responses to every second infusion, following normal 180min responsiveness, eventual return to
normal release pattern; (cf (Carlsson and Jansson 1990) figure 2, 3 and 4); GH infusions are indicated
by short lines above the non-sampled GH profiles.
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Based on the model, the effects of the infusions appear to be a combination of
GH's feedback on GHRH and somatostatin. The inhibitory GH-GHRH feedback is
probably responsible for the slightly delayed GH response to some of the infusions,
temporarily inhibiting GHRH release. The GH pulses which are already rising during
the infusion show a period of inhibition, with a fall between peaks within the pulse.
The similar time frame here between the model and the real data supports the short
5min GH-GHRH feedback delay. The major effect, disturbing the GH pulse cycle, is
due to GH feedback on somatostatin, triggering a refractory period following each
GH infusion. The match with the real data is further evidence that the model is a
good representation of the real system.
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Modelling Spike Firing in Oxytocin Cells
Chapter 5
5.1 Introduction
This chapter moves away from the GH model to study a new modelling technique
for the analysis of the spike firing patterns in neurons. The GH system eludes direct
measurement while it is functioning, but it may be possible to find out more about
the neurons by analysing what recordings we have and attempting to find general
properties of their behaviour. However, in the first instance of this study, the firing
patterns being studied are from oxytocin cells. These are large magnocellular
neuroendocrine cells in the supraoptic nucleus of the hypothalamus that project to the
posterior pituitary to release oxytocin into the bloodstream. These cells are relatively
easy to record from and we already know a lot about their function and
electrophysiological properties.
5.1.1 Previous Work
The new model is a development of previous work (Leng et al 2001) which
produced a version of the classic integrate and fire model (Tuckwell 1988) for
oxytocin and vasopressin neurons. The model was successfully used to explain the
unusual linear increase in firing activity in response to increased input stimulation,
demonstrating the apparently counter intuitive idea that this could be achieved by
giving an equal amount of excitatory and inhibitory input pulses. It was able to
predict and explain what had previously appeared to be contradictory experimental
results. It was also successfully tested experimentally by blocking the inhibitory
input transmitter GABA, the release of which had been detected in response to the




The main aim of the new work is to investigate a strange effect which can
discovered by analysing long recordings from oxytocin neurons, looking particularly
at the intervals between spikes. If the firing of each spike is independent from
previous activity then there should be no relation between the length of a particular
spike interval and those which come before. A plot of inter-spike intervals (ISIs)
against the mean interval one spike before should be flat, indicating no relation.
However, by progressively taking a large number of intervals of a particular length
and plotting this interval length against the mean ISI previous to these intervals, a
downward slope does emerge, indicating that a longer ISI is more likely to be
followed by a shorter interval and vice-versa. This means that there must be some
component of the oxytocin cell's behaviour which causes it to effectively remember
previous firing activity. This would have to be an unusually long lasting
electrophysiological effect, and the prime candidate for this was the after hyper-
polarisation (AHP).
The AHP is a very small magnitude electrophysiological effect which is not
normally detected when recording from oxytocin cells but can be observed by giving
a very high frequency train of input pulses. The AHP then appears as a very long
lasting (several seconds) hyper-polarisation which reduces the cell's ability to fire by
lowering the membrane potential and increasing the amount of input activity required
to reach firing threshold.
In order to test the ability of the AHP to produce the memory effect in oxytocin
cells, the first stage of the new work was to reproduce the previous model and then
add the AHP. This was then used to produce trains of artificial ISIs which could be
analysed in the same way as the long oxytocin cells recordings. The artificial data
with no AHP showed no relation between interval sizes, but by adding in the AHP
the model's artificial data was able to replicate the interval relation discovered in real
cells. The work has progressed to examine the effect in a more quantitative manner
by attempting to fit the model to recordings from real oxytocin cells and produce
values for the magnitude and time course of the AHP. The difficulty of detecting the
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AHP and the relation between ISIs has meant that a new technique has had to be
invented for measuring fit between sets of such data. Getting a sufficiently accurate
measure of fit requires the model to be run for a very large number of spikes and
many time intervals have to be compared between the generated and real sets of data,
making this a very computationally intensive process. It has however been able to
successfully produce values for the AHP parameters in comparison with real
recordings and has been used to get a better understanding of how the AHP relates to
the other properties of the cell. The model and the fitting process provide a powerful
tool for analysing cell recordings and discovering behavioural properties which may
not have been previously observed.
5.2 The Basic Oxytocin Firing Model
The previous model was a leaky integrate and fire model which simulates the
firing response to a series of random input pulses, usually small exponentially
decaying spikes. These represent the excitatory and inhibitory post-synaptic
potentials (EPSPs and IPSPs) on the cell's dendrites. When these input spikes sum to
a value above threshold the neuron fires an action potential, its timing is recorded
and the following refractory period known as the hyper after-polarisation (HAP) is
simulated by increasing the firing threshold value (measured in mV) and then
allowing this increase to quickly decay away exponentially. In real cells this HAP
(illustrated along with the AHP in figure 5.1) is the action of some ion channel (or
channels) which hyperpolarizes the cell following an action potential, temporarily
preventing firing and limiting the maximum firing rate. The HAP is of a large
magnitude, effectively raising the firing threshold by the order of 60mV, but decays
very quickly giving a refractory period of usually 10 to 20 ms. The model also
includes the real resting potential, spike threshold, and excitatory and inhibitory input
reversal potentials measured from oxytocin cells.
The first stage of the new work was to reproduce the previous model and its results
and this is the work which is described immediately below. The reproduction of the
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model is identical to the previous version except for a minor change to one of the











Figure 5.1 : The major post spike components in a supra-optic nucleus (oxytocin or vasopressin) cell.
The AHP and the DAP are normally too small in magnitude compared to the HAP to be observed
after a single spike, and so an artificial train of high frequency input pulses are given to make the
AHP and DAP large enough to be visible. The model so far does not include the DAP, which is
thought to be more dominant in vasopressin cells. The slow AHP is also not separately included. The
upper and lower red lines show the respective effects of knocking out the AHP and DAP, which
normally act against each other to make the AHP appear smaller and the DAP appear later. Figure by
Dr. Colin Brown.
5.2.1 The Model Equations
The model uses two variables, v, representing the membrane potential and ttime.
which measures the time since the last output spike. It runs over discrete 0.1 ms time
steps. At each step the model generates EPSPs and IPSPs according to the input rate
specified by the parameters Ire, which gives the EPSP frequency, and Iratio which
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gives the ratio of IPSPs to EPSPs. Equal numbers of excitatory and inhibitory inputs,
for example, would be Iratio = 1. The timing of individual input spikes is generated
by a random Poisson process. Two equations give the time until the next input spike :
-log(l- rand)
eP{M = 7 + eptiepf
-logfl -rand)
V*i+1 = ^-7 L + lPfi
ipf
Where epti is the current epsp time point, rand is a random number in the range 0 to
1, and epf = /re/1000 to give the mean number of EPSPs per ms; iptj gives the
current IPSP time point and ipf = Ire * Iratio / 1000 to give the mean number of
IPSPs per ms.
At each time step these equations are run repeatedly generating time points for
new input spikes until the next spike is due after the current time step. At each run
through of the equations the model increments the number of spikes which fall in the
current time step. Input pulse magnitude is calculated using the reversal potential and
scaled by a parameter so that the spike magnitude at resting potential is 4mV. These
scaling parameters are the values a and b for the EPSPs and IPSPs respectively in the
two post-synaptic potential (PSP) height equations :
ePh =a(ve-v)
iPh =b(vi ~v)
Where epi, and ipi, are the epsp and ipsp magnitudes (mV) and ve and v,- are the
reversal potentials. The total input is calculated by summing the products of the
number of spikes and spike magnitudes for the EPSPs and IPSPs using the equation :
input = ephepcount ~iphipcount
Where epcount and ipcount are the number of EPSPs and IPSPs for the current time step.
The input value is then added to v. Instead of modelling the decay of each input spike
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individually, a single decay component is added to v which makes it decay back to
resting potential at a rate determined by the half life of the PSPs, gamma. The decay
component is represented by the equation :
(v - vrest) * hstep * gamma
Parameter hstep defines the time step size in ms. This gives the complete equation
for v :
v = v - (v - vresl) * hstep * gamma + input
The firing threshold (vti,resh) is modelled by an equation which combines the basic
firing threshold (v,/ire) with the effect of the HAP :
Vthresh = Vthre + HAP
The exponentially decaying HAP is modelled by the equation :
HAP - k* exp(-/l * ttime)
The two parameters k and X give the initial magnitude and decay rate respectively. If
v is larger than vthresh then an action potential spike is fired. The model records the
time point of the spike, resets v back to the resting potential and generates a new
HAP by setting ttime back to 0. The model then continues to run for a fixed number
of time steps or until a fixed number of spikes have been generated.
The Matlab implementation of the model defined the firing threshold (vthresh) as :
Vthresh = ^ rest + (Vthre ~ V rest ) * (1 + HAP)
= V,hre+(.V,hre-Vres,)*HAP
making the size of the HAP dependent on the threshold and resting potentials.
Whether this was intended is unknown, but here it was simplified to make the HAP
magnitude depend just on parameter k. Otherwise, the basic model was left unaltered




The model can display membrane potential against time by storing v at each time
step, giving a trace which displays the input spikes (figure 5.2). It can also display a
representation of the output action potential spikes by recording and displaying
vthresh against time. On this trace each output spike appears as a sudden large
increase in firing threshold followed by a steep decay back to the normal threshold,
or interrupted by another spike. However, the normal output from the model, which
is used for most results, is the record of spike timings, a series of time points at
which the model fired an output spike. These are turned into a series of inter-spike
intervals (ISIs) by calculating the time between each successive spike. This series of
ISIs gives the most important output from the model, a form which can be analysed
to determine the properties of the cell's firing pattern and can be compared to the
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Figure 5.2 : Model cell input voltage with equal levels of excitatory and inhibitory input. Because of
random timing, input pulses can still sum to a level high enough to cross firing threshold. In this trace,
firing threshold is crossed twice to fire 2 spikes in the 500ms period. Lines mark threshold and resting
potential.
The most common form for displaying the ISIs is the inter-spike interval histogram
which counts up the number of ISIs within a series of short, usually uniform, time
ranges (bins) and displays these as a graph showing the distribution of time intervals
between spikes. This shows many features including the range over which the
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intervals are spread, the most common size of interval and the minimum interval
between spikes, indicating the refractory period.
5.2.3 Parameter Values
The parameter values (apart from the model step size obviously) are all based on
electrophysiological data from real oxytocin cells. Some of them are fixed exact
values that can be accurately derived from real experiments and others are rougher
estimates.
EPSPs and IPSPs can be detected by intracellular recording from oxytocin cells.
These input pulses have a magnitude in the range 2-5 mV and last for 5 to 10 ms. For
the model we make the assumption that the excitatory and inhibitory potentials have
equal and opposite magnitude and have a size in the same 2-5mV range with a half
life of 3.5 to 20 ms. For all of the initial results here the magnitude and half life have
been fixed at 4mV and 7.5ms. The resting and threshold potentials for oxytocin cells
have been measured at approximately -62mV and -50mV (Bourque and Renaud
1990). The reversal potentials for EPSPs and IPSPs are set at -38mV and -72mV
from estimates in (Randle et al 1986). The default parameter values for the HAP and
the input pulse rates, Ire and Iratio, are rougher estimates mainly based on early
experimentation with the model in order to produce a firing rate within the normal
range for an oxytocin cell. These less well defined values are the main ones that are
varied during experimentation with the model.
The table below summarises the set of parameters and their default values
Parameter Name Description Default Value
hstep model step size 0.1
Vrest resting potential -62mV
Vthre threshold potential -50mV
a EPSP height scaling 0.4
b IPSP height scaling 0.04
ve EPSP reversal potential -38mV
Vi IPSP reversal potential -72mV
k HAP height 60mV
X HAP time constant 0.1
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Ire EPSP frequency 300Hz
Iratio IPSP/EPSP ratio 100%
5.3 Results from Real Oxytocin Cells
As a preparation for working with the model we need to examine the real data
which is to be reproduced and so here we follow previous analysis (Leng et al 2001).
By taking long recordings from oxytocin cells which give the timing of individual
action potentials we can construct an inter-spike interval histogram for the cell in
order to examine the distribution of ISIs and fit functions so that the distribution can
be described in formal mathematical terms. The histograms for each cell show a
skew distribution with a mode in the range of 40 to 60ms and a long tail, indicating
that the majority of spikes are fairly close together but can still fall over a large range
of intervals. The tail of the histograms can be well fitted by a single exponential
suggesting that after a certain interval, around 80ms, the timing of spike firing is
essentially random. Extrapolating the exponential curve over the front end of the
histogram shows a deficit of spikes in the 0 to 40ms range indicating a refractory
period, likely to be caused by the hyperpolarizing after potential (the HAP). What the
randomness indicates about the functional properties of the oxytocin cells is that
activity is dominated by factors independent of previous activity, properties that are
constant for the cell or activity within a time window that only affects a single spike
such as resting potential and rate of synaptic input. The deficit of activity in the 40 to
80ms range indicates the time period where the HAP is decaying away and gives us
an estimate of its half life. For the effect of the HAP to become negligible (well
below 0.5mV) would take at least eight half lives giving a half life of no more than
10ms to fall within the 80ms range. The default value for X in the model, 0.1, gives
an HAP half life of approximately 7ms. In the paper the model is fitted to the data
from one of the real cells with X = 0.08, giving an 8.7ms half life.
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5.3.1 Fitting the Model to Real Data
The first experiments with the model used it to fit the data from real cells by
comparing the ISI histograms from the real cells with those produced by the model.
For all the cells tested it was possible to fix the parameters for resting potential,
threshold potential and PSP amplitude and half life to the default values in the table
above. The model obtained a good fit to all the cells with HAP parameters k = 60 and
X in the range 0.08 to 0.15 and each cell could be fitted by varying just X and Ire, the
EPSP rate. These fits were not unique however; equally good matches could be
produced with larger or smaller amplitude input pulses or a more depolarised resting
potential by compensating with the input rate, and different values of k could be
compensated by adjusting X. These experiments to fit real data used only EPSPs, but
adding in IPSPs has no effect on the overall shape of the histogram and can be
compensated just by increasing the input rate (figure 5.6).
With a fixed value for k every oxytocin cell could be characterised by a unique
value for X and by values for vrest, Ire and Iratio, which change the output rate but
have little effect on the actual shape of the histogram, only shifting it to the left or
right to match the cell's output rate. The paper goes on to test this by producing
histograms for a real cell with varied amounts of input activity, controlled by
increasing the level of osmotic stimulation. These were successfully fitted with the
model by varying only the parameters controlling the input rate and membrane
potential and keeping a the same value for X.
5.3.2 First Experiments with the Model
The first stage of working with the new implementation of the model was to
reproduce some of the results in the previous paper in order to validate the new
version. For comparison with the previous paper experiments were chosen which
examine the effect of varied input rates on the shape of the histogram and the output
rate, since these test a range of values and give a suitably well defined target to
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reproduce. The aim of these tests was to investigate what effect the parameters that
had to be altered to fit the real cells are having on the model cell's behaviour, how
they affect the output rate and the shape of the histogram and how this relates to the
cell at a functional level.
Although not stated in the publication, the results in the paper use two different
implementations of the model, an older version coded in C and a new Matlab
version. These both implement the same integrate and fire model but use different
representations for the cell's membrane potential and input pulses. Both models
produce very similar results and qualitatively are identical, but the varied
implementations mean that the scaling varies between the two versions and so they
produce results which are slightly different quantitatively. The new version of the
model being used here and the equations described above are based on the Matlab
version of the model but the new version is re-implemented in C++. It does however
produce results which are identical to the paper's Matlab version.
5.3.3 Pulse Input Rate
The model's input consists of a train of randomly timed excitatory and inhibitory
post-synaptic potentials of uniform magnitude following a Poisson process governed
by an average input rate. The rate for the EPSPs is defined by the parameter, Ire and
the IPSP rate is defined proportionally to the EPSP rate by Iratio. The aim is here is
to test the effect of input rate on the shape of the ISI histogram and measure how it
affects the cell's output rate. We also want to examine how the two parameters for
excitatory and inhibitory input interact and whether they can compensate for each
other.
For these experiments all of the parameters except the ones being varied were set
to the default values in the table above and the model was run for 50000 spikes. The
ISI histograms were created using 5 ms bins. A range of values for Ire was chosen
which produces spike output rates within a range comparable with the real cells. The
results with varied Ire and Iratio = 0 (no inhibitory input) are as follows :
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Ire Output Freq ISI Mode Mode Height Mean ISI
50 0.37 140 106 2709.2
75 1.58 100 412 634.3
too 3.81 60 990 262.4
125 6.75 45 1819 148.1
150 10.02 50 2782 99.8
175 13.18 40 3771 75.9
200 16.25 45 4949 61.6
225 19.13 35 5979 52.3
250 21.88 30 7324 45.7
The rate of increase in output rate initially climbs very quickly as the input activity
increases (figure 5.3a). This highly non-linear relationship between input and output
rate is observed in most neurons. The rate of increase in output rate only slows as the
cell approaches the maximum firing rate governed by its refractory period. The table
below shows the equivalent results with Iratio = 1.
Ire Output Freq ISI Mode Mode Height Mean ISI
50 0.16 275 54 6393.4
100 1.09 70 301 916.1
150 2.60 60 662 385.3
200 4.24 60 1064 235.8
250 5.84 50 1498 171.2
300 7.27 45 1892 137.6
350 8.51 45 2147 117.5
400 9.78 45 2604 102.2
450 10.88 40 2859 91.9
500 11.89 40 3127 84.1
600 13.74 40 3673 72.8
700 15.26 40 4185 65.5
800 16.75 40 4657 59.7
900 17.90 35 5118 55.9
1000 18.96 35 5437 52.7
Figure 5.3b shows the non-linear increase in output rate with increased input activity,
the rate of increase slowing as Ire increases. The later part of the curve is very
similar to that with Iratio = 0, however with inhibitory input the output rate increases
with input activity in a much more linear form. This first part of the curve, with
output rate in the range 0 to 10Hz best represents endogenous activity and this shows
a much more linear response (compared to figure 5.3a) with mixed excitatory and
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inhibitory input. This was one of the first major results for this model, explaining
what had previously appeared to be a counter intuitive result when measured in real
cells.
input rate (Hz) input rate (Hz)
Figure 5.3: a. EPSPs only, non-linear increase in firing rate with increased input; b. EPSPs and
IPSPs, slower, more linear increase in firing rate with increased input.
Figure 5.4a shows the histograms for some of the values for Ire. As Ire increases
the histogram's mode increases in height and shifts to the left, indicating an increase
in the number of short ISIs and an overall increase in firing rate which is also shown
by the increase in output rate and reduction in mean ISI. With a smaller input rate the
histogram's tail shows more longer intervals between pulses although the actual
range of intervals doesn't change, with long intervals still occurring occasionally
even with high levels of input. The slope can still be fitted by an exponential but
becomes more linear with lower input rates.
The effect of reducing Iratio with a fixed value for Ire is very similar (figure 5.4b),
more short intervals and an increased overall firing rate with the same effects on the
shape of the histogram. Even with equal amounts of inhibitory and excitatory input
the cell continues to fire, although with a reduced firing rate. The inhibitory input
depresses the membrane potential but because of the exponentially decaying form of
the input pulses and the random timing, the excitatory pulses are not entirely
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Figure 5.4 : a. ISI histograms with varied input frequency (Ire), range 200 to 400Hz, highest mode =
highest Ire; b. ISI histograms with varied levels of inhibitory input (Iratio), range 0 to 1, highest mode
= lowest Iratio; histograms generated from 50000 spikes
This is best illustrated by looking at a trace of membrane potential overlaid with the
firing threshold in order to show where the cell is firing an output spike. The trace in
figure 5.2 shows a run with equal amounts of excitatory and inhibitory input (Iratio =
1). With the inhibitory input the average membrane potential is much lower but
because of the random nature of the pulse timings it does still occasionally pass the
firing threshold and fire an output spike. The linearising effect of Iratio is
demonstrated for a range of values of Iratio by figure 6D in the paper. This
experiment was reproduced here (figure 5.5). The version in the paper uses the newer
Matlab version of the model and so the data here matches it exactly. As Iratio
increases the plot of output rate against input activity becomes progressively more
linear. With lower levels of inhibitory input the curve is almost sigmoidal, initially
curving up quickly before straightening out and then curving back towards a
shallower climb as it approaches the maximum firing rate controlled by the HAP.
Higher values of Iratio stretch out this curve to form a more steady, slower climb.
This gives the cell the important property of producing uniform increases output in
response to an increase in stimulation, independent of current activity. Without the
inhibitory input the cell's response to a fixed level of added stimulation would
depend very much on existing activity.
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Figure 5.5 : Plots of output rate against input rate with varying Iratio, shows the increasingly linear
response with increased inhibitory input.
To test whether the input rate could be increased to compensate for the effect of
inhibitory input on the ISI histogram the model was tested over a range of values for
Iratio with the output rate fixed at 10Hz (to within 0.05Hz) by varying Ire. The table
below shows the values used :
Iratio Ire Output Freq ISI Mode Mode Height Mean ISI
0.00 150 10.00 45 2795 100.0
0.25 183 10.01 50 2727 99.9
0.50 229 10.03 45 2664 99.7
0.75 299 10.00 40 2597 100.0
1.00 410 9.98 40 2596 100.2
1.25 586 10.00 45 2630 100.0
1.50 870 10.01 50 2584 99.9
Figure 5.6a shows the overlaid histograms for each value of Iratio. They are almost
identical, except that the mode is slightly lower with the lower overall input rates.
This indicates that Ire can be increased to compensate for the higher ratio of
inhibitory input to get the same output rate without affecting other properties of the
cell's behaviour. This simplifies further testing of the model since it shows that input
rate can be treated as a single variable. For most experiments it will be sufficient to
















Figure 5.6: a. Overlaid ISI histograms varying lratio (0 to 1.5) and compensating output frequency by
adjusting Ire\ b. Varying vrest with frequency compensation.
The other parameter which directly affects the ability of input spikes to raise
membrane potential above the firing threshold is the resting potential (vrest). This
defines the level of concurrent activity required to fire an action potential. A similar
test was performed, varying Ire to compensate against vrest as with lratio. Ire was
varied to fix the output rate at 10Hz and Iratio was fixed at 1. The results are
presented in the table below and the overlaid histograms in figure 5.6b.
Vrest Ire Output Freq ISI Mode Mode Height Mean ISI
-44 1275 10.01 50 2517 99.9
-46 880 10.00 40 2558 100.0
-48 605 10.04 50 2581 99.6
-50 410 10.02 45 2541 99.8
-52 270 9.99 45 2637 100.1
-54 169 9.99 45 2677 100.1
-56 96 10.02 50 2765 99.8
The result is very similar to the compensation of Ire against Iratio. With higher
values for Ire the mode is slightly higher but otherwise the histograms are identical
with no change in the slope or range of ISIs. The experiment also demonstrates a
non-linear relationship between the change in vrest and the value for Ire required to
achieve the same output rate. A change of 12mV in vrest (shifting the difference
b
interval length (ms) interval length (ms)
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between vrest and vthresh from 6mV to 18mV) requires a more than 10-fold increase in
Ire with Iratio = 1.
The result here again allows us to conclude that we can investigate the effects of
other parameters by varying only one of the excitation parameters, Ire, Iratio and
Vrest since they can compensate against each other without affecting other properties
of the cell's behaviour.
5.3.4 Mapping X against Input Rate
The HAP is the only component of the basic model which is specific to the type of
cells being studied, particularly oxytocin cells, and so this is the most important part
of the model to understand for the purpose of fitting the model to real data and using
the model as an accurate representation of real cells. Parameter X controls the half
life of the HAP and so will affect the time course of the refractory period following
an action potential. The first experiment here tests the effect of varying X on the
shape of the ISI histogram and cell firing rate. A smaller value for X produces a
longer half life and so we would expect a longer refractory period, reducing the firing
rate and pushing the mode of the histogram to the right. For the experiment, the
model was run for 50000 spikes with the default parameters, Ire fixed at 300Hz and a
set of values for X which cover the realistic range. The table below gives the results,
including the half-lives in ms :
X HAP half-life Output Freq ISI Mode Mode Height
0.01 69.31 2.40 370 944
0.02 34.66 3.73 205 1219
0.04 17.33 5.32 110 1510
0.06 11.55 6.22 80 1657
0.08 8.66 6.85 65 1810
0.10 6.93 7.26 45 1924
0.12 5.78 7.61 45 1961
0.14 4.95 7.83 35 1942
0.16 4.33 7.99 35 2019
0.18 3.85 8.16 30 2154
0.20 3.47 8.32 25 2156
0.30 2.31 8.82 15 2170
0.40 1.73 8.92 10 2232
0.50 1.39 9.11 10 2365
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The results show output frequency increasing non-linearly as the half life of the HAP
is decreased, reducing its effect on the cell's firing rate. As the half life becomes very
small the HAP has little effect on firing and the change in output rate flattens out
(figure 5.7a). The mode also shifts to the left and increases in height as the as the
area of histogram representing the refractory period is reduced. The effect on the
shape of the histogram, showing this shift to the left, is illustrated in figure 5.7b.
a b c
Figure 5.7: a. output rate varying with the HAP decay rate (A.); b. Overlaid ISI histograms with X
varying from 0.01 to 0.50. Highest mode = smallest A..; c. Overlaid ISI histograms varying A. with Ire
adjusted to match output frequency at 7Hz. Highest mode = smallest A..
For the next experiment the effect of changing X while maintaining a constant
output rate is examined. The input rate (Ire) is shifted to get an output rate of 7Hz for
each value of X, in a similar manner to the experiments compensating Ire against
Iratio and Vrest. This also compares with the experiment in figure 5A of the paper.
The table below gives the values used for Ire to match the 7Hz output rate :
X Ire Output Freq ISI Mode Mode Height
0.05 370 6.99 85 1985
0.07 320 7.00 70 1926
0.08 307 7.00 55 1876
0.10 292 6.98 50 1831
0.12 283 7.01 45 1779
0.15 273 7.00 40 1780
0.20 265 7.02 30 1747
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The results are best observed by looking at the histograms in figure 5.7c. As X
increases the mode shifts to the right and falls in height, although slowly. However
the tail end of the histogram does not vary between the different values of X, where
the HAP has decayed away and behaviour is entirely defined by the output rate.
Ire (EPSPs/s)
Figure 5.8: Plots of output rate against input rate with varying X, non-linearity is reduced as A, is
increased and the HAP has a greater influence over firing rate
The relation between output rate, Ire and X is further studied in another experiment
which reproduces data from the paper, figure 6B, which plots output rate against Ire
for a range of values for X, with no inhibitory input (Iratio - 0). The data created
with the new version of the model is displayed in figure 5.8. The paper's version was
generated with the newer Matlab version of the model and so new data here matches
it perfectly, although the version here was generated with a larger number of spikes
and shows smoother curves with smaller errors in the output rates.
The graph shows the familiar non-linear increase in output in response to
increasing input activity but as X is reduced, increasing the half-life, the HAP has a
greater influence over the firing rate and the non-linearity is reduced, particularly
when the input rate is higher and the cell's firing rate comes closer to the limit
imposed by the refractory period. At lower output rates, when the HAP plays less of
a role, the curves are very similar.
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5.3.5 Fitting Against Real Data
The aim here is to attempt to reproduce the experiments in the paper fitting the
model to ISI histograms produced from real data, recorded from oxytocin cells. The
new version of the model should be able to get fits as good as in the paper but the
parameter values will likely be slightly different due to the different implementations
of the model. The fitting experiments in the paper were performed with the older
version which differs from the version used here. The value for k is also going to be
differently scaled because of the modification made to the HAP equation made for
the new version of the model. The equivalent value in the new version of the model
is equal to the old k multiplied by (v,/ire - vrest). In the fitting section of the paper this
difference is fixed at 12mV and so k=5 in the paper is equivalent to £=60 in the new
version. The new value for k gives the initial amplitude of the HAP in mV. The new
version also uses reversal potentials which were not implemented in the older version
of the model.
The first data from the paper to be fitted is figure 4, which gives an example of a
single oxytocin cell fitted by the model. The parameters used are the same as the
defaults specified above, except with X = 0.08 and Ire = 380. The figure in the paper
displays the histogram from the real cell overlaid with the histogram from the fitted
model cell. The paper states that the cell's output rate is 6Hz, however reanalysing
the same data here shows that it in fact 5Hz. The results which demonstrate how the
excitation parameters can be compensated against each other to produce the same
output rate indicate that it is only necessary to alter one of these to fit the model. The
one which is normally used here is Ire, the overall input rate. A simple protocol for
fitting was developed, of first adjusting Ire to match the output rate and then
adjusting X to match the shape of the histogram. Fit was assessed by eye with the two
histograms graphically overlaid in the model software. Altering X affects the output
rate and so with each change in X, Ire is shifted to match the output rate again. Using
this process and the default parameters, which are based on those in the paper, it was
only necessary to alter X and Ire to get a good fit. The values using the new version
of the model are different however, a good fit was obtained with X = 0.1 and Ire =
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230 (figure 5.9). The next set of data to be matched from the paper was figure 5B
which fits the model against four sets of data from the same cell with varied levels of
input activity, controlled by increasing the level of osmotic stimulation. Here there
are also problems with apparent discrepancies between the values for output rate in
the paper and those detected by the model, although unfortunately only the
histograms from the real data were available and so the model's values for the output
rate are approximated.
Figure 5.9 : a. oxytocin cell recording ISI histogram fitted with the model (a=0. 1, 7re=230).
However, there are also values for the output rates in a spreadsheet, from which the
paper data is derived, which disagree with the paper. The fits here use the estimated
values for output rate produced by the model. The 12.8Hz data in the paper is
estimated at 12Hz by the model (agreeing with the spreadsheet), the 9.3Hz estimates
at 9Hz (again matching the spreadsheet) and the 4.8Hz data estimates at 5.8Hz.
Unfortunately this one doesn't have a figure in the spreadsheet to compare with. The
final one is more problematic, the paper states 2.5Hz which almost matches the
2.6Hz marked in the spreadsheet, but the model estimates 5Hz. This particular
recording only measures around 2000 spikes (compared to over 12000 on the highest
output rate data) and so has the roughest histogram and output rate measure. The
histogram data also only goes up to a 500 ms interval and it is likely to be missing
some longer interval spikes from its tail, which will be making the model's
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calculated output rate higher than the true rate. Although the model can produce
quite a good fit, the fit looks better at the front end of the histogram with the higher
output rate (5Hz) and better at the tail end of the histogram using 2.8Hz. Close
examination of the original figure which is reproduced in the paper shows that the
paper's model fit falls below the real data at the front of the histogram which would
match the 2.8Hz figure given in the paper. The table below gives the figures for the
fits using the new version of the model:
Real Data Set Output Freq Fitted /. Fitted Ire
A 12.0 0.14 440
C 9.0 0.14 340
H 5.8 0.14 230
E 2.8 0.14 180
The 0.14 figure for X differs from the paper's 0.08 figure which uses the older
version of the model, but in common with the paper the new version of the model has
fitted all of the real data, which comes from the same cell, with a single value for X.
The only parameter which varies between the four fits is the value for input activity,
Ire. As stated in the paper, this demonstrates that the varied response to different
levels of stimulation are due to increased levels in synaptic input and do not involve
other changes to the cell's behavioural properties such as post-spike excitability
governed by the HAP.
5.4 Modelling the AHP
The AHP behaves in a similar manner to the HAP, forming a hyper-polarisation
after an action potential fires, with the difference that it is of much smaller magnitude
(a shift of membrane potential in the range of less than lmV compared to the 60mV
HAP hyper-polarisation) and has a much longer time course, around 1 sec or more.
The modelling of the HAP is relatively simple since the cell never fires another spike
before most of the HAP has decayed away, meaning that there is only ever a single
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HAP being modelled. With the longer time course and smaller magnitude of the
AHP, the cell will be able to fire before the AHP has decayed away and so the effect
of several successive AHPs must be maintained. However, because each AHP decays
at the same rate, it is possible to sum the effect of successive AHPs and treat them as
a single value, in a similar manner to the modelling of the input spikes. The AHP
component adds a new equation to the model for the AHP and adds this AHP value
to the equation representing the cell's current firing threshold. The equation below
models the AHP with its decay during the current spike interval :
ahpt = ahpt-i * exp(-k2 * ttime)
The variable ttime measures just the time during the current interval. When a spike is
fired the current remaining AHP level is stored and then added to the new AHP
generated by the new spike. The new value then decays with a reset time component.
Intuitively it would seem necessary to maintain the two separately, keeping
independent time counters but it is in fact mathematically equivalent to take the
remaining level and then reset the decay timer so that the AHP from the previous
interval can just be added to the new AHP and tracked with a single decay
component. The new AHP is simply calculated as :
ahpi = k2 + ahpi.i
The parameters k2 and X2 are the AHP size and decay rate values, equivalent to the
HAP's k and k. The value for the current AHP level is simply summed with the
equation for the current spike threshold :
Vthresh = Vthre + k* exp(-A * ttime) + ahpt
The initial testing values for the two new parameters are rough estimates based on
real data. The AHP's exact magnitude is very difficult to measure since it can only
be detected by making a cell fire quickly enough for a number of successive AHPs to
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overlap but it is likely to be smaller than 1 mV and so an initial value of 0.5 mV is
used for k2. A further complication is that there more than one AHP or it may have
two components. The normal AHP is thought to last around 1 second but there may
also be an even smaller and longer lasting AHP of around 6 seconds duration. Here
we only model a single AHP, based primarily on the larger 1 sec. duration version
but hopefully capable of taking account of the AHP effect as a single component.
The initial value for X2 is 0.002 which gives a half-life of 347 ms allowing the AHP
to decay to 1/8 of its initial size in roughly 1 sec.
5.4.1 Initial Experiments with the AHP
The first experiments with the new version of the model incorporating the AHP
test the effect on the previous results, how much the AHP affects spike response and
the shape of the ISI histogram. These tests are all run for 50000 spikes with the
default parameters and Ire set at 300 except where stated.
The first of these tests maps the effect of the new parameters, X2 and k2 on output
rate and the histogram's mode and maximum height. Ranges of k2 and X2 were
chosen that cover a realistic range of values. The results are presented in appendix
table 1. Adding the AHP has what initially seems like a surprisingly strong effect on
the output rate. As k2 increases, the output frequency is reduced, at a rate controlled
by A.2. The histogram's mode shifts to the right and its maximum height falls with
more longer intervals between spikes and an increased refractory period. These
effects are better observed by looking at pictures of this data. Figure 5.10a shows the
ISI histograms for k2 ranging from 0 to 1 with X2 fixed at 0.002. Even with an AHP
of lmV, very small in comparison to the HAP, there is a large effect on firing rate
and the distribution of spike intervals, producing a similar effect to a large change in
input rate (figure 5.4a). In order to eliminate the effect on output rate, to examine the
more subtle effects of the AHP, the same range of values for k2 were run with varied
input rate in order to match the output frequencies. The results are in the table below
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kl Ire Output Mode Height
0 291 7.02 50 1783
0.2 332 6.98 55 1757
0.4 378 6.99 50 1698
0.6 430 7.02 50 1688
0.8 482 6.97 60 1638
1.0 544 6.98 50 1603
Figure 5.10b illustrates the ISI histograms. At a gross level the plots are very similar,
but in comparison with other frequency matched plots such as figure 5.6a or 5.6b
there are some variations, particularly towards the mode. At lower values for k2 the
mode is slightly higher but more importantly the approach is also steeper suggesting
that the AHP is having an effect on the number of short intervals even while the HAP
still hasn't decayed away. This must indicate that the summing effect of the AHPs
across several spike intervals is playing a large role in controlling firing. This was
tested by repeating the experiment with a modified version of the model which does
not carry on the AHP into the next interval. The results are below :
kl Output Mode Height
0 7.24 50 1883
0.2 6.97 55 1775
0.4 6.74 55 1698
0.6 6.54 60 1661
0.8 6.26 50 1582
1.0 6.02 55 1540
Figure 5.10c shows the effect this has on the histograms, compared to figure 5.10a.
There is still the variation in slope approaching the mean but the variation in height
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Figure 5.10: a. Overlaid ISI histograms with AHP magnitude (k2) varied from 0 to lmV, highest
mode = lowest k2\ b. similar to a. with Ire adjusted to match output frequencies, lower k2 values have
slightly higher mode and steeper mode approach; c. similar to a. with no AHP accumulation between
spike intervals.
A similar set of experiments was carried out to compare the effect of varying the
AHP's decay rate, A.2. For these k2 was fixed at 0.5 mV and X2 was varied between
0.001 and 0.01. The pattern of results is similar to varying k.2, with a slower decay
rate producing a larger negative effect on the output rate, increasing the number of
long spike intervals and reducing the height of the histogram's mode (figure 5.11a).
When the output rates are matched the variation between the histograms (figure
5.11b) is eliminated, and the same effect is observed when there is no accumulation
of the AHP (figure 5.1 lc). In the case of the AHP, output rate matching has a similar
effect since this is also effectively eliminating the variation in the ability of the
AHP's to overlap and accumulate. The variation in effect with longer time courses
seems to be entirely due to the effect of accumulation, which is of course itself
controlled by the length of time the AHP lasts. The AHP's magnitude is so small that
even a much longer half life seems to make very little difference to its effect over the
course of a single interval, a very different result to the large effects observed with
changes in the HAP's decay rate.
A single AHP has little effect on firing rate but the long time course means that
over the course of several spikes it can have a large effect on cell firing if the firing
rate is fast enough for the AHP to accumulate. This means there is a complication to
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interpreting the results of varying the AHP. While the individual AHP is of a larger
magnitude, the output rate is lower, but this in turn reduces the cumulative effect
with longer spike intervals increasing the firing rate, so there are two competing
effects on the AHP's ability to influence firing. In this way it is somewhat self
regulating and because it affects the firing rate, this may be passed on to make the
cell's firing rate self-regulating. Faster firing produces a larger accumulation of the
AHP which would reduce the firing rate. Slower firing would have the opposite
effect and so make the output rate tend more towards a middle value, reducing the
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Figure 5.11: a. Ovedaid ISI histograms with AHP decay rate (\2) varied from 0.001 to 0.01, highest
mode = highest X.2; b. similar to a. with Ire adjusted to match output frequencies, differences between
histograms eliminated; c. similar to a. with no AHP accumulation between spike intervals.
In a final experiment for this section this was investigated by measuring the
standard deviation of the spike intervals over a range of values for k2. The difficulty
in making such a comparison is that the range of interval lengths is dominated by
firing rate and so the standard deviations with varied k2 were compared with the
same results for a range of values for Ire chosen to produce roughly the same output
rates, but with no AHP. The results are below :
181
Chapter 5














These clearly show a smaller variation in spike interval size for the equivalent output
rates suggesting that the AHP does work to reduce the randomness of spike firing.
However, the other possible interpretation is that lower input rates increase variation
and it is impossible to differentiate between the two without more sophisticated
analysis.
5.5 Detecting the AHP in Spike Data
The AHP's small magnitude means that it has a fairly subtle effect on oxytocin
cell firing rate, mostly dominated by the HAP and input activity. It does however
have a small effect on the cell's chance of firing. While the AHP still has some size
and the HAP has mostly decayed away it could make the difference between a border
line level of input activity being able to trigger an action potential, a least delaying it
by a small amount of time. When spikes are closer together such that a single AHP
runs over several spike intervals, the AHPs get a chance to accumulate increasing the
effect on the cell's ability to fire. The way to detect this effect is to examine the
relation between the lengths of spike intervals and the immediately proceeding
intervals. However, for a single interval the effect will be well within the noise level
created by the random nature of the input activity, making it impossible to
distinguish an AHP effect. What is required is to take all the intervals of a particular
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length and then examine the average length of their respective proceeding intervals.
This is repeated for increasing interval lengths and then each pair of values (interval
length, average proceeding interval length) is plotted against each other. If there is no
relation between the two then the average proceeding interval should always be
roughly the same, producing a flat line. If there is a consistent relation between the
two which relates to the interval length then there should be some sort of slope. This
analysis can be extended by taking the average of a series of proceeding intervals
instead of just one. This is called here spike train or AHP detection analysis.
5.5.1 Detecting the AHP in Real Data
The first test of this detection system is a newer set of real spike data, not used in
the previous paper, recorded from an oxytocin cell in the female rat. Before
calculating the values for detecting the AHP the data is subjected to some basic
analysis for comparison with the basic experiments with the model. The results are
presented below :
Dataset mludwl
Number of spikes 5206
Recording time 15 min
Mean ISI 172.8 ms
Output Rate 5.79 Hz
ISI SD 137.47
Histogram Mode 55 ms
Mode Height 150 (1441 normalised)
The ISI histogram is presented in figure 5.11. The normalised value for the height of
the mode is in comparison with the 50000 spike trains used for the previous model
generated data. The values are all similar to those observed in the model data and it




Figure 5.12 : ISI histogram for 5206 spike oxytocin cell recording mludwl, mean firing rate 5.79Hz
The next stage in the AHP detection process is to generate the average values for
spike intervals and their proceeding intervals. Values are generated for progressively
larger series of preceding intervals and the intervals are numbered in reverse time
order, with the current interval known as TO and the proceeding intervals Tl, T2, T3,
etc. Average values can be calculated for any number of proceeding intervals but the
results displayed here show sets where the number of proceeding intervals is
progressively doubled. In order to reduce the error and get a large enough variation
to be observable and statistically significant, each of the averages is calculated from
200 spike intervals, taken in groups after sorting the spike intervals into order of
length. So the first average is calculated from the shortest 200 intervals, the second
from the 201st to 400th shortest and so on. The proceeding intervals (Tl, T2, etc)
remain indexed to their original corresponding TO intervals and so these averages
remain independent of the reordering of the TO intervals. These values calculated for
the real data are shown in appendix table 2.
The first plot of this data, in figure 5.13a, although noisy, clearly shows a
downward correlation between TO and Tl indicating that a longer interval is more
likely to be proceeded by a shorter interval. As the plots progress over longer series
of proceeding intervals the correlations at first become steeper before levelling out
until the plot becomes flat, indicating no relation between the interval TO and the
average length of the proceeding series of intervals. Assuming that the AHP as
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represented in the model is the cause of this correlation, this would suggest that the
correlation becomes stronger until the series of proceeding intervals begins to include
intervals which are too long before TO for their AHP to have any effect. These
intervals will have no correlation with TO and so as more of these are included in the
series the correlation will die away. The correlation with each successive (in a
reverse time order) proceeding interval will be weaker as its AHP decays but because
the correlations are being summed the total correlation becomes stronger over the
first sets of intervals. This effect was measured by fitting straight lines to each of the
plots for a range of series lengths and recording the gradient of the fitted line. Good
fits can be achieved for plots which use up to 13 of the proceeding intervals. After
this point the error in the fit becomes too great to achieve statistical significance but
the fits have been measured for up to 32 proceeding intervals. The fitted line
parameters are given in appendix table 3.
Figure 5.13b illustrates how the gradient changes with sums over longer series of
intervals. It increases quite quickly and in a fairly linear fashion until using 8
intervals where it begins to decrease, again in a fairly linear form but less steeply. It
is likely that the point at where the gradient begins to reduce depends on the decay
rate of the AHP and the size of the spike intervals (determined by firing rate).
Testing this is left for future work.
This method has successfully been used to detect a correlation between spike
interval lengths which indicates some behavioural component which affects the
chance of firing a spike based on previous activity. The properties of this effect so far
detected are consistent with it being caused by the AHP. The next stage in testing
this is to attempt to produce the same result with the model.
185
Chapter 5
Figure 5.13: a. AHP detection in applied to oxytocin cell recording, binned spike interval lengths
(TO) plotted against the mean previous interval length (Tl), downward slope in fitted (non-linear
regression) line indicates negative correlation between TO and Tl; b. plot of fitted gradients (with
estimated fit error) for progressively longer spike trains (Tl, T1+T2, etc.), shows an initial steep
increase in correlation followed by gradual decay back to no correlation. The fit is only statistically
significant up to 13 intervals in the spike train.
5.5.2 Detecting the AHP's Effect in Model Data
The aim here was to run the model with the AHP and perform the same analysis
used to detect the AHP in real data by examining the relation between spike intervals
and the length of those immediately proceeding. Assuming that the same type of
correlation is found it would also be useful to compare the gradients of lines fitted to
the plots of TO against Tl, T1+T2, etc. To generate the data the model was run for a
matching 5206 spikes with the default parameters and an AHP generated using
values k2 = 0.5 and \2 = 0.002. The spike intervals were run through the same type
of analysis as that used with the real data above. The basic dataset analysis results are
presented in the table below :
Dataset modgenl
Number of spikes 5206
Mean ISI 189.3 ms




Histogram Mode 70 ms
Mode Height 150(1441 normalised)
The data generated with the default model parameters has a slightly slower output
rate (5.28Hz compared to 5.79Hz), with the mode slightly further to the right, but has
a similar height at the mode. The model data also has a slightly larger variation in ISI
length, but overall this data a quite a close match without doing proper fitting. This
rather vague matching is deliberate in order to test the ability to detect the AHP
independently of specific data parameters but still using model data which has a
chance of producing a similar result to the real data. Appendix table 4 presents the
equivalent analysis results.
The figures show a similar downward trend to the real data, suggesting that adding
the AHP to the model produces a similar effect to that detected in the real data. The
data is illustrated in figure 5.14, showing the noisy but consistent downward trend in
the plot of T1 against TO. Each series ranging from TO to T16 was plotted and fitted
with a straight line to produce measures of these gradients. These values are in
appendix table 5.
Figure 5.14: a. Spike train analysis applied to artificial data (modgenl) generated with AHP, fitted




The gradients show an increase similar to the real data but they do not flatten out
at the same rate. After 17 intervals the fit is no longer statistically significant and the
trend in gradient becomes erratic sometimes decreasing and sometimes increasing
again. However, within the range of series lengths which produces reliable results,
the technique for detecting the AHP's effect on spike intervals has detected the same
trend in model generated data. The control test of this is to compare the result with
model data generated with no AHP. For this the model was properly fitted to the real
data by adjusting X and Ire, with k2 fixed at 0, to give no AHP. The basic analysis
and fitted parameters are given below :
Dataset modgen2
Number of spikes 5206
Mean ISI 171.2 ms
Output Rate 5.84 Hz
ISI SD 140.93




This model data has an output rate very close to the real data and the fitting process
has given it an almost identical ISI histogram. Appendix table 6 gives the results of
the interval length analysis.
The values immediately show the lack of any obvious trend against TO. Plotting
T1 against TO shows no significant downward gradient and the result is the same for
each length of series. The fit gives a flat line indicating no relation between TO and
the proceeding intervals. This comparison of model data with and without the AFfP
proves that at least in the model data, the AHP is responsible for the correlation
between spike interval lengths. The similarity with the results in real data is good
evidence that the AHP is also responsible for this effect in real cells. This also casts
doubt on the fitting results (including those published in the paper) which do not use
the AHP. Although the model without any AHP can be made to accurately match the
ISI histogram of real data, there are clearly properties of the cell's firing behaviour
which are not adequately represented by the histogram alone, specifically those
which affect firing at a level which involves activity beyond the time course of a
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single spike. However, the AHP is the only major known electrophysiological
property (except perhaps the DAP which is thought to be more significant in
vasopressin cells, but more on which will come later) which is missing from the
original model and so adding this should be sufficient to produce a good model of
oxytocin cell firing. The next stage therefore is to reattempt the ISI histogram fitting
with the addition of the AHP.
Interval Length (ms)
Figure 5.15: Real dataset mludwl fitted with the model (dataset modgen3, parameters below)
5.5.3 Fitting the Model to Real Data With the AHP
The starting point for the fitting process is the fit without the AHP. The AHP does
affect the front of the histogram but this is very dependent on output rate and it was
hoped that this effect could be compensated by changing Ire without changing X, the
HAP's decay parameter. This in fact turned out to be the case; when the AHP was
added with its default parameters, k2 = 0.5 and X2 = 0.002, the front of the histogram
changed in gradient, with the mode shifting to the right. Readjusting the output rate
to match the real cell by increasing Ire improved the fit again but still with a deficit
of short spike intervals. To improve this, k2 was reduced and then Ire adjusted again
to rematch the output rate and this produced a good visual fit between the two
histograms, shown in figure 5.15. The process for adjusting k2 is similar to that for X,
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adjust k2 and then compensate the output rate with Ire. The final fit uses the
parameters shown below with its basic analysis :
Dataset modgen3
Number of spikes 5206
Mean ISI 174.2 ms
Output Rate 5.74 Hz
ISI SD 137.72






All of the measured values are close to those for the real data, including the ISI
standard deviation which is a closer fit than the model data (modgen2) that was fitted
without the AHP and had a slightly higher value for the standard deviation. The
output rate with modgen2 was slightly higher, but this would tend to make the ISI
variance smaller rather than greater. This new model dataset was then tested by
applying the AHP detection analysis (values presented in appendix table 7).
These new results immediately appear very similar to the equivalent figures from
the real data. The plot of T1 against TO shows a downward gradient similar to the
real data which can be fitted with a statistically significant straight line. The fitted
gradients for each of the series presented in the table above are given below, with the
equivalent value from the real data for comparison :







Over the shorter series the model data produces a close match to the real data and the
model data is definitely showing the same correlation between interval lengths, but in
a similar manner to the earlier set of model data generated with the AHP, the plots
against the longer series do not show the same decline in gradient as the real data.
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This really needs to be tested by running the same analysis on more sets of real and
model generated data to see whether this is a consistent result. If it is then the model
must either be missing some behavioural element which exists in the real cells or
there is a problem with model's implementation of the existing functional elements.
The close match so far makes it appear likely that the AHP is responsible for the
correlation between interval lengths in the real cell and given this assumption we can
make some predictions about what results we would expect from the analysis. The
effect of the AHP relative to a particular interval has to die out because of its decay.
With the value for X2 used here the half life is 346.6 ms. At the output rate of 5.74Hz
the start of the 32 spike series will on average be over 5.5 sec before the interval TO.
With this half life, any significant remaining AHP is not likely to come from any
longer than 2 sec before interval TO and so the relation between TO and the sum for
the proceeding series of intervals should be reduced no later than when the series
gets beyond this 2 sec point. Beyond this the average for the proceeding intervals
should just level out and the gradient should gradually disappear. This is exactly the
result which the real data produces but not what the analysis of the model data
shows. The simplest explanation would be a difference in XI between the two sets of
data and the way to test this is to run the model data with a more quickly decaying
AHP. Previous results have demonstrated that adjusting XI and then changing Ire to
match the match the output rate has no detectable effect on the histogram and so
fitting the data by comparing ISI histograms does not necessarily fit XI. The results
for the model data with XI - 0.003 and Ire - 270 are given below :
Dataset modgen4
Number of spikes 5206
Mean ISI 175.3 ms
Output Rate 5.71 Hz
ISI SD 138.13








This change in %2, which reduces the half life of the AHP to 230 ms, almost
eliminates the detectable effect of the AHP. Fitted lines still produce a negative
gradient, but much smaller than with the previous set of model data and not with a fit
which satisfies statistical significance. This suggests that the previous match in
gradients with the real data over shorter series already indicated a good fit with %2
and it appears unlikely that this parameter is the cause of the lack of gradient decay
in the model data. The other simple explanation could just be error in the results. The
effect of the AHP is of a very small magnitude compared to most of the model cell's
behavioural components and so there is a large error in detection which requires the
use of the large bins over interval lengths. The measure of gradient for long series of
summed intervals is likely to carry a very large error. This was tested by re-running
the model with identical parameters to the mode dataset modgen3, the best fit to the
real data. The new results are below under model run 2 :
Series Model Run 1 Model Run 2 Real Data Gradient
T1 -0.0785 -0.0678 -0.0739
T1+T2 -0.1245 -0.0896 -0.1125
T1+..+T4 -0.1480 -0.1395 -0.2037
T1+..+T8 -0.2008 -0.1819 -0.2400
T1+..+T16 -0.2009 -0.1676 -0.1881
T1+..+T32 -0.2867 -0.1121 -0.0406
This data shows similar values for the shorter series of intervals but very different
results at the longer series which show a decrease in gradient in the same manner as
the real data. The conclusion is that the current analysis technique has too great an
error to properly detect the gradients of longer series. Improving the technique is left
to later work, but although the current form is not good enough to accurately map the
gradient as it falls back to a flat line, it has consistently detected the increasing
gradient over shorter series of intervals where the AHP is still active relative to TO.
Therefore it is sufficient to detect the effect of the AHP which it has successfully
done in real and model generated data.
At this stage the data has been fitted as well as it can be by using just the ISI
histogram to make a comparison. The form of the histogram is dominated by the
output rate and what we now need is a more sensitive fitting mechanism which is
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sensitive to the behavioural properties which are observed over a longer time course,
particularly the relation between spike interval lengths. The next stage is to develop
such a measure of fit, which can compare model data to a real data set by examining
trains of individual spikes instead of just the histogram, which examines just the
overall distribution of activity.
5.6 Measuring Fit Over Spike Trains
The idea here is to take a set of spike interval data and calculate the probability of
each individual interval length based on the proceeding intervals being run through
the model, i.e. present the model with the real spike timings and compare what would
happen in the model with the real next spike.
A cut down version of the model takes the series of known spike firing times and
simulates the AHP following each spike so that the model can produce a value for
the summed AHP following the train of spikes. It is sufficient just to consider the
AHP at this stage since this is the only value which is stored across spike intervals,
and in fact it is this simplification that makes it a tractable problem to use the model
to calculate fit based on spike interval lengths. This AHP value is then used to run
the model for a single spike firing to match the one being examined in the real data.
By repeatedly running the model for that single spike a histogram can be built up
showing the probability distribution of spike intervals following the train of known
intervals from the real data. This histogram is then used to get an approximate
probability value for the actual interval length. The final measure which is used is the
natural log of the probability value. This process is repeated for each spike interval in
the real data so that the log probabilities of each spike interval can be summed to get
a measure called the log likelihood. The set of model parameters which best match
the real data should produce the highest value for the log likelihood. Likelihood in
this context is defined as 'the hypothetical probability that an event which has
already occurred would yield a specific outcome', in this case the set of proceeding
spike intervals and the one being examined. The log likelihood gives a measure of
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the likelihood of observing a whole set of data given a specific model. The
assumption here is that the basic model is a good enough representation of the real
system, and the set of varied specific models are based on just changes to the
parameters.
5.6.1 Formalising and Implementing the Likelihood Measure
The likelihood of getting a predetermined series of spike intervals given the model
with a specific set of parameters is represented by :
L(0) = P(Si, , 6n | 0)
= P(8! | 0) P(521 8,, 0) ... P(5n | 8„-i,...,8i, 0)
where 0 is the set of parameters and 8i,...,8n are a series of n spike intervals with 8i
representing the interval after the first spike fired by the cell. To calculate the exact
value requires the product of the probabilities of each interval length given the model
parameters and all those spikes which have come before. The log likelihood uses the
sum of the logs of these probabilities instead of the product. Since we only have a
limited record, of the cell's most recent activity, the simplification is made that the
probability for each spike is conditional on a finite number of proceeding spikes,
rather than all previous activity. This gives the form :
logL(0) = J]log(P(<5) | Sj,0)) s.t. i>j>i-20
i
where the likelihood is calculated from the last 20 spikes.
Each of these probabilities can then be calculated by using a cut down version of
the model to generate the initial AHP for each spike, and then using a histogram to
produce a probability distribution, as noted above. It is likely that similar values for
the generated AHP levels will reoccur many times over the thousands of spikes being
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examined and so the process is made more efficient by generating a table of
histograms for all possible AHP values within the range that are found in the set of
spike data.
The complete process is as follows :
1. For each spike use AHP portion of model to generate AHP level before that
spike, store these
2. Analyse set of generated AHPs to find range of values and generate set of
probability histograms to cover this range
To do this, for each AHP value the model is run thousands of times (usually 50000
runs) to produce a map of all possible spike intervals following the specified initial
AHP level (the sum of AHPs from previous spikes). All of the generated spike
intervals are then counted within short length ranges (bins) usually of 10ms. These
bins are normally of uniform length over the whole range of spike intervals but they
can also be sized on a logarithmic scale so that the front of the histogram where there
are more spikes uses shorter bins and the tail where there are fewer spike uses longer
bins. The size of the bins is a compromise between how finely the histogram can be
indexed and the number of spikes which fall in each bin. More bins gives more
accurate, finer indexing but too few spikes means that there will be too high an error
in the count for that bin. The model in fact generates two versions of the histogram
using uniform and logarithmically sized bins. These generate results which are
slightly different by a small scaling factor and the result which is normally used is
the one generated from the log binned histogram. A final issue with the bins of spike
counts is that there is a small possibility of a long interval (at the tail of the
histogram) occurring in the test data which does not occur during spike generation,
giving a bin which has a zero count. This would return a 0 probability which can not
used with the log function. To alleviate this, each bin is initialised with a count of 1.
This has a small scaling effect on the final result but has no relative effect on the
ordering of results from different tests.
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The histogram forms an approximation of the probability distribution for the
possible range of spike intervals. The probability for a specific spike interval is given
by accessing the corresponding bin (which makes an approximation) and dividing the
count for that bin by the total number of spikes. Generating a larger number of spikes
for the histogram gives more accurate probability values but it is a very
computationally expensive process and so is limited by the need to calculate a value
within a reasonable time. The process is further approximated by binning values over
the range of generated AHPs. The bin size is set so that approximately 100
histograms are generated for the AHP range. A typical range might be 0 to 5mV and
so AHP values for indexing the histograms would be approximated to the nearest
0.05mV. This is still quite a fine measure and unlikely to compromise accuracy but it
can be tested by repeatedly running to process to get a measure of the variation in the
results.
3. For each spike interval in real data, access its initial AHP from previously
generated values and then use this to index table of histograms
4. Index histogram using spike length to get probability value (count / total
spikes in histogram)
5. Calculate log of probability and repeat for each spike summing log
probabilities
The final value is the log likelihood, the measure of fit for the model and a specific
parameter set, to the spike data being analysed. Because the log is being taken of
values which are all below 1, the log values are negative and so the final total is
negative number. A larger (or smaller if you take the absolute) value indicates that
the probability scores were higher overall and so the fit is better. The log value is
used to scale the probabilities which will usually be very small numbers.
This process generates a measure for just a single set of parameters. In order to fit
the model it will be necessary to search over a range of values, over several
parameters requiring many uses of the mechanism for measuring fit. The cost of this
more sophisticated measure of fit is that it is a very slow process. Even on fast
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modern computers searching the parameter space for a single set of real data can take
days of run time. It is desirable to reduce the number of parameters which need to be
varied to as few as possible. Some parameters can be fixed by using data from real
cells which gives reliable values which apply across all cells of the specific type. The
work here has also shown that it should be possible to fit some parameters, especially
those which only effect behaviour over the course of a single spike interval, by
matching the ISI histograms generated by the model and from the real data. These
fits however are not unique and any of the parameters which may directly or
indirectly affect behaviour beyond the range of a single interval (activity dependent
behaviour) will still need to be searched with the more sophisticated interval analysis
fitting system. A third way to reduce the parameter search space is by attempting to
understand the dependencies between parameters. This can be used to simplify the
search by replacing two parameters, treated independently, by a method where one is
varied and the other is given a value calculated from the first. It is such dependencies
which some of the earlier results in this chapter attempt to investigate but it can be an
ambiguous and difficult process and only sometimes can the relations be well enough
understood in order to eliminate a parameter from the search space. There can be
middle ground however where knowledge can be used to at least limit a parameter's
range.
5.6.2 Testing the Likelihood Measure
The first stage in using the new measure is to test that it does indeed return the best
score for known best fits of parameters. To do this, instead of using real data, a
dataset is artificially generated using the model. This gives a controlled set of data
which definitely is represented by the model and has a known set of parameters.
When the fitting mechanism is run with these parameters it should return the best fit
value. The best value will vary between different datasets because they are calculated
from spike interval distributions and so datasets with a higher output rate and
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relatively taller columns in the histogram (larger numbers of short intervals) will be
capable of returning higher log likelihoods.
The likelihood measure has been implemented in the model software so that the
model can load a set of test data (either real or artificially generated by the model)
and given a set of parameters, test the model with these values against the test dataset
and produce a value for the log likelihood. The model software has also been adapted
so that it can repeatedly generate fit measures for a range of parameter values,
outputting the results to a text file.
A graph plotting the log likelihood against a single parameter being varied should
show a peak at the true value for the parameter, the value which was used to generate
the data. This graph is the form of the first tests of the fitting process. The first
experiments test the two AHP parameters k2 and \2. These are likely to be two of the
most important parameters in fitting data on the basis of spike intervals since it is
appears to be the AHP which controls the relation between interval lengths.
The artificial data set was generated using the default model parameters with AHP
parameters k2 = 0.5 and \2 = 0.002 and contains 10000 spikes. Its basic analysis is
below :
Dataset modgen5
Number of spikes 10000
Mean ISI 187.1 ms
Output Rate 5.34 Hz
ISI SD 141.20






When generating the fit scores (log likelihoods) the model was run with all the same
parameters as the test data except for those being varied and 10000 spikes were used
to generate each of the probability histograms.
In the first experiment the log likelihood was generated with a range of values for
X2, varying from 0.0005 to 0.1. This more than covers all reasonable values for this
parameter. Increments over this range were chosen to give enough values to
accurately follow the resulting plot of log likelihood values, roughly varying the
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change in the parameter value inversely with the rate of change in the fit score. The
result is illustrated in figure 5.16a. The peak is at exactly 0.002, the value used to
generate the test data and so the likelihood measure has correctly identified the true
value for the data. The other important features are the slopes on either side of the
best value. With lower values for 12 the fit quickly degrades but higher values follow
a much shallower slope, even if we plot 12 over a logarithmic scale (figure 5.16b). It
makes sense to plot 12 on a logarithmic scale because its equation uses it in an
exponential function. A similar plot to figure 5.16b is obtained by replacing 12 in the














Figure 5.16: a. Measuring fit against model generated data (modgen5), varying 12, true value is
>.2=0.002; b. as a. with x-axis plotted on log scale, best fit measure at >.2=0.002, matching value used
to generate data. Curve becomes less smooth, indicating larger error, at larger values for 12.
The slope also gives some indication as to how difficult it will be to search for the
correct value. A shallower slope will make the correct value harder to find with
similar fit measures over a larger range of parameter values. A final feature to note is
the less smooth curve for larger values of 1. This suggests a greater error in the log
likelihood at larger values for 12 and in fact the error becomes greater than any
detectable slope. One of the problems with this method of measuring fit and the
binning of data used to calculate values is that the amount of error will depend on
parameters which determine the range of output values. If output values are over a
greater range (for example a large range of spike interval lengths) then binning will
0.00 0.02 0.04 0.06 0.08 0.10 0.0005 0.002 0.007 0.02 0.05 0.1
AHP decay rate Iambda2 AHP decay rate Iambda2
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not have much effect on accuracy, being small relative to the range of values, but if
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Figure 5.17: a. Measuring fit against generated data (modgen5), varying /re, true value = 300; b.
testing fit against kl, true value = 0.5; both plots show maximum fit score at the true value, plot
gradients indicate how difficult finding true value might be in parameter searching, more gradual
gradient makes searching harder
The second experiment repeats the same process for kl. This works as a more
linear parameter and so we only need the single plot, figure 5.17a. Values for kl
were used covering a realistic range from 0.1 to 1.5 mV. The graph peaks at the true
value for the dataset at 0.5mV with curved downward slopes on either side, of
increasing gradient. This suggests that k2 will be an easier parameter to search than
A.2 with a well defined peak and reasonably steep slopes on either side giving lower
fit scores for values which are too large or too small. The plot shows no obvious
evidence of variation in error in the fit values.
The third experiment tests the log likelihood against variation in Ire. The true
value for the test data was 300Hz and to generate fit values the parameter was varied
over the range 100 to 500Hz. The plot (figure 5.17b) shows a clear peak at the
correct value, sloping away to the left and right of the peak. With smaller values the
log likelihood falls rapidly but not so quickly with larger values and with a more
linear slope. Again there is no obvious variation in error in the data and the smooth
slopes suggests that the error is small.
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5.6.3 Error in the Log Likelihood Measure
To properly test the error in the log likelihood the fitting process was run
repeatedly with the same set of parameters and a fixed number of spikes for the
probability histogram on the test dataset. Ideally the error needs to be measured with
different parameter values in order to show how the parameters affect error, but this
is limited by the time taken to run the fitting process. The first plotted results (figure
5.16) with varied parameter values suggest that the error increases with larger values
for X2 and so this is also tested by varying X2. However this initial test just measures
the error with two different sizes of probability histogram, 10000 spikes and 50000
spikes and two values for X2. More thorough testing is left for later work.
A larger number of spikes should reduce the error but it is difficult to predict by
how much since there are other factors which approximate the log likelihood such as
the bins for indexing the AHP size to the probability histogram. Each test is based on
50 runs. The results are in the table below :
Histogram Spikes 10000 50000 10000 10000
Mean Log Likelihood -30346.32 -30365.37 -30446.00 -30813.75
Maximum -30333.22 -30359.43 -30433.34 -30799.87
Minimum -30359.88 -30372.35 -30458.01 -30834.25
Range 26.66 12.93 24.67 34.38
Standard Deviation 6.11 3.11 6.50 6.71
Standard Error 0.87 0.44 0.93 0.96
n 0.002 0.002 0.001 0.004
The results using 50000 spikes clearly show a reduced error in the log likelihood but
it also produces a mean which is shifted to a lower (more negative) value. When the
binned histogram is used to calculate probabilities the number of intervals falling
within the bin's range is divided by the total number of spikes. This means that
initialising the bins with a count of one has a greater biasing effect when the number
of spikes is lower, resulting in a higher log likelihood. This effect probably explains
the variation in mean log likelihood observed here. The alternative to using 1 unit
initialised bins is returning a very small value, epsilon when the bin is empty but this
can result in similar problems when fewer spikes leave more empty bins and epsilon
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is used more often. The results here show no significant variation in error with 72,
although the slightly larger error with 72 = 0.004 is still consistent with this idea. It
would require to be tested with a larger number of spikes and a larger range of values
for 12 to prove this properly. Unfortunately this takes a very long time to run and is
left for future work.
Relative to the size of the log likelihood scores the error here is very small
although whether it is small enough to be insignificant in searching for a best fit will
depend on the gradients in the search space. If these gradients are very shallow with
little variation in search score over a range of parameter values, as is suggested by
the plot of fit against 72, then the error may play a role in making the search more
difficult.
5.6.4 Varying Two Parameters
Fitting is very easy with only a single parameter to vary since the search space of
possible parameter values is only a single dimension and so it is only necessary to
search a reasonable range of values on this single line to find the peak fit and best
parameter value. However with real data, even if the HAP parameters can be
sufficiently uniquely and reliably fitted using just the ISI histogram, and other
parameters which have remained fixed so far can stay so, it will be necessary to vary
at least Ire, k2 and 72 to find the model's best fit to the data. This will give a three
dimensional search space and it is likely to be much more complicated than just a
single peak with simple continuous slopes leading to the best of parameter values. It
is likely to have many peaks which may be close in height to the true peak and may
have deep valleys nearby the true maximum making it difficult to find. More
dimensions also mean a far greater number of parameter combinations (essentially
vectors if each parameter is considered as an axis of the search space) to test, which
grows exponentially with the number of parameters.
It is only possible to easily visualise a two dimensional search space since a third
dimension is required for the measure of fit. The two parameters being investigated
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here are k2 and \2 since these are likely to have a complex and important
relationship to the model's fit to the data. Here the model is tested in a factorial
manner, essentially a grid of values for these two parameters, varying one parameter
over its full range, changing the second parameter by one unit and then repeating to
test every pair of values over a range for each parameter. The log likelihood is
plotted as a third dimension against the two parameter values. To show this in a two
dimensional figure a contour plot is used, where the two parameters form the two
dimensions of the surface and the third height dimension is represented by variation
in colour or contour lines, similar to a map. This depicts the search space as a
landscape with areas of low and high fit scores represented by peaks and valleys. The
shape of the search space should give some indication of how best to go about
searching the parameters for the best fit in real data, particularly suggesting how fine
the increments in parameter values may need to be and how to relate changes in
value between the two parameters. With dependent parameters such as these two it
should be possible to find ways of changing them in a non-independent manner, i.e.
changing one parameter only relative to the other, which will greatly cut down the
search space.
5.6.5 The k2-Xl Search Space
To investigate this space, the model was run to generate log likelihoods for the test
dataset modgen5 with k2 varying from 0.1 to l.OmV in O.lmV increments and X2
varying from 0.0005 to 0.03 in varied increments chosen to get a good idea of the
search space's form. The model was run using 50000 spikes to generate the
probability histograms. The fit scores were then plotted as a coloured contour plot of
k2 against \2 with shade and contour lines indicating the log likelihood. Scores were
also rescaled to give a more linear contour distribution. The plot with rescaled height
values (figure 5.18) illustrates the shape of the search space. The highest point (in
red) matches the true values for the parameters at k2 = 0.5 and X2 - 0.002 but there is
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Figure 5.18: Contour plot of fit measure (indicated by colour, red=best fit) against k2 and 12; model
generated dataset modgen5, k2=0.5, 12=0.002; log likelihood score rescaled, shows diagonal ridge
indicating best fits, ridge becomes wider as k2 or 12 increases, low gradient along ridge makes finding
exact maximum difficult. Local peaks on the ridge correspond to parameter resolution rather than the
true form.
There is a slope in the ridge up towards and down from the point with the real
parameter value but it is very shallow particularly in the direction towards higher
values of k2 and 12. This ridge corresponds to pairs of 12 and 12 values which all
generate good fits to the dataset, with 12 increasing as 12 increases in an almost
linear relationship. The description of the linear form of the ridge is based on initial
observation of the plot. It does also suggest that the ridge may curve to the left at
higher values for 12 but at this point the ridge also becomes wider and less sharp and
there may be a larger error in the fit values with the larger values for 12. The exact
form needs to be traced by running the model with larger numbers of spikes to
reduce the error and using finer increments in the parameter values. The fit values
slope away steeply to the left of ridge and slope downwards at a more shallow
gradient to the right, in a similar manner to the plot of 12 (figure 5.15) which
dominates the form over 12, with its more extreme gradients. If the 12 axis is
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replaced with the AHP half life, which essentially linearises the axis with respect to
time, the ridge remains but curving upwards as X2 increases.
Ideally this plot would be repeated for at least varied values for the parameter Ire
but unfortunately the amount of computation required to construct this plot using
sufficient numbers of spikes to reasonably reduce the error restricts this so far.
However it is unlikely that the basic form would change. It appears that there is a
linear relationship between k2 and XI with respect to the best fit value, and it should
be possible to use this in searching by fixing one of the two parameters and then
finding the best value for the other. The search routine would then restrict itself to
searching along the ridge by using the relationship to calculate the value of the
second parameter given the first. Assuming the linear form is reliable it should be
possible to discover the relationship for any set of test data by finding the best score
for two values of one parameter to find a line between the two (or more to reduce the
error if finding reasonably exact values is difficult) and then using this to generate a
formula for the relationship.
5.6.6 The k2-X2 Ridge
In this experiment the ridge in the k2-X2 search space was further investigated by
plotting it with finer increments in the two parameters, searching, with values for k2
ranging from 0.1 to 2.0mV, to find the X2 value with the best fit score, in order to
trace the ridge. The probability histograms were generated using 50000 spikes. The
results are plotted in figure 5.19a. This clearly shows a linear relation between k2 and
X2 and the log likelihood. A straight line can be fitted very closely to the points on
the plot. The gradient for the fitted line is very close to the ratio between the true
values for the two parameters indicating that the best value for X2 can be predicted
using the formula X2 = k.2 / 250. The plot also illustrates the increase in error at
higher values for X A second figure (figure 5.19b) plots the log likelihoods at these
points against k2. This shows a well defined peak, covering a fairly small range of
values for k.2. The best score is at a k.2 value slightly higher than the true best fit at
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0.5, but the difference in score is well within the error in the log likelihood. A
difference of about 0.5 covers the range of k2 values within the error range of being




















Figure 5.19: a. plot of 72 values corresponding to best log likelihood scores over a range of k2 values,
shows a distinct linear relationship between the two parameters, corresponding to the ridge observed
in figure 5.18; b. plot of the corresponding best log likelihood scores over k2, showing the gradient
along the ridge, does show a maximum but error in log likelihood scores mean this covers a range of
k2 (and corresponding 72) values.
The second plot shows that the linear relationship between k2 and X2 cannot be used
to reduce the two to a single parameter, but it does demonstrate that it should be
possible to use this relationship to vastly reduce the search space by using the
method described in the previous section. If the ridge can be found and accurately
defined by a formula relating k2 and A.2 then the search between these two
parameters will be reduced to a one dimensional space.
5.7 Searching the Parameter Space
The work here has suggested some ways of searching the parameters for the best
fit but this is in the limited scope of just two parameters. The method may still work
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with more parameters but it will not be so simple, and testing this properly is
currently out of range of the time available. The third parameter to consider is Ire
and with other parameters fixed it should be possible to fit this just on the basis of
output rate, although this relies heavily on having good values for the other
parameters.
The first search method which is to be tested is a standard method for finding the
best fit in a multiple parameter search space called the downhill simplex method
(Nelder and Mead 1965). This is a method for moving through the parameter space
which attempts to go in a direction which leads to better fit scores eventually finding
the best set of parameter values. A multiple parameter search space contains so many
possible sets of parameter value that it is only ever possible to evaluate a small
proportion of these sets of parameters, especially when, as is the case here, the
evaluation function (running the model to get the log likelihood) is very expensive
computationally. It is necessary to use some sort of rules to govern how to move
through the search space. In simplex searching a set of parameter vectors is
maintained which consists of a single apex point and then a set of points which each
vary from the apex in just a single, unique, dimension, i.e. just one parameter value
varies from the apex. The simplex has one more point than the number of parameters
(dimensions). In three dimensions the simplex takes on the form of a triangular
pyramid. The simplex moves through the search space by changing one of its points
(parameter vectors) at a time using several different methods including stretching one
point away from the others, reflecting itself, shrinking, or tilting onto another side.
The simplex can use many more than just 3 parameters, in which case it becomes
more difficult to follow a geometric interpretation. Its goal is to have all of its points
(sets of parameter values) all within a specified range of the best fit score it has
found. This type of method is classed as 'evolutionary' since it consists of a
population of solutions (parameter sets) that it is gradually evolved towards an ideal
based on some measure of fitness.
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5.7.1 Implementing Simplex Search
The simplex search has been added in to the model software directly using the
code from Numerical Recipes (Press et al 1992). A fitness function interfaces the
simplex search procedure with the model's log likelihood generation by converting
the parameter set into a form that can be passed to the model and also filtering
parameter values which are beyond the accepted range (limits which go well beyond
the range of biologically realistic values) by immediately returning a very low fitness
score (a value lower than any that can be returned by the log likelihood). These





The final output is a text file detailing each fitness evaluation made during the
search, including each set of parameter values tested and the final set of parameter
vectors which achieve the best fitness score. If the simplex search successfully
converges and manages to get all the points (parameter vectors) within the specified
range then this gives a final set of parameters fitted to the test data. This range is
specified by a parameter, ftol, which defines the range relative to best score. The
value currently used for this is 0.0001. With scores in the range of -30000 this means
the scores for the final set of points must be within around 3 units. This is well within
the error in the log likelihood but setting a larger range would risk the simplex
converging before getting very close to the true parameter values and so choice of
the range against which to test for convergence is based on a compromise between
getting the fit scores for each point to eventually converge and not converging before
each score is reasonably good. This can be tested empirically to find the best value
and the initial value used here is already based on early testing. Even if it does not
converge within a reasonable amount of time, the search can be halted and the
current set of parameter vectors taken as the result. The simplex tends to reduce its
step size to a very small value as it gets close to the best fitness score and it can
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sometimes have effectively already converged without getting scores for the
parameter sets that satisfy the range test. In this case the process is stopped and the
current set of parameter sets taken as the result.
The simplex method is fairly economical in terms of the number of fitness
evaluations (tests of a particular set of parameters) required to search the space, on
the order of 100 when varying three parameters, but given the already
computationally expensive fitness test, running the model around 200000 times to
generate a probability histogram, the search takes a long time, around 24h when
varying 3 parameters. This has limited the range of testing that has been done so far.
5.7.2 Initial Parameter Sets
The only major issue in using the simplex method, after selecting which
parameters to vary, is the choice of initial parameter sets, of which with 3 parameters
for example there need to be four. The problem of choosing the initial parameter sets
is related to choice of step size for each parameter. The version of the simplex
method used here varies step size for each parameter as it searches, so step size is not
such an important factor in search but it does play a role in setting up the initial
simplex, which will affect how well the search progresses. In fact, the current version
of the method uses the distance of each parameter set from the apex to define the
initial step size for the parameter which is being varied by that particular set (each
initial parameter set varies from the apex set in just one parameter). An old paper,
(Yarbro and Deming 1974) deals with this problem. The two options are either to
start with a small simplex and step size and let it grow in the appropriate direction
towards the best solution or to start with a larger simplex and step size and let the
simplex shrink and refine itself down a set of ideal parameter sets. Which method is
best will depend on the particular problem and so both of these methods will be
tested. A small simplex would consist of an apex set either somewhere in the middle
of the range of sensible parameter values or at the lower end of each range with other
points spaced by a small step (sized relative to each parameter range) away from the
209
Chapter 5
apex. A large initial simplex would use an apex with parameter values at the lower
end of each range and other points which alter one parameter towards the upper end
of its range.
5.7.3 Testing the Simplex MethodWith Artificial Data
The first stage in testing this search method is to test whether it can find the true
parameter values for data which has been generated by the model. With such
artificial data it is known for certain that the model is a perfect fit and the parameters
not being varied are controlled. In order to give the simplex a more linear range for
£2, it works with a logarithmic function of the parameter value. Where the simplex
uses the value x, £2 is calculated using the formula below :
£2 = exp(-x)
This reduces the non-linear variation in the effect on the fit score with parameter
value steps of a similar size.
The first test varies just a single parameter. The simplex search was run on the test
dataset modgen5 (£2=0.5, £2=0.002), using 10000 spikes for the histogram, varying
£2 and using the following initial parameter sets :
Initial Set 12 (mapped value)
1 0.00091 (7.0)
2 0.49700 (0.7)
The simplex search ran for 17 fitness evaluations (testing a set of parameters with the
model) and finished with the following parameter sets :





The search has successfully found two good parameter sets, one with the exact true
value for 72, 0.002 and another which is very close. The second test varies just the
parameter k2, which already works on a linear scale and requires no re-mapping such









These results are both close to the true value at 0.5 and so the simplex has
successfully found the true parameter value. Both of these initial tests use sets of
initial parameters (just one in this case) which cover the range of normal values
giving a large initial step size. In the case a single parameter this appears to work
well. Future work should add a test with a smaller initial range.
The next experiment moves to varying two parameters, 72 and k2. A range of
values for k2 and 72 along the ridge previously described produce very similar
fitness scores, within the error in the log likelihood and the simplex is likely to have
problems differentiating values which fall along this ridge. For this experiment the
simplex was tested with three different sets of initial parameter sets, these and the
respective result sets, including the ratio of k2 to 72, are given below :
Initial Set 12 (mapped) k2
1 0.00091 (7.0) 0.0
2 0.49700 (0.7) 0.0
3 0.00091 (7.0) 5.0
Result Set 12 k2 ratio Fitness score
1 0.0037 0.9821 265.4 30343.09
2 0.0029 0.7475 257.8 30344.06
3 0.0028 0.6055 216.3 30344.01
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Initial Set X2 (mapped) k2
1 0.00248 (6.0) 0.1
2 0.01111 (4.5) 0.1
3 0.00248 (6.0) 2.0
No sufficient convergence in fit scores (although close)
Stop at 12 = 0.0046, k2 = 1.04 (ratio = 226.1)
Initial Set >.2 (mapped) k2
1 0.00091 (7.0) 0.1
2 0.01111 (4.5) 0.1
3 0.00091 (7.0) 2.0
Result Set M k2 ratio Fitness score
1 0.0045 1.1910 264.7 30343.15
2 0.0034 0.8097 238.1 30344.62
3 0.0023 0.5750 250.0 30343.31
The first test uses a set of initial parameters which covers the range of normal values
and finished searching after 20 fitness evaluations. Its results are close to the true
values although all of them have values which are higher than the perfect k2 = 0.5
and X2 = 0.002. The ratio between the two appears to follow the ridge, which relates
k2 and X2 by the exact value 250. The second test uses initial parameter values which
cover a smaller range, although they still vary on either side of the known true value.
This run failed to find three parameter sets with sufficiently close fitness scores and
was stopped, with the simplex testing the values shown. These are again fairly close
to the true values, following a similar ratio. The third test uses a mix of the first and
second initial parameter sets and successfully converged after 16 fitness evaluations.
The results are similar to the first test but one parameter set is very close to the true
values with the exact 250 ratio. The final fitness scores for the two converged runs
are very similar and are toward the lower end of the range of scores obtained testing
the log likelihood with the true parameter values and 10000 spike histograms. On the
basis of the log likelihood and the error in its calculation the simplex is fitting the
parameters as well as it can. The varied initial parameter sets have had no effect on
the quality of the final fit, at least on the basis of the scores.
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5.7.4 Fitting Artificial Data with Three Parameters
The third parameter to be added to the simplex search is Ire, the PSP input rate.
The work in earlier sections of this chapter suggests that a more intelligent way to fit
this parameter would be to match the output rate of the test data but the trouble with
this is that it assumes that the other fixed parameters, and the model itself, are a good
fit to the test data. While this is known with the artificial test data, it will not be so
certain with real data and since this is a very important parameter and one which is
difficult to estimate a value for from general experimental data, it makes the ideal
parameter to add to the search. The range of initial values for Ire had been chosen to
vary on either side of the true value, 300.
The first test is detailed below :
Initial Set 12 (mapped) kl Ire
1 0.00091 (7.0) 0.0 100
2 0.01832 (4.0) 0.0 100
3 0.00091 (7.0) 5.0 100
4 0.00091 (7.0) 0.0 500
Result Set U k2 ratio Ire Fitness score
1 0.0013 0.2374 182.6 284.2 -30349.34
2 0.0012 0.2319 193.3 288.0 -30349.40
3 0.0013 0.2292 176.3 283.8 -30351.39
4 0.0012 0.2316 193.0 287.5 -30350.29
This run converged after 46 fitness evaluations. The final parameter sets are all very
similar and fairly close to the true parameter values. The k2 values are all quite low
however and should be slightly higher relative to this value for 12, indicated by the
low ratio which ideally should be 250. This is probably partly due to the slightly
lower than true (300) Ire values which compensate against lower k2 values (see
section 5.4.1). For the next experiment the same test was repeated using 20000
spikes to generate the probability histograms, it converged after 37 fitness
evaluations :
Result Set M kl ratio Ire Fitness score
1 0.003214 0.8570 266.6 297.8 -30352.90
2 0.004625 0.8889 192.2 285.2 -30349.96
3 0.004566 0.7218 158.1 273.0 -30357.24
4 0.003285 0.8823 268.6 304.9 -30350.21
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These are better fits than those obtained with 10000 spikes. Although the fitness
scores are similar it must be remembered that they tend to be more negative with a
larger number of spikes and so these are actually better scores. The parameter set
(number 3) with the worst &2/A.2 ratio and lowest Ire value has the worst fit score.
The k2 values are all higher than the true 0.5 value but they have good matching 12
values, particularly sets 1 and 4 which also have the best values for Ire, very close to
the true 300. This is more evidence that there is a relation between the ratio and the
value for Ire, with lower Ire values coinciding with a lower k2H2 ratio.
For the final testing (so far) of the simplex search with artificial data a new test
data set was created with different parameter values for k2 and Ire :
Dataset modgen6
Number of spikes 10000
Mean ISI 119.4 ms
Output Rate 8.38 Hz
ISI SD 84.89






This new dataset has a smaller magnitude AHP and faster input rate, producing a
higher output rate than the modgen5 dataset. Different datasets have a different range
of log likelihood scores and so to find the ideal score for comparison with the
simplex results the new dataset was first tested by running the model 5 times with
20000 spikes histograms to produce a range of fit scores with the true parameters.
The results were as follows :
Histogram Spikes 20000








With a higher output rate and larger numbers of spikes in a smaller spread of
intervals this dataset will tend to get higher probability scores, with fewer spike
intervals falling in long interval bins with low numbers of spikes, and the final log
likelihoods are correspondingly higher. The range of values is smaller but the
number of trials here is too small to really compare with the earlier more thorough
error analysis.
This new dataset was tested with the simplex using 20000 spike histograms and
two different initial parameter sets :
Initial Set 12 (mapped) k2 Ire
1 0.00091 (7.0) 0.0 100
2 0.01832 (4.0) 0.0 100
3 0.00091 (7.0) 5.0 100
4 0.00091 (7.0) 0.0 500
Result Set 12 kl ratio Ire Fitness score
1 0.000819 0.2727 333.0 552.62 27812.52
2 0.000823 0.2698 327.8 548.85 27823.66
3 0.000811 0.2711 334.4 551.09 27823.48
4 0.000840 0.2720 323.8 545.63 27819.16
Initial Set 12 (mapped) kl Ire
1 0.00091 (7.0) 0.1 500
2 0.01832 (4.0) 0.1 500
3 0.00091 (7.0) 5.0 500
4 0.00091 (7.0) 0.1 200
Result Set 12 kl ratio Ire Fitness score
1 0.002065 0.2719 131.7 422.37 27815.26
2 0.002064 0.2707 131.2 421.93 27815.07
3 0.002080 0.2704 130.0 421.69 27813.38
4 0.002060 0.2708 131.5 422.42 27808.87
The first test has found quite a poor fit with a small value for X2 and a high value for
Ire. The k2/X2 ratio is much higher than the ideal score of 100 (0.2 / 0.002) for this
dataset. It appears that the low value for X2 and the high input rate have compensated
against each other to create good fit scores. The second test run has found a much
closer match to the true parameter values. The value for k2 is still slightly high but
the X2 and Ire values are much closer to the true parameter values at 0.002 and 400
215
Chapter 5
respectively. The &2/A.2 ratio is correspondingly much closer to the true value, 100.
The values for the ratio and Ire are consistent with the previous relationship observed
with modgen5, with a higher k2 compensating against the higher input rate (/re).
These experiments have demonstrated that the simplex search can find a close
match to the real parameter values. As would be expected it becomes more difficult
as the number of parameters increases, with the quality of the final set of parameters,
in terms of their closeness to the true values, varying between runs and different sets
of initial parameters. The search does however always find parameter sets which
have a fitness close to the best which can be achieved. Unfortunately the error in the
log likelihood means that there are a range of parameter values which can achieve
very high fitness scores. Attempts so far have not been able to reduce this error
without making the amount of time required to run the tests impractical. One of the
most important results here is the ability to relate the variations in parameter values
between each other. When just k2 and X2 are varied, the fit which the search finds
always lies close to the k2-X2 ridge in the search space, and since this ridge is a
straight line this can be measured by calculating the ratio between these two
parameter values. With three parameters this ratio can in turn be compared with the
value for Ire. As was demonstrated in the early experiments with the AHP, variations
in X2 and kl can be compensated by varying Ire, at least to match the ISI histogram.
These compensations can be related to the values found by the simplex, with a higher
value for Ire corresponding to a lower X2 or higher k2 value and a matching increase
in the ratio between k.2 and A.2. It may be possible to better prove and extend these
relations with further testing of greater ranges of values but this is left for future
work.
Whether these relations will hold with real data will depend on how well the
model in general and the other, fixed parameters fit the real data. The earlier results
comparing the model and real data with the ISI histograms suggest that the model is
a good fit to the real data and these experiments also demonstrated how to fit some of
the parameters before experimenting with the AHP. It should be possible to use these
techniques to attempt to fit the real data with the simplex using a fairly small number
of varied parameters. The major difficulty with real data compared to the artificial
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data is assessing how good the resulting parameter sets are, without knowing the true
parameters or the best possible fit scores. The only way to test the found parameters
will be to run the model with them and then compare the ISI histogram and the fitted
line gradients using the spike interval analysis AHP detection technique.
5.7.5 Testing the Simplex Method With Real Data
The first tests of the simplex with real data go directly to running the simplex
search with the current default parameters and just allowing X2, k2 and Ire to vary.
The purpose of this is to compare the results with later experiments, yet to be run,
which allow the simplex method to vary a larger number of parameters, and attempts
to fit some of the other parameters such as X before fitting with the simplex. The aim
of this is to test how consistent the results with real data are and to find out more
about how the parameter fits which are found might be affected by varying more
parameters or using different values for the fixed parameters. The overall goal is to
be able to produce a consistent and confident fit to real data with parameter values
that relate directly to real neuronal components, or failing that identify how the
model needs to be changed to achieve this. This is ambitious but if it could be
achieved then the model would provide a powerful tool for measuring otherwise
inaccessible properties of neurons and their firing patterns.
The first experiment tests the simplex with the real dataset mludwl and was run
using 20000 spike histograms. The initial parameter sets are similar to those used
with the artificial data. The results show two identical runs which both failed to
converge but did end with fairly consistent final parameter sets :
Initial Set 12 (mapped) k2 Ire
1 0.00091 (7.0) 0.0 100
2 0.01832 (4.0) 0.0 100
3 0.00091 (7.0) 5.0 100
4 0.00091 (7.0) 0.0 500
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The first run was ended with the parameter set:
Result Set te kl ratio Ire Fitness score
1 0.0078 0.18 23.1 258 -30071
The second run ended with :
Result Set 12 kl ratio Ire Fitness score
1 0.0056 0.193 34.5 259.6 -30067
All of the four parameter vectors in each set were very similar, identical to 3
significant digits, and so just a single parameter set is shown for each run. The two
sets are similar with very close values for Ire and a slightly higher k2 and lower X2
giving a higher ratio on the second run. The parameter values all fall within the
normal range of values used with the model data although the k2/X2 ratio is smaller
than with the artificial data. In earlier work this real dataset was fitted using the ISI
histogram and also by comparing the fitted line gradients in the spike train analysis.
The values for the fitted AHP parameters were k2 = 0.3 and X2 = 0.002 and Ire was
fitted at 290Hz. The only fixed parameter which varied with the previous fitting was
the HAP X at 0.11 compared to the 0.10 used with the simplex search. The next
experiments here should be to run the simplex search with X = 0.11 and to produce a
set of model data using the parameter values found with the varied values for X for
comparison with the real data's ISI histogram and spike train analysis, but these are
yet to be run.
The final experiment tests a second real dataset, mludw2, with the simplex using
two different initial parameter sets. The basic analysis for this real dataset is
presented below :
Dataset mludw2
Number of spikes 13000
Recording time 45 min
Mean ISI 208.1 ms
Output Rate 4.81 Hz
ISI SD 139.88




This is a longer recording than mludwl and has a lower average firing rate
(compared with 5.74Hz) with a slightly higher ISI standard deviation. The simplex
search was run using the default fixed parameters and 20000 spike histograms. The
results for the two runs are shown below :
Initial Set 12 (mapped) k2 Ire
1 0.00091 (7.0) 0.0 100
2 0.01832 (4.0) 0.0 100
3 0.00091 (7.0) 5.0 100
4 0.00091 (7.0) 0.0 500
Stopped at:
Result Set 12 k2 ratio Ire Fitness score
1 0.0043 1.55 360 300.9 -30565
Initial Set 12 (mapped) k2 Ire
1 0.00091 (7.0) 0.1 500
2 0.01832 (4.0) 0.1 500
3 0.00091 (7.0) 5.0 500
4 0.00091 (7.0) 0.1 200
Stopped at:
Result Set 12 k2 ratio Ire Fitness score
1 0.0073 2.88 394 299.1 -30545
These two runs use the same initial parameter sets as the final experiment with the
artificial data. The first initial set is the same as the test run with mludwl.
Both runs produced almost identical values for Ire but the second run fitted a
much higher value for k2. However this is matched by a higher value for XI and the
k2/X2 ratios are quite a close match. The fitness scores for the second run are slightly
better. The fitted parameter values are all still within the range of values considered
to be realistic although the higher value for k2 is beyond what has previously been
tested with the model. The fits with both of these real datasets have close values for
the k2!X2 ratio suggesting that there may be a similar ridge in the search space to the
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artificial data. The way to proceed with this dataset is to attempt the same type of
fitting with the ISI histogram used with mludwl to get estimated values for the HAP
and AHP parameters and then use these to run the simplex search again. These fits
can then used to be used to generate artificial datasets which can compared with the
real data using spike train analysis. It may also be worth testing the simplex with
more varied sets of initial parameters, to test how consistent the fits are, and to better
define the relations between the different sets of fitted parameters.
5.8 The First Future Work
Many of the experiments presented can themselves be extended, and this has
already been outlined. The main limitation has been the computational load of
calculating the log likelihood. It will be important to extend the number of real
datasets tested, to test the consistency of results, and also to further develop the
parameter relations with respect to the search space in order to make search for the
best fit more efficient and accurate. There may be better search algorithms to use.
The search space is very gradient sensitive and there are other multi-parameter
search algorithms which are specifically designed to take gradient into account. A
further way of exploring the behaviour of the AHP will be to detect how much it
summates between spikes. When it climbs to a higher level it slows down firing rate,
limiting its own accumulation. It is therefore likely to have some form of equilibrium
level. It will be possible to compare the value detected with the model to equivalent
measures in electrophysiological experiments.
Another direction will be to expand the model by including the DAP. This is more
dominant in vasopressin cells, but it is also thought to be present in oxytocin
neurons. Its effect is usually masked by the AHP. An important test will be whether
adding this has a significant effect on the existing results. It will also allow the model






The aim of the GH project was to examine the experimental evidence and use this
to build a model of the GH release system. Modelling provides a structure in which
to formalise existing knowledge and test theories on how the system might function
as a whole. The goal was also to keep the model as simple as possible, in order to
understand the system in its barest functional form. A model was successfully built
which is able to reproduce the behaviour and functional properties of the real system.
This was used to go on and test more complex versions, incorporating more system
components, suggested from experiments, testing what role these might play in the
system. The final version of the model produces output which closely resembles the
qualitative and quantitative properties of the real data, in both male and female rats.
Matching the system's behaviour using components suggested from experimental
data is good evidence that the model is an accurate representation of the real system.
On this basis, the model is able to predict and aid the interpretation of experimental
data and should provide a powerful tool for further studies of the system, as well as
suggesting general techniques for modelling other brain systems.
The first part of the chapter summarises the GH system modelling before moving
on to discuss the work within the more general context of research into the system.
The final section discusses the oxytocin cell spike firing model.
6.2 Modelling the GH Release System
It's well established that GH release is controlled by the two hypothalamic
peptides, GHRH and somatostatin. Somatostatin controls the overall pulsatile pattern
of release by exerting permissive control over the ability of GHRH to trigger GH
release at the pituitary. The form of individual GH pulses is controlled by the pattern
of GHRH release. Experiments with the complete system, and tests with the pituitary
model, suggest a fairly square wave pattern of somatostatin release, matching the
periods of low GH release in the male rat. GHRH release must correspond to the
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individual peaks of GH, suggesting an irregular pattern of pulses at roughly 15min
intervals. GH feeds back to regulate its own release by stimulating somatostatin and
inhibiting GHRH release. The cross-gender variation in the release pattern appears to
due to modulation of GH-somatostatin feedback by gonadal steroids. The GH-
somatostatin feedback in particular seems to act with a long delay, indicated by
experiments administering GH to the system, measuring GH release and also
measuring the Fos response at the periventicular nucleus. This inhibitory feedback
combined with the delay produces a cycle which creates the pulsatile release pattern.
GHRH and somatostatin are controlled by the GHRH neurons in the arcuate
nucleus and the somatostatin neurons in the periventricular nucleus of the
hypothalamus. GH appears to feedback directly to the somatostatin neurons, and also
through the NPY neurons in the arcuate nucleus. GH-GHRH feedback also appears
to be mediated by the NPY neurons and also the group of somatostatin neurons in the
arcuate nucleus, acting on the sst2 receptors on the GHRH neurons. The sstl
receptors of the GHRH neurons probably mediate an inhibitory signal from the
periventicular somatostatin neurons. The best evidence for this connection is the
electrophysiological experiments which demonstrated suppressed electrical activity
at the GHRH neurons in response to periventicular stimulation. More circumstantial
evidence also suggests an reciprocal inhibitory connection from the GHRH to
somatostatin neurons, mediated by galanin. The main excitatory input to the GHRH
neurons appears to come from another part of the brain, probably an adrenergic
driving input.
6.2.1 Designing the Model
This evidence formed a sufficient base from which to build the model, starting out
with as few components as possible in order to generate pulsatile release. The
pituitary model had been established as a reliable starting point, producing GH
release from GHRH and somatostatin and accurately representing the dynamics of
the real system. The first two additions were the delayed GH-somatostatin feedback
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and the inhibitory somatostatin-GHRH connection. This was sufficient to produce
the pulsatile GH pattern, but the multiple peaks within each GH pulse also required a
pulsed input to the GHRH neurons. Although somatostatin already inhibits the
release triggering action of GHRH at the pituitary, this isn't strong enough alone to
produce the almost undetectable levels of GH release observed inter-pulse in the
male rat. Later work with the model, attempting to reproduce the GH rebound
following a somatostatin infusion, also suggested that the central somatostatin-
GHRH block is required to increase GHRH sensitivity at the pituitary. On the basis
of the pituitary model (and also probably in the real system given the matching
results between real experiments and the model) even when somatostatin blocks GH
release, GHRH continues to desensitise its receptors. Blocking central release
prevents this and allows the high inter-pulse somatostatin levels to recharge pituitary
GHRH sensitivity.
The first version of the model implemented these connections as crude switch-like
sigmoidal curves. The second version improved on this by replacing these with Hill
equations and also by using a more sophisticated GH-somatostatin feedback
mechanism. The first version of the model originally used a central somatostatin-
GHRH rebound mechanism to trigger GHRH release for each GH pulse. This
became redundant once an external pulse input was added but designing it developed
a new modelling form, a releasability variable, allowing a substance to increase a
readily releasable pool of another substance rather than directly triggering its release.
Release is then generated as the product of the releasable pool and electrical activity.
This gives the system a form of memory, recording the effect of a signal, rather than
immediately responding. In the model this allowed GH to charge the releasable pool
of somatostatin so that the period of high somatostatin release would not depend
directly on delayed GH activity, allowing a longer period of high somatostatin
release with a shorter feedback delay. The real mechanism by which GH triggers the
long period of somatostatin release is still unknown and the model's form gives a
mechanism to test in the real system. The dynamics of this mechanism, the charge
and discharge rate, were set by matching the model's output with the magnitude and
timing of real GH release. It would be better if these could be measured more
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directly at the somatostatin neurons, assuming such a functional mechanism exists.
Releasability in the model is a deliberately vague term. In the real system it would
relate to some mechanism such as vesicle mobilisation creating a readily releasable
pool at the cell membrane or increased synthesis.
Sampled Release Profiles
The model built from these components was able to reproduce the qualitative
behaviour of the real system. The important step in going on to reproduce the
quantitative details was to introduce the simulation of the sampling involved in
measuring real GH profiles. This has a dramatic effect on the appearance of the GH
output, reducing the apparent height of GH peaks, and also reducing the number of
visible peaks and changing their height order. Testing the pituitary model, and later
the full model in combination with a sample rate matching real data allowed a better
guess at the real pattern of GHRH release, suggesting that a 15-30min pulse interval
is required to produce the observed form of the GH pulses. More frequent pulses
actually produce fewer GH peaks in the sampled data.
Random GHRH Pulse Input
The other important step in reproducing the form of real GH release was to make
the GHRH input pulse intervals random. This did not disturb the overall pattern of
GH pulses but did produce the irregular pattern of GH peaks, and slightly varied
inter-pulse intervals observed in real data. This was first tested with the pituitary
model and later added into the full system model. Function with the random input




6.2.2 Extending the Model
After successfully reproducing the male rat's pattern of GH release, the next aim
for the model was to reproduce the female release pattern with the goal that this
should be possible just by parameter modulation. The female release pattern is
thought to be due to a more constant low level release of somatostatin, caused by
varied GH feedback on somatostatin. Developing the model had identified another
way to modulate the system to produce the female release pattern, by modulating the
inhibitory effect of somatostatin on GHRH release, increasing the threshold for
somatostatin to trigger inhibition of GHRH release. Both of these methods were able
to reproduce the female release pattern. However, modulation of GH-somatostatin
feedback is the method best supported by experimental evidence. This could be
reproduced in the model either by reducing the charge rate for somatostatin
releasability or by reducing the maximum level for somatostatin releasability.
Attempt to use in-vitro preparations test the variations in the periventricular
somatostatin release mechanism have so far produced results which contradict in-
vivo behaviour (Murray et al 1999b). Stimulation in an explant preparation from a
female rat produces higher levels of release than from a male preparation, despite a
higher somatostatin content in the male. It has been shown that levels of somatostatin
mRNA are higher in the male and this is consistent with the model result suggesting
a larger store of releasable somatostatin, or a larger effect of GH on charging the
store.
GHRH-Somatostatin Inhibition
This was added to model in order to test what functional role such a connection
might play in the system. What it did was to produce bistability in GHRH activity.
Smaller GHRH pulses, below threshold to inhibit somatostatin were blocked by the
somatostatin-GHRH inhibitory connection. Medium size GHRH pulses however,
remove their own inhibition by inhibiting somatostatin, becoming larger GHRH
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pulses. This had the effect of making GH pulse size more regular and reducing the
number of small GH peaks at the start of pulses observed in the model. This made
the model more robust and allowed the steepness of somatostatin-GHRH inhibition
to be reduced. However it did not make any major functional contribution to the
model, and in order to maintain simplicity, this was not permanently added to the
model at this stage.
GH-GHRH Feedback
The final major development of the model was to add in GH feedback at the
GHRH neurons in an attempt to generate the pattern of GHRH input activity without
such a defined external input. This was successfully implemented and was able to
generate the required pattern of pulsed GHRH input to produce individual peaks
within the GH pulses. The best results were achieved using a very steep inhibitory
curve in the relation between the GH level and GHRH activity, in order to form the
sharp GHRH pulses required to get the corresponding sharp peaks within the GH
pulse. This steep activation is plausible in the real system, particularly given that
GH-GHRH feedback appears to be mediated through arcuate NPY and somatostatin
neurons. Several layers of non-linear relations is one way to produce a very steep
non-linear relation. GH-GHRH feedback also required a delay in the range of 5-
15min in order to produce more than 2 peaks within the GH pulse. This matches
experimental data that shows activation of arcuate neurons in response to GH
occurring without the long delay observed with periventricular neurons.
Although this new component was able to replace the need for the external input
to produce distinct peaks within the GH pulse, it still produced GH output which was
more regular than observed in the real system. This was fixed by adding a higher
frequency external input with mean 5min interval pulses.
226
Chapter 6
6.2.3 Reproducing Real Experiments
The model was now able to produce a good match to normal GH profiles in male
and female rats. The next important test was to attempt to reproduce the effects of
injections and infusions of GHRH, somatostatin or GH itself. This would further
validate the model and help to interpret the results of these experiments. The first of
these was injections of GHRH at varied intervals. The real experiments were
important results because they were one of the best demonstrations of feedback in the
system, with the endogenous pulse pattern becoming entrained into the artificial
input. The model easily reproduced the results with injections at 180min intervals but
had problems with the more frequent injections. The pituitary model had not
previously been tested with maximal dose injections of GHRH and produced a much
higher GH response during high levels of somatostatin than in the real system. To
reproduce the real results the non-somatostatin modulated GHRH triggered release
component was reduced in size and the steepness of the somatostatin controlled
inhibition was also increased. This may have knock on effects for other parameters in
the pituitary model and future work will involve rechecking the parameter fitting
with these new adjustments.
With these changes the model was also able to reproduce the effects of
somatostatin and GH infusions, producing very good matches to the real
experimental results. Results with the model suggest that exogenous somatostatin
must be able to act on the hypothalamus in order to produce the observed rebound
release. In the model the rebound is produced by charging pituitary GHRH
sensitivity to a high level and this requires GHRH release to be blocked. Because the
model is already able to produce the rebound effect, a hypothalamic rebound
mechanism cannot be tested without changing the pituitary model. This change
would likely make the model less representative of the real system. The model
suggests that the hypothalamic involvement is the requirement for a pulse of GHRH
release to trigger the large GH release. Testing the model against experiments
infusing short pulses of GH provided evidence in support of the short GH-GHRH
feedback delay on the basis of matching the delayed GH response to GH infusions.
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The response to longer infusions supports a GH-somatostatin feedback delay of
approximately lh.
It was actually surprisingly easy to get the model to reproduce the real results,
requiring no changes to the model equations or parameters that were used to produce
the normal release pattern, apart from the adjustments to the pituitary model, which
had no significant effect on the previous results with the final version of the model.
6.3 GH Model Discussion
Discussed below are some particular issues which developed during the design and
testing of the GH model. These are mainly to do with the model components which
had to be hypothesised rather than directly based on experimental data. When adding
such components the most important final aspect is that they produce something that
can be tested in the real system. In this way modelling forms a circular process of
basing components on real data, designing a more complete version, filling in
uncertainties and then testing the result of this back in the real system.
Effect of the Pituitary Model
One of the major influences at the beginning, and throughout the modelling work,
was the fact that it had started with, and continued to use as a major component, the
existing pituitary model. Treating this model as sufficiently well tested to be
considered 'correct' and fixed meant that the hypothalamic components had to
satisfy extra demands that may not have been there if the new modelling work had
started from scratch. For the most part this was probably a good thing, having to deal
with a realistic representation of the pituitary dynamics instead of some simplified
representation, with the risk of it being tailored to make the hypothalamic
components easier to design. The problem is that the pituitary model was tested
against, and designed to reproduce, results from in-vitro experiments. The features
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identified at this level will almost certainly still manifest in the natural, in-vivo,
system, but possibly with varying emphasis. An example of this is the rebound effect
observed in-vitro. At this level it presents as a major feature of the pituitary systems'
functional description, and likely provides good clues to the mechanisms behind the
pituitary components. However, considering the whole system, the rebound
involving the hypothalamic systems is of a much larger magnitude, and more
significant to the whole system's behaviour. The later work with the model,
reproducing the experiments designed to trigger the rebound, suggested that the
larger rebound also uses the pituitary mechanism, but attempting to produce the
rebound with just the pituitary model may have resulted in an unnaturally high
weighting to the non-GHRH and non-somatostatin controlled GH release
components in the pituitary model.
It is these components, particularly the non-somatostatin controlled GHRH
triggered GH release component (k4) that have formed the problems with the
pituitary model which became apparent when testing the model's response to
simulated GHRH injections. Component k4 is an odd, counter-intuitive feature which
came to exist as an artefact of the pituitary model's development path rather than as a
designed feature. It was always given a much smaller weighting than the
somatostatin inhibited GH release component, but was still left with a fairly large
(approx 10% of the normal somatostatin controlled component) parameter value
following fitting of the model to in-vitro data. How this final value was derived is not
clear unfortunately. For the fitting process, a simplified version of the model with
fewer parameters was produced, but there is no record of how the fitted values for
the reduced model were translated back into the full version.
The other pituitary model parameter which had to be altered is the strength of
somatostatin's inhibitory effect on GH release. The required increase in inhibition
only became apparent when challenging the system with very high doses of GHRH,
comparable to the maximal dose injections. The pituitary model was fitted against
dose response curves but was likely never directly tested against a maximal dose of
GHRH, which may also vary in magnitude between the in-vitro and in-vivo system.
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The effect of the weakened somatostatin controlled inhibition during the
development of the hypothalamic components was to place more importance on the
inhibition of GHRH release at the hypothalamus than was necessary. High
somatostatin levels at the pituitary were not sufficient to generate the periods of very
low inter-pulse GH release, and so GHRH had to also be blocked at the
hypothalamus by the inhibitory somatostatin connection. Whether the model, with
the adjusted pituitary parameters can function with the hypothalamic somatostatin-
GHRH inhibition reduced in strength (weaker inhibition) remains to be tested. The
later work with the model suggests that hypothalamic inhibition of GHRH is
required, not to block GH release, but to maintain sensitivity to GHRH at the
pituitary. This assumes that the pituitary model's interpretation that desensitisation to
GHRH takes place at the receptor and early second messenger level is correct, which
on the basis of the lack of cross-desensitisation between GHRH and GHRP seems
likely to be the case.
Fortunately the model's structure and its dependence on individual elements was
kept sufficiently flexible that the pituitary model could be altered at the later stages
in chapter 4 without having a large effect on the results.
The GHRH Input Pulses
Of the model's elements this is the part which was most purely hypothesised rather
than being based on experimental evidence. Evidence for an essential adrenergic
input to the GHRH neurons does exist, but not on what form it might take. Adding
inhibitory GH-GHRH feedback demonstrated that even constant, non-pulsatile input
to the GHRH neurons could still produce multiple peaked GH pulses, but these still
lacked the form of the sharp GH peaks observed in real GH profiles. The final
version of the model in chapter 4 uses randomly timed input pulses overlaid with the
GH feedback control to produce the sharper, more randomly spaced GH peaks that
more closely resemble the real data. The justification for this defined input is that it
is a specification of the final release triggering activity at the GHRH neurons rather
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than an actual input. The input could be a more variable form of activity that is
processed through a threshold to produce the on-off pattern of input pulses. One
experimental method for testing this might be to stimulate GHRH neurons with
patterns of activity varying between distinct pulses to continuous activity, measuring
the resultant GH release, similar to the experiments in (Dickson et al 1993).
GH-Somatostatin Feedback
The most distinct feature of this component is the absolute delay required by the
model, usually set to 60min. The only direct evidence for such a delay in the
literature reviewed by this thesis is (Minami et al 1992) where stimulation of NPY
neurons produces a delayed response (of a similar time magnitude) at somatostatin
compared to GHRH. However, this would not account for the delayed response to
GH acting directly at the somatostatin neurons. It may be that the delay is due to the
process by which GH is transported from pituitary release to the periventricular
nucleus. This will require some special method of transporting the large GH
molecules past the blood brain barrier, either by some special cross-membrane
transport mechanism or following a reverse route up the neuronal projections to the
median eminence. Alternatively, the delay may be part of the process by which GH
triggers increased somatostatin release. The model suggests that GH charges the
level of somatostatin ready for release, and this process may take time, for something
such as vesicle transportation. Actual increased somatostatin synthesis would be on
too long a timescale. One manner of experimentation might be to use an explant type
in-vitro preparation to measure somatostatin release from the periventricular neurons
in response to electrical stimulation, first to establish measurable release in response




6.4 Previous and Contemporary Modelling Work
The first published attempt at modelling the GH release system [Chen et al 1995.]
produced a model with a similar set of components to this one but with a very
homogenous structure including all possible connections, and using standard highly
parameterised relations between components. The model was able to reproduce the
qualitative properties of basic GH release but contained a very large number of
parameters (-80) and such an abstract structure that it could not be properly analysed
or related back to the biological system.
The second published attempt (Wagner et al 1998) was much simpler,
incorporating just GH-somatostatin feedback and somatostatin-GHRH inhibition
represented by Hill equations, with a very basic representation of GH release in
response to GHRH and somatostatin. This model successfully reproduced the basic
pattern of GH release but relied upon a regular lh interval input to GHRH to drive
the system.
The most recent attempt (Farhy et al 2001) produced a model very similar to the
one presented in this thesis, incorporating GH feedback to somatostatin and GHRH,
and somatostatin-GHRH inhibition, also represented by Hill equations. It uses no
external GHRH input and instead generates the pattern of individual GH peaks
within each pulse using GH-GHRH feedback, with a 7min delay. GH-somatostatin
uses a 60min feedback delay. Giving the current model a constant level of GHRH
input and adjusting the GH-GHRH feedback parameters produces very similar output
to the model presented in the paper. A second paper (Farhy et al 2002) also goes on
investigate reproducing the female release pattern using a very similar method of
reducing the feedback effect of GH and somatostatin. The random element is release
is produced by adding Gaussian noise to the pattern of somatostatin release, based on
unpublished evidence from endogenous somatostatin release measured in ewes. The
paper also adds the simulation of sampling.
The main difference from the current work is the more abstract forms for the
relations between substances, particularly GH-somatostatin feedback, although this is
likely to have similar functional properties to the construction in the current model. It
232
Chapter 6
also lacks the more sophisticated model of pituitary action. The only unique
component presented in the current model is the inhibitory GHRH-somatostatin
connection.
For the most part the work is remarkably similar and serves to confirm the
approach and results of the current model. The main overall advantage of the work
here is that it maintains a closer connection to the biology, which makes it a better
system for maintaining a relationship with experimental work with the real system.
The enhanced representation of the pituitary makes this model better at explaining
many of the experimental results, particularly the GH rebound in response to
somatostatin withdrawal, and also in justifying the nature of the hypothalamic
components, rather than just demonstrating that they work. The careful construction
of this model has demonstrated the 'necessary' as well as the 'sufficient' quality of
the model's components. An example is the need for distinct GHRH pulses to
produce the individual GH peaks observed in real release data. This is a feature
missing from the published material on the Farhy model. It is never as strictly
compared with real release patterns as this model, basing it's comparison purely on
the basic characteristics of endogenous release patterns rather than a direct detailed
comparison of the forms. Despite varying amplitude, the Farhy model maintains
regular spacing between GH peaks, each pulse consisting of two peaks when
simulating normal activity in the male rat. Timing of each GHRH pulse is entirely
controlled by inhibitory GH feedback, which is itself determined by the GH-GHRH
feedback delay of 7.5 min. In the most advanced version of the current model, GH
peaks are determined not only by GH feedback, but also the background of random
GHRH input pulses. The Farhy model effectively uses a constant input to drive
GHRH, similar to the continuous input to somatostatin used in the current model.
The current model can also function with just a constant background input to GHRH,
and, doing this, produces a similar output to the Farhy model.
The Farhy model creates the variation in GH pulses by adding a random
component to somatostatin release. This produces variation in the amplitude, but not
timing of GH peaks. Unfortunately the determination of how regular these peaks
really are in real data is limited by sampling, but it seems unlikely that release is so
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regular in the real system. The varied substrates for randomness in the system leaves
an interesting variation between the two models which makes predictions which are,
at least theoretically, open to experimental investigation.
6.5 Future Work
The model makes many predictions for the function of the real system and the way
forward is for these to be tested experimentally, particularly the dynamics of GH's
feedback effect on somatostatin and somatostatin's inhibition of GHRH. This would
work well in combination with the recent advances in detecting and specific blocking
of somatostatin receptor subtypes. The model's predictions for the endogenous
patterns of GHRH and somatostatin release are not currently testable at sufficient
temporal resolution. An advance to the model might be to add in GHRP and use the
model of a tool for finding the best method for treating GH deficiency. The model's
accurate reproduction of real GH release suggests that it is sufficiently reliable for
such a task. Another approach is to use the form of analysis developed with firing
patterns in oxytocin cells to examine the firing properties of GHRH neurons in
response to stimulation.
Treating the Model as a Theory
To take a more general view, the approach from this point is test the model to
destruction, place the assumption that the model is a correct representation of the real
system, and work to show why this isn't true. The model can be attacked from two
sides, reflecting the combined bottom-up (basing the model on known components)
and top-down (aiming at a known output) approach that was used to build it in the
first place. The first of these is to keep testing it against real experimental data, in a
similar manner to the later part of chapter 4. This should go on until the model fails,
is unable to reproduce the real experiment. At this point, the model, maintaining the
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rigours of biological plausibility and the essentials that had made it successful thus
far, should be altered to try and match the offending experiment. Failing this, the
model fails and has to be rejected. The further the model gets (and indeed it is
arguably already at this stage) the less likely this occurrence should be. This process
will continue to validate the model, and also further explain experimental results.
The second manner of attack, and perhaps also the most important manner of
advance, is to test the basis of the model. Some of the model's components and based
on well established knowledge of the real system, but other parts are more postulated
and require to be searched for, and found, in the real system before they can be
established as true representations of the real system. This is the form of the
experiments suggested earlier in this chapter. The model should also be checked to
be sure that it's abstract forms do represent established knowledge. A thorough
version of this process would involve carefully formalising the properties of the real
components and then comparing these with the model counterparts.
More Detailed Modelling
In order to establish some of the model's more abstract components, such as the
GH-somatostatin feedback mechanism it may be necessary to produce more detailed
models, focussing on these mechanisms, when there is sufficient experimental
evidence to do so. This can test how such a component might work and properly
establish its functional properties. This however should be seen as a temporary step,
a manner of properly justifying and determining the functional properties of a
component before returning to the more minimal model of the system. Following a
reductionist path of adding more and more complexity to explain behaviour will
result, not in explaining or understanding a system, but merely achieve a replication
of the complexity, albeit a more controlled and accessible one. The brain, for all its
complexity, includes much homogeneity, and the only way to make understanding it
a tractable problem is to derive general principles and more abstract understandings
of its goings on.
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A final conclusion is that this project has demonstrated the usefulness of
modelling as a technique. Many investigations within neuroscience would benefit
from tandem efforts combining modelling and experimental work.
6.6 The Oxytocin Cell Firing Model
In relation to the GH modelling project, the aim of this work was to investigate
how electrophysiological properties of a particular type of neuron might be detected
by analysing recordings from the cells. The eventual aim would be to apply this
technique to cells such as the GHRH neurons in which normal activity is difficult to
detect, in this case due to its blocking by anaesthesia. The oxytocin neurons are
already relatively well understood and accessible to recording, under a range of
conditions, making them an ideal system in which to begin developing such a
method.
The Limitations of ISI Histograms
The previous work, which developed the oxytocin cell version of the integrate and
fire model did all of its comparisons with real data on the basis of the ISI (inter-spike
interval) histograms. The first part of the new work recreated this and looked at how
the histogram forms related to the model parameters, and how much information they
preserved. The main conclusion was that the histogram was dominated by firing rate,
and could not be used to distinguish between different parameters that can affect
firing rate, such as the inhibitory to excitatory PSP ratio (Iratio) and the overall PSP
rate (Ire), with it being possible to use these to compensate against each other to
produce identical histograms. However, this result also produced the ability to mask
the firing rate effects of parameter changes which also had more subtle effects on the
ISI distribution, such as the HAP parameters. This was able to isolate the effects of
the HAP on the front end of the histogram, and produce a technique for fitting the
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model to real data by matching firing rate in combination with matching the front
end of the histogram.
The limits of using histogram matching to fit the model to real data were really
revealed when using spike train analysis to look for a relation between adjacent ISIs.
The model without the AHP can match a real recording on the basis of the histogram
without being able to reproduce the negative gradient revealed by spike train
analysis.
Log Likelihood and Simplex Search
The version of log likelihood used here gives a measure of fit that preserves the
relations between individual ISIs, allowing it to take account of properties such as
the correlation detected by spike train analysis. The main limitation with this
measure is that the practical manner of calculation is an approximation, and creates
error in the final value. This means that only a range of parameter values where the
best fit lies can be determined, rather than exact values. Examining the search space
with model generated data varying the two AHP parameters shows an almost flat,
straight, ridge of the best fit values, with AHP magnitude and decay rate increasing,
compensating against each other. A peak can be detected at the true values used to
generate the data, but the gradient along the ridge is very shallow, giving a range of
pairs of values falling within the error in the fit measure. One way to proceed here
will be to test how the size of this range varies with the AHP magnitude, the idea
being that a larger AHP may have a less well distributed (over following spike
intervals) effect, making it more distinguishable from a smaller AHP with longer
duration. The linear relation between the two parameters and the best fit can be
defined by a single ratio value. The results presented here have also begun to indicate
a relation between this value and the PSP input rate. Further work may be able to
determine a precise relation.
How well this will all apply to real data is difficult to predict. These precise
relations are in model generated data where the parameters are all known and
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controlled. The basis for believing that similar relations may apply to real data, if less
precisely, is the early fitting work with the ISI histogram which was able to get good
fits to real recordings from different cells without varying many parameters.
However, this of course is qualified by the limitations of fitting with the histograms.
If a similar linear relation between parameters can be found in real data then this will
allow the search to be reduced to just one parameter for the AHP, finding the ratio,
and then searching along the ridge.
Simplex search is a method of moving through a multiple parameter search space
which alters all of the parameters in parallel, rather than fitting each parameter in
turn, in the manner of some other multiple parameter search methods. Considering
the interaction between parameters, this is likely to be the best type of method for the
search space here. It makes a good job of finding the best fit with one or two varied
parameters, but results are more variable with three parameters, depending partly on
the initial parameter set. Results here vary between using initial parameters which
cover the range of expected values (i.e. k = 0 and k = 5) or defining a smaller initial
simplex with values all in the range of those normally used with the model (i.e. k =
0.1 to k = 1). Unfortunately the time required for a simplex run has limited the range
of initial parameters tested so far, and there is so far not enough data to find a
relation between the result parameter sets and the initial parameters, assuming a
regular pattern is to be found.
Simplex search does always manage to find a result set which gets the best
possible fit score for a spike dataset, and the varied results from different initial
parameter sets can be related by the AHP magnitude-decay rate ratio and also to the
input rate, although the later relation is less well defined. Additional tests (not
shown) have established that repeated runs with the same initial parameter set
produce the same result set. The way to proceed with this is, in the first place, more
results, testing more varied parameters with model generated datasets, and more
varied initial parameter sets. It will also be necessary to test with a larger number of
varied parameters, such as input spike magnitude, or the HAP parameters. The
ultimate aim is to be able to take a real recording and then use the search mechanism
to analyse the data, producing reliable parameter values that can be directly
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translated back to electrophysiological properties that could not otherwise be
detected.
The AHP
Adding the AHP to the model allowed it to reproduce the ISI correlation detected
by spike train analysis in real cell recordings. Combined with the knowledge that the
AHP exists in the real cells, this suggests that it is the AHP that is responsible for this
correlation in real data. Since it is a fairly intuitive process to understand the AHP
having this effect, in combination, it seems like a reasonably safe conclusion. The
question from here is 'What's it for ?'.
Functionally, the AHP works in one direction; more rapid firing increases the size
of the AHP and effectively increases the firing threshold, reducing the firing rate,
assuming that the input rate isn't also increasing. As the firing rate slows, the AHP
decays away, restoring the firing threshold, eventually allowing the firing rate to
increase again. This is what creates the correlation observed by spike train analysis,
the slight bias towards longer ISIs after short ISIs and shorter ISIs after longer ISIs.
This acts to reduce the variation in the ISIs. Results show this effect, showing a
smaller ISI standard deviation in model generated spike trains using the AHP,
although more work is required to conclusively separate this effect from being
caused purely by the reduced firing rate. So, in a single cell, the AHP forms a short
term memory for previous firing activity, acting to reduce firing in response to high
activity, modulating the firing rate, limiting the maximum firing rate, and also
increasing (although in effect reducing, because it's working against a stronger non-
linearity in the opposite direction) the non-linearity of the relation between the input
rate and spike firing. Conceivably the AHP ion channels could also activate other
mechanisms, beyond its effect on membrane potential, perhaps more directly using
the AHP as a form of memory.
In oxytocin cells, the AHP is likely to play a role in the varied firing modes, which
occur to trigger different forms of oxytocin release, which varies between slow
gradual release and very large discrete pulses, such as during parturition and milk
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ejaculation. These pulses correspond to a rapid increase in firing rate which may
normally be switched off partly by the existence of the AHP. The tentative prediction
here is that the AHP detected in recordings during these phases of intense firing
should have a smaller magnitude or faster decay rate, reducing its effect.
Within a network with several output neurons competing to respond to a shared set
of inputs, the AHP could work to reduce the dominance of cells which fire very
often, (assuming a mechanism that limits the number of responding cells, such as
inhibitory interneurons) giving a chance back to other cells, so that particularly
common input pattern doesn't preclude the learning of other patterns by dominating
the feedback that strengthens synaptic connections to the output cells. It would be
interesting future work to test this in some network (perhaps for pattern recognition)
using a more sophisticated representation of the individual neurons, such as the
integrate and fire model.
To Conclude
Beyond the AHP, there may be a lot that can be done with the new analysis and
fitting techniques, detecting neuronal properties from cell recordings. The next step
will be to continue development to a point where reliable parameter estimates can be
produced, for a limited number of parameters. At the current stage, testing has only
just begun attempting to fit real data, but, as noted above, it does seem hopeful that
the fitting process can be used to get accurate parameter values, perhaps by getting
values defined relative to another parameter (such as the magnitude / decay rate
ratios) and then converting them to absolute values by using another source to
determine one of them. One of the current limitations is that a constant mean input
rate is assumed. The limits the type of cell activity that can be used for fitting, but if
a cell's properties can be well defined then it may be possible to use the model and
fitting process to test possible input patterns against measured output activity. The
work here could potentially create an important new tool for exploring neuronal




Table 1 : Varied AHP parameters
k2 A2 Half-life Output Rate Mode Height
0.0 0.001 693.1 7.26 45 1927
0.2 0.001 693.1 5.54 60 1368
0.4 0.001 693.1 4.59 55 1112
0.6 0.001 693.1 3.97 65 931
0.8 0.001 693.1 3.53 55 805
1.0 0.001 693.1 3.18 70 713
0.0 0.002 346.6 7.27 45 1865
0.2 0.002 346.6 6.28 50 1520
0.4 0.002 346.6 5.59 60 1338
0.6 0.002 346.6 5.09 55 1185
0.8 0.002 346.6 4.67 70 1038
1.0 0.002 346.6 4.31 60 963
0.0 0.003 231.0 7.28 55 1893
0.2 0.003 231.0 6.61 55 1642
0.4 0.003 231.0 6.03 65 1449
0.6 0.003 231.0 5.64 65 1302
0.8 0.003 231.0 5.29 55 1221
1.0 0.003 231.0 4.96 70 1092
0.0 0.004 173.3 7.28 45 1847
0.2 0.004 173.3 6.75 55 1665
0.4 0.004 173.3 6.36 50 1548
0.6 0.004 173.3 5.96 65 1386
0.8 0.004 173.3 5.70 45 1331
1.0 0.004 173.3 5.41 65 1201
0.0 0.005 138.6 7.23 45 1860
0.2 0.005 138.6 6.85 50 1770
0.4 0.005 138.6 6.51 60 1555
0.6 0.005 138.6 6.24 50 1466
0.8 0.005 138.6 5.94 60 1415
1.0 0.005 138.6 5.71 55 1318
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Table 2 : Real data spike train analysis
TO T1 T1+T2 T1+..+T4 T1+..+T8 T1+..+T16 T1+..+T32
27.85 190.15 382.29 733.01 1422.86 2781.42 5542.90
37.33 193.39 381.48 739.05 1447.03 2828.10 5592.91
44.35 180.01 342.20 709.06 1429.34 2801.09 5597.57
50.72 174.48 342.20 684.57 1380.79 2767.48 5477.98
57.39 186.43 364.36 709.45 1395.37 2810.72 5546.69
64.11 177.99 346.62 708.52 1374.39 2763.23 5452.84
71.22 176.00 363.94 716.57 1422.65 2772.64 5567.47
78.54 168.34 333.96 703.59 1392.69 2789.43 5565.77
86.62 175.96 347.54 697.08 1369.20 2708.22 5449.63
94.82 176.07 353.12 711.98 1401.46 2787.03 5513.45
104.60 183.25 367.65 727.94 1387.18 2752.33 5515.01
114.22 175.44 366.57 701.45 1415.10 2783.83 5513.50
125.16 167.57 332.18 676.33 1401.88 2771.25 5540.28
136.25 183.07 361.11 710.72 1393.90 2764.46 5506.70
149.10 186.12 365.56 695.17 1411.72 2770.66 5530.20
161.80 187.05 356.27 702.74 1407.43 2823.32 5608.76
176.99 174.54 332.57 680.70 1375.01 2742.66 5481.82
193.07 170.61 347.53 704.12 1388.21 2787.90 5532.19
211.85 171.20 334.45 686.12 1347.83 2714.68 5513.24
232.65 156.96 335.79 682.83 1350.21 2744.56 5495.58
257.52 165.93 320.86 664.18 1378.02 2785.20 5591.60
286.46 161.99 333.85 658.92 1349.61 2774.46 5558.68
322.23 149.95 318.69 650.69 1355.90 2709.92 5487.46
367.40 159.13 327.95 679.11 1372.71 2778.48 5565.34
432.01 150.88 332.37 656.22 1320.36 2708.65 5496.38
582.49 150.76 296.25 586.41 1258.97 2656.42 5499.82
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Table 4 : Model generated data spike train analysis
TO T1 T1+T2 T1+..+T4 T1+..+T8 T1+..+T16 T1+..+T32
32.32 206.16 399.17 802.92 1550.73 3074.18 6133.705
43.24 196.00 422.49 794.70 1558.99 3073.05 6157.59
51.45 196.93 391.44 774.32 1540.93 3074.24 6113.57
58.93 191.33 396.82 791.60 1556.29 3067.21 6102.43
66.89 197.08 381.85 768.24 1538.62 3064.22 6078.78
74.45 205.87 386.09 766.30 1510.95 3027.38 6009.26
82.85 173.46 370.04 764.78 1511.33 3016.79 6038.46
91.64 191.38 399.36 761.96 1537.58 3005.47 6039.82
101.18 192.51 380.54 752.56 1532.38 3099.55 6155.58
111.14 186.32 398.37 779.93 1538.18 3061.91 6050.85
121.84 185.18 378.88 741.72 1515.30 3027.61 6054.81
132.59 198.78 370.48 780.21 1551.61 3036.07 6002.12
143.33 202.03 375.74 765.44 1558.04 3021.60 6025.99
154.95 201.90 381.90 758.53 1527.24 3038.44 6103.20
168.14 178.43 374.97 743.23 1525.80 3036.75 6050.79
181.70 197.01 385.40 774.68 1526.38 3088.16 6070.09
197.49 192.45 375.80 737.48 1483.73 3017.50 6098.62
215.24 168.72 349.45 742.26 1484.04 2987.29 6020.40
233.27 189.27 378.83 745.14 1490.85 3068.19 6062.64
252.79 209.48 369.26 753.18 1508.27 3049.06 6064.19
275.61 191.61 363.96 755.59 1475.76 2975.18 6058.89
303.51 176.00 382.82 754.89 1484.05 2981.66 6014.77
337.07 165.37 356.59 740.30 1498.20 2960.53 5974.67
381.54 180.41 362.56 726.73 1477.37 2993.53 6030.63
454.34 175.97 360.82 694.37 1440.07 2922.57 5933.97
635.01 172.14 350.80 717.76 1449.10 2959.16 5983.46
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Table 6 : Model generated data spike train analysis (no AHP)
TO T1 T1+T2 T1+..+T4 T1+..+T8 T1+..+T16 T1+..+T32
28.55 171.04 337.72 656.99 1320.95 2708.72 5404.61
37.67 161.86 340.02 691.89 1339.70 2666.89 5354.49
45.16 171.14 341.53 704.60 1341.90 2700.85 5490.44
51.72 170.84 336.42 696.64 1385.71 2733.81 5418.82
58.77 180.91 361.99 698.31 1398.64 2720.09 5514.65
65.78 157.81 313.79 664.29 1342.12 2711.77 5433.26
72.37 173.16 354.86 693.69 1378.13 2720.79 5417.23
79.59 173.29 354.54 700.83 1384.43 2760.72 5458.85
87.39 164.63 331.93 673.67 1380.40 2756.04 5492.72
94.91 171.16 331.47 679.82 1337.56 2693.76 5455.77
102.95 195.91 348.48 699.78 1393.94 2810.49 5553.08
112.27 162.17 334.73 656.71 1365.95 2758.05 5445.49
121.80 185.87 365.95 714.43 1402.31 2803.70 5501.90
132.77 186.99 366.48 713.25 1436.26 2822.23 5555.54
144.04 157.91 325.66 664.07 1351.78 2693.43 5491.14
157.44 169.76 328.83 677.54 1387.66 2778.01 5526.80
172.02 169.61 336.35 678.02 1364.01 2763.98 5493.15
187.38 175.14 350.67 708.95 1408.26 2756.30 5506.91
204.51 189.04 362.74 704.36 1365.52 2752.20 5506.72
224.16 153.04 319.49 673.73 1336.77 2710.11 5420.78
247.38 158.21 343.86 679.96 1378.04 2746.28 5507.52
276.20 160.98 336.28 701.59 1355.86 2691.46 5478.09
314.63 176.50 349.35 679.89 1374.83 2736.44 5443.63
358.78 187.49 343.00 660.52 1357.64 2733.89 5522.24
434.56 158.30 334.87 640.45 1325.38 2668.04 5402.31
607.76 166.69 345.00 679.86 1379.00 2775.49 5568.22
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Table 7 : Fitted model generated data spike train analysis
TO T1 T1+T2 T1+..+T4 T1+..+T8 T1+..+T16 T1+..+T32
28.48 180.43 355.21 705.26 1433.50 2841.41 5576.77
37.84 178.28 357.32 711.57 1408.73 2849.14 5605.36
45.10 187.65 375.10 724.74 1437.21 2825.75 5645.02
52.15 180.05 345.28 695.88 1394.77 2743.40 5538.87
59.10 185.46 361.17 718.55 1416.76 2807.75 5643.75
65.77 186.40 371.25 722.18 1426.27 2806.56 5602.33
73.57 185.54 366.97 701.99 1405.94 2786.69 5577.17
81.76 197.36 372.17 719.43 1421.29 2801.64 5600.86
89.97 178.11 357.77 719.34 1396.72 2784.08 5554.07
98.61 184.05 372.57 738.23 1466.02 2872.72 5686.59
108.31 169.00 350.97 707.34 1420.65 2850.59 5637.59
117.95 167.44 357.04 710.11 1396.49 2791.11 5612.34
127.36 181.77 361.05 715.06 1392.51 2798.59 5567.45
137.95 168.48 349.77 686.75 1388.81 2794.01 5589.59
151.64 181.08 355.09 707.65 1389.24 2792.19 5603.37
165.72 168.26 335.84 686.79 1401.82 2762.94 5557.29
180.65 158.37 342.88 689.60 1360.71 2762.31 5566.43
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